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Abstract  
 As more complex biotherapeutics are produced, the numbers of antibodies 
exhibiting aggregation phenomenon has increased greatly. It is therefore of growing 
importance to understand the products and origin of these phenomena and to be 
able to select candidates that show the greatest stability. The purpose of this work 
was to assess different methods for determining protein stability and the aspects of 
stability they measure, analysing the different aggregate species produced to offer a 
platform solution when dealing with different aggregate phenomenon during process 
development.  
 The effect of reversible self association (RSA) on the purification of a product was 
evaluated and shown to only critically effect the operation of viral filtration steps in a 
typical bioprocess through blockage of filter pores. A custom made, rotating disc, 
interfacial shear device was evaluated along with thermal, spectroscopic and 
molecular modelling methods for their ability to determine the relative stabilities of 
antibodies to aggregation. A capillary interfacial shear device with 10 fold reduced 
volume was designed and tested, showing comparability of monomer loss in the 
capillary with the coefficient of monomer decay in the disc device. This surface 
related damage was further studied by comparison to thermal methods with a range 
of known modifications to IgG structures, using modelling techniques to indicate 
aspects of protein structure key to loss of stability. The interfacial shear device 
provides an orthogonal measurement related to modification of exposed protein 
residues whereas thermal techniques trend with intramolecular stability. 
 It was also concluded that for full characterisation of an aggregate profile SE-HPLC, 
Nanosight and Microflow Imaging should be used to enable capture of the entire 
size range of aggregate species from 10nm to 100μm. The work highlights the 
future prominence of molecular modelling techniques as part of a fully integrated 
aggregate mitigating solution to determine aggregation hot spots. 
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3D  3 dimensional 
ADCC  Antibody-dependent cell-mediated cytotoxicity 
AFFF  Asymmetric field flow fractionation 
AUC  Analytical ultracentrifugation 
CCD  Charge-coupled device 
CD  Circular dichroism 
CDC  Complement dependent cytotoxicity 
CIP  Clean in place 
DBC  Dynamic binding capacity 
DLS  Dynamic light scattering 
DoE  Design of experiment 
DSC  Differential scanning calorimetry  
DSP  Downstream processing 
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EDMA  Electrospray differential mobility analysis 
EDTA  Ethylenediaminetetraacetic acid 
FcRn  Neonatal Fc receptor 
FTIR  Fourier transform infra-red spectroscopy 
GLP  Good lab practice 
GMP  Good manufacturing practice 
HETP  Height of equivalent theoretical plate (m) 
HPLC  High performance liquid chromatography 
IgG  Immunoglobulin G 
mAb  Monoclonal Antibody 
MALDI  Matrix assisted laser desorption ionisation 
MALS  Multi angled light scattering 
MFI  Micro flow imaging 
Mins   Minutes 
NTA  Nanoparticle tracking analysis 
PBS  Phospho-buffered saline 
PDB  Protein database 
PDC  Protein decay coefficient 
PES  Polyethersulfone 
QA  Quality assurance 
RPM   Revolutions per minute 
RPS   Revolutions per second 
RSA  Reversible self association 
SAP  Spatial aggregation propensity 
S.D.   Standard deviation 
SDS-PAGE Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
SEC  Size exclusion chromatography 
SIC  Self interaction chromatography 
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SINS  Self interaction nanoparticle spectroscopy 
SLS  Static light scattering 
THT  “Threonine - Histidine - Threonine” amino acid sequence  
UF/DF  Ultrafiltration/Diafiltration 
UV  Ultraviolet 
V/V  Concentration of substance by volume (%) 
W/V  Weight of substance by volume (%) 
WT  Wild type 
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1 Introduction 
1.1.1 Project aims 
 The aim of this project is to better understand antibody stability in relation to 
aggregation phenomenon and to find a way to mitigate the problem in industrial 
bioprocesses. In achieving this goal the best methods and techniques to quantify 
antibody presence as well as determine antibody stability will be discerned.  
 Antibodies aggregate in many different ways to form species with many properties, 
but regulations only dictate that the levels of aggregates above a certain size have 
to be kept below certain thresholds. The regulatory reason for removal of 
aggregates centres on the health risks associated with the injection of aggregated 
proteins into patients, including the eliciting of immunological responses and the 
ability to mechanically block capillaries, causing reduced microcirculation in 
postischemic patients.  
 From an industrial standpoint, it is important to focus on the issue to gain a more full 
understanding of what affects antibody stability and how to measure this most 
efficiently. Some aggregates can lower the efficacy of drug products and can limit 
the drug storage time once produced. More efficient screening of potential drug 
molecules for stability during manufacturing, shipping and storage can decrease 
time to market and increase the time a drug is sold under patent as well as 
potentially allowing smaller doses and less unused drugs wastage. 
1.1.2 Objectives 
 The overall goal of the project is to be able to understand the products and origin of 
these phenomena and to select candidates that show the greatest stability. In this 
project we aim to assess different methods for determining protein stability and the 
aspects of stability they measure, analysing the different aggregate species 
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produced to offer a platform solution when dealing with different aggregation 
phenomena during process development. This is broken down into a series of sub-
objectives designed to build towards the final goal. 
1 Complete characterisation of the custom UCL disc interfacial shear device 
 This is required to determine the optimal conditions for collecting the most reliable 
results with the interfacial disc device and will involve characterising individual un-
optimised parameters of operation. Milestones include: 
 Determining cooling jacket operating conditions 
 Determining the wavelength of light used in SE-HPLC analysis 
 Determining the optimal disc speed 
 Determining the optimal antibody concentration 
2 Develop a higher throughput method of gaining comparable results to the 
disc shear device 
This would be required to increase throughput when determining antibody sample 
stability with respect to interfacial interactions. This will allow for more samples to be 
screened earlier in process development, giving more information prior to lead 
antibody selection. This will involve the design of a fundamentally different device 
and testing different parameters of operation. Milestones include: 
 Determining the mode of operation of the device 
 Determining the conditions in the device 
 Determining the operating conditions of the device 
 Comparing the device results to the disc interfacial shear device 
3 Finding an appropriate way to analyse aggregates formed through 
processing 
 This is required to fully characterise the aggregation profiles formed from antibodies 
so the mechanisms of aggregation can be assessed. This will involve determining 
current best practice from the literature and breaking the size range into 
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manageable chunks since no one method can cover the entire range required. 
Milestones include: 
 Using the literature to determine the overall size range 
 Using the literature to determine the individual size ranges required 
 Determining the difference in aggregates formed through thermal and interfacial 
degradation 
 Determining the best device for each size range 
4 Determine the effect of RSA on bioprocessing of a target molecule 
This is required to understand the effects of this newly observed phenomenon on 
processing and to determine the disc shear devices’ reaction to it. It will also show 
the consequences of this issue on the downstream processing of a drug. This will 
involve finding an appropriate antibody and determining the conditions needed to 
produce RSA. It will then require the running of the individual purification steps to 
determine the effect of the phenomenon. Milestones include: 
 Determining the effect of conditions on RSA expression using DoE 
 Determining the effect of RSA presence on accelerated stability and disc shear 
device results 
 Determining the effect of RSA on the capacity of protein-A chromatography 
 Determining the effect of RSA on viral filtration 
 Evaluating molecular models of RSA prone antibodies 
5 Comparison of disc interfacial shear device with thermal methods as tools 
for determining antibody stability and the use of molecular modelling to 
explain differences 
This is required to put the disc interfacial device into context with the other 
techniques for determining antibody stability. It is designed to allow for a conclusion 
to be drawn on the mechanism of aggregate formation at the solid/liquid interface. 
This will be done by comparing the results for five modified antibodies tested with 
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the disc shear device, differential scanning calorimetry and accelerated stability 
techniques. Molecular models would then be used to determine the cause of the 
difference in stability. Milestones include: 
 Determining the PDC of the antibodies with the disc shear device 
 Determine the stability of the antibodies using DSC 
 Determine the stability of the antibodies using accelerated stability 
 Comparison of the stability prediction technique results 
 Evaluating molecular models of different antibodies  
1.1.3 Description of thesis 
 The literature review has been structured to explain the background of each 
concept from the ground up, for instance, beginning with the biochemistry basics 
then leading to the reasons to remove aggregation. The review then moves on to an 
increasing order of complex detection methods before going into depth about the 
general factors that effect aggregation, the factors that occur in different unit 
operations, aggregation mechanisms and finally to look at cutting edge molecular 
modelling techniques to determine antibody stability. 
 The experimental section covers a definition of the standard methods to be used in 
the studies including conditions for use of a custom interfacial shear device before 
beginning by looking at the techniques available for analysing the aggregates 
formed. It then aims to find a higher throughput method for determining the 
interfacial shear stability before looking at a phenomenon known as Reversible Self 
Association (RSA) to determine its impact on bioprocessing. The work concludes by 
comparing the interfacial stability measurement with other techniques for 
determining protein stability. It proposes a mechanism for aggregation occurring at 
the solid/liquid surface drawing on both experimental results and a molecular model 
based understanding for the loss in stability of the antibodies tested. 
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2 Literature review 
2.1 Antibodies 
2.1.1 Immunoglobulin G 
 
Figure ‎2-1: 3D model representation of an IgG1 antibody. Protein sequence 
downloaded from PDB file 1HZH and modelled using Discovery 
studios. 
 
 This study will primarily look at IgG1 and IgG4 antibodies and their homogeneous 
and heterogeneous interactions within bioprocessing. These are globular plasma 
glycoproteins with a mass of around 146 kDa (Wang and Ghosh, 2009) consisting of 
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two light and two heavy peptide chains folding to form two beta sheets, creating a 
sandwich shape held together by conserved cysteines and other charged amino 
acids. 
 The two identical γ heavy chains contain around 450 amino acids and consist of a 
constant and a variable domain. The light chains contain around 215 amino acids 
and again consist of a constant and a variable domain. These variable domains are 
the origin of protein specificity based both on their stereo-chemical and ionic 
characteristics  (Janeway, 2001). 
 The heavy chains contain a linker region held together by sulphide bonding, which 
is flexible. This allows the dimeric heads to form the characteristic Y shape which 
will remain dynamic in solution allowing the arms to conserve more hydrophobic 
regions on the Fc region (Dangl et al., 1988). The correct glycosylation is essential 
for the IgG to bind to its receptors (Male, 2006). 
2.1.2 The bispecificity of IgG4 
 IgG subtype 4 behaves differently from normal IgG1 antibodies. They were found to 
be unable to precipitate purified antibodies (van der Zee et al., 1986) since they are 
unable to cross-link two antigens due to monovalent behaviour (Aalberse et al., 
1983). Additionally, it was found that IgG4 half molecules were present in SDS-
PAGE analyses of normal molecules (Colcher et al., 1989, King et al., 1992) but 
under non-denaturing conditions these half-molecules were not detected 
(Schuurman et al., 2001). Finally, with the use of size exclusion chromatography, a 
large number of IgG4 molecules were found to be bi-specific, due to the presence of 
two different antigen binding sites. This led to them being less effective at inducing 
inflammatory responses and in fact made them able to inhibit the inflammatory 
effects of other antibodies (Schuurman et al., 1999).  
 It has been posited that the Bispecificity is a result of a single Amino Acid change 
relative to IgG1, which is the change of a proline to a serine in the core of the hinge 
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of IgG1 (Aalberse and Schuurman, 2002). This allows the molecule to disassociate 
from this hinge and give two identical monomeric halves, each containing one light 
chain and one heavy chain. The bi-specificity is observed when two different IgG4 
monomeric halves reform together to give a whole bi-clonal antibody. 
2.1.3 The IgG hinge 
 Considerable work has gone into defining the role of the hinge on the effector 
functions of an antibody. For IgG this hinge can generally be divided into upper, 
middle and lower regions. The middle hinge stretches from the first to the last of the 
cysteines that form disulphide bridges and is believed to be rigid due to inter-heavy-
chain disulphide bridging and subsequent formation of polyproline helices (Lu et al., 
2007). It is considered that the hinge region acts as a spacer effecting segmental 
flexibility and allows the Fab arms to move in relation to the Fc (Dangl et al., 1988). 
Further work shows that changes in the amino acid sequences could affect the 
rigidity of the hinge, which in turn affected the effector function of the antibody 
(Dall'Acqua et al., 2006a). Studies show that IgG4 has less flexibility in the hinge 
region than IgG1 and that this correlates with a reduction in stability between the two 
subgroups (Heads et al., 2012, Kilar et al., 1985). This correlates with a perceived 
greater stokes radius of the IgG4 subtype. 
2.1.4 Protein aggregation 
 Protein aggregation is a major concern in the production of recombinant protein 
therapeutics in bioprocessing (Jimenez et al., 2007). In simple terms, it is when 
many protein monomers adhere to each other through a variety of different types of 
bonds to form a larger multimer. There is no real end to an aggregation process with 
many different routes to get to an aggregated state. Very little is known about the 
specific reactions that drive the process. 
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 Changes in conditions that alter the proteins chemical and physical stability can 
result in precipitate or aggregate formation (Pease et al., 2008). Precipitation can be 
used advantageously in certain bioprocesses such as the precipitation of IgG from 
bovine serum albumin (Venkiteshwaran et al., 2008), but for the majority of 
purposes aggregates are a negative phenomenon. 
 Protein aggregates can form from protein-protein interactions alone or from 
nucleation on foreign micro and nanoparticles that have been shed into the system. 
The levels of these aggregates can be changed by many factors relevant to the 
commercial production of proteins. 
 Stresses, such as shear, directly disrupt the shape of native protein molecules, 
causing hydrophobic portions of the proteins to then become exposed to the 
aqueous environment. Interaction of hydrophobic portions allows binding to other 
similarly affected proteins (Bekard and Dunstan, 2009) and significant amounts of 
aggregates can form over the typical timeframes relevant to modern 
pharmaceuticals and under the stress conditions they are exposed to. 
 It has been well established that these protein aggregates in therapeutic protein 
products can enhance immunogenicity, leading to the need to remove the 
aggregates from the product (Carpenter et al., 2009). 
 To be able to study aggregation, it is necessary to be able to define the type of 
aggregate that will be discovered. It has already been mentioned that there are 
different routes to arrive at an aggregate, but due to the lack of classification criteria 
available it is hard to create discrete classifications of aggregates. Previous work 
(Philo, 2006) has suggested the use of multiple categories to classify protein 
interactions, which are further defined: 
 
Reversibility 
 
 This is a measure of whether the aggregate, once formed, will revert back to active 
monomers. There should be a distinction between aggregates that perform this 
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process of their own accord over time, and those that have to be re-suspended with 
the aid of an operator or technician. In general, only the smaller species are 
reversible. Reversible Self Association (RSA) is a further phenomenon that relies on 
weak intermolecular interactions and will be described in full later. 
 
Size 
 
 Definition of size would need the use of several ranges. A sensible division (Mahler 
et al., 2009) would be: 
Small multimers, such as 2 to 10 monomer units 
Small sub-visible, soluble particles, up to 1μm in size 
Large sub-visible, insoluble particles, up to 25μm in size 
Large visible, insoluble particle 
 
Type of Bond 
 This is a measure of the strength of the forces used to hold the proteins together in 
the aggregate. Weak bonding could be through forces such as Van der Waals 
interactions, hydrogen bonding, hydrophobic and electrostatic interactions (Mahler 
et al., 2009). Stronger covalent interactions can be the result of disulphide bond 
linkages or non-disulphide cross-linking pathways (Andya et al., 2003). 
 
Protein Conformation 
 
 The conformation of the aggregated protein subunits can form a measure of the 
amount of change in protein native structure that was required to cause the 
aggregation. 
 
 It has to be noted that in some cases, insoluble aggregates can be related to the 
precipitation of host cell protein impurities, and not the product itself (Shukla et al., 
2007a). 
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2.2 Reasons for prevention and removal of aggregation  
 With the expanding production of bio-therapeutics, removal of protein aggregates, 
either by stopping their formation or by physical or chemical removal, is of ever-
greater importance to the bioprocess industry. Since 2007, antibodies have been the 
highest selling category of biologics, with a market value of around $50 billion which 
is estimated to rise to just under $70 billion in 2015 (Visiongain, 2008). In a recent 
review of pharmaceutically relevant monoclonal antibodies and Fc fusion proteins, 
around half of them were found to possess aggregation issues following protein-A 
purification (Shukla et al., 2007a). If it is possible to stop or reverse 10% of the 
aggregates formed and removed throughout the process, this will be greatly 
financially beneficial. 
 A highly important factor is the loss of bioactivity of the formulation (Sluzky et al., 
1991, Pease et al., 2008), which will effect the dose required by a patient. This again 
affects the profitability of the process, as a higher level of protein in each dose will 
mean less overall doses per batch. 
 Of greatest importance is that aggregates can elicit an immunological response in 
patients (Joubert et al., 2012, Chennamsetty et al., 2009a) that could involve 
neutralisation of antibodies, cross reactive neutralisation of endogenous protein 
counterparts or anaphylaxis. This is the reason for the strict guidelines on their 
removal. 
 There are currently very few published studies to comprehensively try and 
investigate the range of parameters that influence the level of immunogenicity of 
aggregates. It has however been reported (Carpenter et al., 2009) that large protein 
assemblies with repetitive arrays of antigens in which there is still a majority of 
natively conformed protein molecules are the most potent at inducing immune 
responses. In the same report, it was found that the adsorption of antigenic proteins 
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to nano or micro particles of different materials have the ability of greatly increasing 
the immunogenicity of the protein. 
 It is likely that patients’ status and the treatment protocols the drug is used in have 
a critical effect on determining the propensity of the drug to produce an immune 
response. 
 Additionally, it has been reported that sufficiently large insoluble aggregates have 
the ability to mechanically block capillaries, causing reduced microcirculation in 
postischemic patients (Lehr et al., 2002).  
2.3 Analytical methods 
 Due to the wide usage of proteins in therapies, there is a great need to be able to 
monitor and characterise protein solutions both in the research phase and during 
bioprocessing. At research phase, there is a great amount of testing to help 
characterise the protein and the solutions produced in the potential processes. At 
production level this monitoring occurs both at various points during production to 
ensure compliance to validated standards and in storage conditions to monitor 
solution degradation. 
 For protein aggregation in bioprocessing, current guidelines state that aggregation 
should be measured using the light obscuration method as described in the 
European pharmacopoeia methods 2.9.19 (PE, 2008) and the US pharmacopoeia 
(USP) <788> (USP, 2008). The guidelines state that particulates greater than 10μm 
in size should be controlled at or below 6000 particles per container, while 
particulates greater than 25μm are to be controlled at less than 600 particles per 
container (Carpenter et al., 2009). 
 The method uses the opalescent properties of the colloidal protein solutions to give 
a measure of the turbidity of the solution. The solution is either compared with a 
reference suspension under defined light conditions to determine the turbidity or an 
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optical density measurement is taken at around a 350nm wavelength, which could 
give comparable results to turbidity, but is dependent on the specified method 
(Mahler et al., 2009). 
 For research purposes, there are a great many more techniques for measurement 
employed, and there is no universal method for characterising protein aggregates. 
This is partially due to the fact that there is no technique that universally covers the 
entire size range of protein aggregates that can range from nanometre to millimetre 
sizes. The size ranges of some common techniques are given in table 2-1.  
 As well as differences in the size ranges measured, the techniques available can 
give different sizes for comparable samples due to differences in what inherent 
property of the protein is measured by the technique. One such example being the 
measurement of the hydrodynamic diameter in light scattering that gives an 
unrepresentatively large size for fibrilar aggregates. 
 
Table ‎2-1:  Table of functional parameters of detection techniques  
 
Method 
Range of 
operation 
V time 
Shape 
estimation 
Static light 
scattering 
1nm to 5μm 50 μL online yes 
Dynamic light 
scattering 
1nm to 5μm 50 μL online no 
Refractive index All 50 μL online no 
Light obscuration 2μm to 300μm 500 μL online no 
Electron 
microscope 
1nm to 70μm 10 μL 1 day yes 
Field Flow 
Fractionation 
1nm to 100μm 10μL 2 mins no 
AUC 1nm to 1μm 150μL 1 week yes 
EDMA 2nm to 250nm 1 mL 1 day no 
SDS-PAGE 
<1nm to 
400nm 
200μL 12 hours no 
SE-HPLC 
<1nm to 
500nm 
10μL 1 hour no 
MFI 3μm to 100μm 0.5 - 300μL 200μL/min yes 
Nanosight 25nm to 2μm 0.3 - 0.5mL 10 mins no 
Circular 
Dichroism 
200nm 0.8 mL 1 hour yes 
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2.3.1 Detecting aggregates 
 
Figure ‎2-2:  Diagram of angle of measurement used by various light techniques. 
 
 There are many different techniques that could be used to determine the size of 
proteins and their larger aggregates. The previous section highlighted a few of the 
most popular and useful methods available. The information given showed that 
there is a lot of variety in the range of operation of the methods, the sample volumes 
needed and the times taken to perform the tests. To find the best way of identifying 
potential aggregate species, all these factors must be taken into account and a 
compromise between range, time, volume and reliability of results must be made. 
 The time taken for measurement may be greater than the lifetime of a reversible 
aggregate, or the measurement techniques themselves may destroy or create 
further aggregates, posing further challenges for analysis (Philo, 2006). 
 Factors involved in the analysis that can perturb the distribution of aggregated 
species include dilution, change of solvent conditions, adsorption to surfaces, 
physical filtration or disruption, concentration on surfaces and shear (Philo, 2006). 
 Figure 2-2 shows the different paths that scattered light can follow, with various 
techniques able to take readings and determine various attributes of the sample. 
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2.3.1.1 Static light scattering 
 Static light scattering is a technique from physical chemistry in which a 
monochromatic light source and multiple detectors are used to measure the intensity 
of the scattered light to give a value for the average molecular weight of the 
macromolecule in solution. By measuring the intensity at many angles it is possible 
to calculate the root mean squared radius of the species. 
 The sample to be tested should be optically clear and can be quite concentrated 
meaning little preparation could be necessary to give real time data. The ability to 
detect in real time can allow the viewing of the kinetics of protein aggregation. 
 To calibrate the machine, the laser intensity and quantum efficiency of the detector 
and the full scattering volume and solid angle of each of the detectors is determined 
by using a known scatterer such as toluene. The calibration will also include 
normalisation of each detector to the 90° angle detector to take into account the 
slightly different quantum efficiencies, gains and scattering volumes using an 
isotropic scatterer. 
 The results from a static light scattering experiment are input into equations, such 
as the Zimm equation, to calculate the average molecular weights of the species 
(Chu, 1991). Furthermore, characterisation of the excess Rayleigh ratio (R) against 
the composition of a multi-component aggregate may determine the stoichiometry 
and equilibrium binding affinity of the system as well as binding and dissociation 
kinetics (Some, 2012).  
2.3.1.2 Dynamic light scattering  
 Dynamic light scattering is another physical chemistry technique where the 
scattered light intensity measured is proportional to the protein concentration and 
the hydrodynamic radius of small particles in suspension (Rosenberg et al., 2009). 
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 The theory of the technique is that the light scattering from the particles will give a 
time-dependant fluctuation that is due to the Brownian motion of the molecules in 
solution changing the distance from the laser source. This light will additionally 
undergo both constructive and destructive interference from the surrounding 
particles. This fluctuation will contain information about the timescale of the particle 
movement. 
 The intensity trace can be used to generate a second order autocorrelation curve to 
elucidate the dynamic information of the particle movement (Chu, 1991). The mAb 
monomer is generally the first peak at 10nm mean hydrodynamic diameter, with 
aggregates typically having diameters larger than 100nm (Rosenberg et al., 2009). 
 A feature of dynamic light scattering is that large particles are very highly sensitively 
detected, due to an exponential increase in light intensity with hydrodynamic radius 
(Ahrer et al., 2003). This means that the technique can be very effective for 
detecting precursors to larger visible particles and tracking sources of stress or 
damage (Philo, 2006). 
2.3.1.3 Refractive index 
 The refractive index is a fundamental physical property of a substance and can be 
used to identify particular substances in solution. It is measured with either a 
refractometer or interferometer in the optical domain. The refractometer measures 
the ability of the substance to bend light that passes through the solution. It is 
intimately related to the extinction coefficient and can be computed with ease 
together with the extinction coefficient to give the complex refractive index. 
2.3.1.4 Light obscuration 
 As previously mentioned, current guidelines state that aggregation should be 
measured using the light obscuration technique. The method is described in the 
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European pharmacopoeia methods 2.9.19 (PE, 2008) and the US pharmacopoeia 
(USP) <788> (USP, 2008). 
 The opalescent properties of the colloidal protein solution are used to give a 
measure of the solution’s turbidity. The method looks at the reduction of light 
intensity due to reflection adsorption and scattering as a particle crosses an incident 
laser beam. This optical measurement is normally taken at around the 350nm 
wavelength. The decrease in light intensity is proportional to the particle size, so if 
the particle is spherical a particle size distribution may be given. 
2.3.1.5 Fluorescent dyes 
 Fluorescence has long been used to detect biological molecules and cells 
(Petushkov et al., 1996, De Foresta et al., 1996). It has not classically been used to 
detect aggregation in protein solution but recently dyes that begin to fluoresce when 
aggregates are present have begun to appear on the market including Proteo-stat®, 
Nile red and Thioflavin T (Hawe et al., 2008, Filipe et al., 2009). The fluorescence 
intensity of these dyes can be correlated to the concentration of aggregate present 
in the sample. 
2.3.2 Particle sizing of aggregates 
 Techniques to determine the molecules in solution are often unable to give a 
reliable result without separating out the components of the solution before testing. 
Many techniques have been developed for the purpose of separating protein 
aggregates and most can be used with the multiple online detectors in series 
‘behind’ the technique. 
2.3.2.1 Asymmetric field flow fractionation 
 Asymmetric field flow fractionation (AFFF) is a powerful analytical technique where 
a sample pulse is made to flow into a perpendicular stream which possess an 
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asymmetrical flow pattern that separates the pulse’s constituents based on their 
molar mass and size. The principle is shown in figure 2-3. Using the technique it is 
possible to calculate the diffusion coefficient and the hydrodynamic size from the 
retention time. It is also possible to use the information to elucidate the structure and 
conformation of the particle. 
 The flow pattern is produced due to two factors. Firstly, the retardation effect of the 
walls of the second stream and the filter on the wall opposite the incoming pulse. 
Secondly, by the shape of the second pipe itself. There is no pre-treatment of the 
sample required and material can be separated over a large range with high 
resolution.  
 
Figure ‎2-3:  Diagram of AFFF fluid velocities and sample injection point. 
 
 The traditional difficulty with AFFF is that the technique is too versatile and so there 
is no simple way of choosing a sub-technique or the experimental variables, which 
include the field type, instrument configuration, channel structure, operating mode 
and experimental conditions. Accordingly, a good understanding of the mechanism 
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of operation and a high level of experience is needed to apply the principles to a 
new process. 
 There are two main sub-techniques which would be applicable to antibodies and 
their aggregates. For the monomers and smaller aggregates, there would be a 
normal mode of operation where the smaller particles would elute first. For particles 
larger than 1μm, steric mode would be used and the larger particles would elute 
first. Around the 1 µm size, a mixed mode separation may also need to be used. 
 For antibody separation, aqueous solutions such as PBS buffer would typically be 
used, with a pH and ionic strength to match the sample solution. Samples would be 
loaded in the solution at concentrations from 0.01-10mg/ml to give sample sizes of 
10μL. Ceramic frits would be used at the inlet and outlets of the system with 
possible detectors including UV, DLS or fluorescence to determine protein size. 
Samples with well known diffusion coefficients or hydrodynamic diameters can be 
used as standards to calibrate the system before use. 
2.3.2.2 Analytical ultracentrifugation 
 
Figure ‎2-4: Diagram of modes of action for sediment velocity and sediment 
equilibrium modes of AUC. 
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 Analytical ultracentrifugation (AUC) is a very powerful technique that involves the 
use of gravitational effects to determine mass (Liu et al., 2006). The process has a 
lengthy run time, requires highly specialised operators and is expensive, but its use 
is becoming increasingly more widespread as a technique. Reasons for the 
increased employment of this technique include the possibility of little sample 
preparation, not having to compare results to any standards and the size range 
achievable, which is from 1 kDa to over 1 gDa.  
 The concept of operation is that of a centrifuge with an optical system synchronised 
to the rotation of the sample. Samples need to have optical densities between 0.1-
1.5 to allow the optical system to detect the aggregates. The peptide backbones can 
be characterised by analysis at the 230nm wavelength. 
 A concentration dependent analysis of the behaviour of the molecule of interest 
gives an information rich dataset which is effective for characterising the solution 
properties of the proteins. For this reason it is common to use at least three different 
concentrations of sample with the widest range. 
 There are two main modes of operation with this equipment shown in figure 2-4: 
 
Sedimentation Velocity 
 High centrifugal forces are used and the sedimentation process times are recorded. 
 Sedimentation velocity can be used to analyse interacting systems and data can be 
collected over a large range of loading concentrations and molar ratios in a wide 
range around the Kd. 
 
Sedimentation Equilibrium 
 Low centrifugal forces are used and the diffusion balances the sediment in an 
equilibrium gradient. 
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 Sedimentation Equilibrium can be performed when there is no change in the 
concentration distribution of any of the components of the solution. The time taken 
to attain results is proportional to the square of the height of the solution column. For 
a molecule of around 200kDa in 100 to 180μL of sample will take between one and 
two days to perform. The information content of the concentration profile significantly 
increases with larger column heights. 
 A lot of analysis is only possible with highly specific software, by fitting 
sedimentation equilibrium data with specific models to determine the binding 
constants 
 The method can distinguish between kinetic dissociation rate constants in the range 
of 10-2 to 10-5 s-1 and affinities in the range of 104 to 108 M-1. The quantities required 
to perform the tests are only between 100 to 400μg of solution. 
 The principle behind the method is that each particle is affected by three forces to 
varying degrees. These forces are gravitational, buoyancy and frictional and the 
balance of these forces will define the behaviour of each species. The definitions of 
these forces are given in equation 2-1. It is important to note that the density effects 
of glycosylation, bound detergents and preferential hydration could all be relevant 
factors in the molecule characterisation (Aziz et al., 2005). 
Equation ‎2-1:  Equations for sedimentation equilibrium mode of AUC. 
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2.3.2.3 Electrospray differential mobility analysis 
 Electrospray differential mobility analysis (EDMA) is a technique that involves the 
electrospraying of aqueous protein solutions to give an aerosolized mass where 
various species are separated according to their electrophoretic mobility using a 
differential mobility analyser (Pease et al., 2008). Conceptually, it is similar to 
electrospray mass spectrometry, with the important difference that its operation at 
atmospheric pressure means that proteins are separated according to their charge 
to aerodynamic size ratio. 
 The Electrosprayed ions pass through a chamber to standardise the charge on 
each droplet to +1, 0 or -1 (Bacher et al., 2001) allowing the effective diameter of the 
particles to be directly determined. Using this method, it is possible to detect 
aggregates from 3 to 250nm with single monomer resolution, thus allowing the 
characterisation of the initial forms of aggregation. Additionally, it is possible to 
distinguish between the IgG’s heavy and light chains after denaturing and cleavage 
of the disulphide bridges (Pease et al., 2008). 
 
2.3.2.4 SDS-PAGE 
 Sodium dodecyl sulphate polyacrylamide gel electrophoresis is a widespread 
technique used in biology to separate out proteins based on a function of their 
molecular weight known as the electrophoretic mobility. 
 The method involves mixing the protein solution to be analysed with SDS and 
heating to 60°C to denature secondary and non disulfide linkage structures then 
applying a negative charge to each protein, proportional to its mass as 
demonstrated in figure 2-5.  
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Figure ‎2-5:  Mechanism of protein unravelling caused by SDS. 
 
 Different anode and cathode buffers are prepared covering the positive and 
negative electrode respectively before the denatured sample proteins are applied to 
the cathode end of the gel with a pipette. Attaching a power source to the electrodes 
will then begin separation of the protein bands by causing the negative charges to 
migrate towards the anode. The proteins will move differentially through the porous 
gel matrix, shown in figure 2-6, based on their size, with smaller proteins able to 
move faster through the gel. 
 The rate of protein movement through the gel is also determined by the voltage 
applied through the gel, with a higher voltage producing a faster movement, but this 
comes at the cost of protein resolution. The voltage is removed after a set amount of 
time, usually a few hours, and the proteins will have been separated roughly 
according to their size. 
 
 
Figure ‎2-6:  Two dimensional representation of the pores available for substrate 
infiltration in a standard polyacrylamide gel. 
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 To view the results, the gels are stained, usually with Coomassie Brilliant Blue R-
250. This shows the separated proteins as distinguishable bands along the gel. 
Molecular markers of known molecular weight are often run in a separate lane in the 
gel to calibrate it and determine the unknown proteins weights (Dunn, 1993).  
2.3.2.5 Size exclusion chromatography 
 The mechanism of separation is dominated by a sieving effect of a complex 3D 
network of beads which hinder the diffusion of the feed into the bead interior (UCL, 
2010). The beads will hinder the components of the solute to varying degrees 
dependent on the size of the components. The smaller the molecule, the more 
complex the route it will take through the chromatography column and therefore the 
longer it will take to exit. Conversely, the larger the molecule, the more it will be 
excluded from the pores and so the faster it will flow through the column. This is 
visually represented in figure 2-7. 
 
 
Figure ‎2-7:  Representation of differential paths available to different sized 
particles in SEC. 
 
 A longer column gives a higher resolution and so a greater separation of the 
aggregates in the feed. The pore size distribution and number of pores of the matrix 
also affects the resolution of the column. 
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 HPLC (High performance Liquid Chromatography) is a specific type of analytical 
chromatography that uses smaller beads and pores to increase the resolution of the 
column. This requires a high pressure pump to push the liquid phase through the 
column and so increases the pressure of the system. To reduce the compression of 
the beads inside the column, very small diameters are used to increase the wall 
support on the column matrix. 
 Insoluble aggregates may be excluded, resolved or modified by the column 
(Rosenberg et al., 2009) and some can have a disproportionate hold time in the 
column because of interactions with the column matrix. This can give false results 
for sizing of aggregates and so chromatography on its own is not advised for 
determining the species. 
 Previous work has been done to characterise eluate from SE-HPLC columns and it 
was determined that a protein complex containing carbohydrates required a method 
involving on-line light-scattering, absorbance and refractive index indicators to 
calculate the Molecular weight and determine the stoichiometry of the molecule 
(Wen, 2008). 
 The method uses a circular argument to find the best fit target molecule within 
multiple assumed stoichiometries that would fit in with the results. To work out the 
molecular weight and stoichiometry of a complex requires the polypeptide extinction 
coefficient but the protein extinction coefficients are usually the only values known.  
The protein extinction coefficients can be used to work out the coefficient for the 
complex that is then used to work out the molecular weight of the complex (Wen, 
2008). 
2.3.2.6 Micro flow imaging 
 Micro flow imaging (MFI) is an imaging technology that has recently been applied to 
detecting and measuring sub-visible and visible particulate matter in protein 
containing solutions (Sharma et al., 2007). The technique captures digital images of 
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particles suspended in a feed as it flows by a digital camera, allowing different sub-
populations within this feed to be counted and archived using different adjustable 
criteria.  
 The software can then create a database of particles and the results can be used to 
create particle distributions and to isolate particle subpopulations. 
 The strengths of this technique are the impressive ranges of operation. It can detect 
concentrations ranging from 5 to 800,000 parts per mL, at volumes between 0.5 to 
300 μL, operating at a rate of processing 200 μL per minute. MFI also allows the 
user to check for any non-conforming particles or any precipitations or dissolutions 
in the sample. The particle size range detectable by MFI is also considerable, 
ranging from 0.75 μm to 100 μm (Huang et al., 2009). 
 This means that the method is able to measure particles both in the visible and sub 
visible size ranges using a limited quantity of material with a reasonable level of 
throughput. 
 Unlike light obscuration, MFI is able to give accurate size readings for non spherical 
protein particles, as well as particles that possess a refractive index similar to their 
solvent (Huang et al., 2009). 
 This allows the accurate and reproducible detection and quantification of protein 
particles to monitor characteristics including shape, size and opacity, which could 
provide a basis for understanding the nature of particle formation. 
 To summarise, MFI offers the advantages of manual microscopy with the benefit of 
higher sensitivity, automation, broad size ranges and low sample requirements. 
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2.3.2.7 Nano-particle tracking 
 
Figure ‎2-8:  Diagram of hardware used in Nanosight analysis. 
 
 The Nanosight is a nano particle tracking system developed by Nanosight Ltd to 
allow the direct visualisation of individual nanoscale particles in suspension to give 
immediate, independent, quantitative estimations for particle size (hydrodynamic 
diameter), size distribution and concentration. 
Top view
Side View
 
Figure ‎2-9:  Mode of action of Nanosight technique. 
 
 The technique uses a finely focused 635nm laser beam and a prism edged optical 
flat to refract the beam onto a liquid layer above the prism. Compression of the 
beam gives a low profile intense illumination which is visualised using a 20 times 
magnification microscope objective and CCD camera operating at 30 
frames/second, as shown in figure 2-8. This camera tracks the Brownian motion of 
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the nanoparticles, separately visualising and tracking each particle and analysing its 
properties as shown in figure 2-9. This can give quick results for poly-disperse 
heterogeneous samples with experiments showing that the diameter readings are 
more accurate than DLS and MALS at multiple concentrations (Nanosight, 2009). 
2.3.3 Determining morphology of aggregates 
2.3.3.1 Circular dichroism  
 Circular Dichroism (CD) gives a measure of the difference in absorbance between 
left and right handed circularly polarised light in the far UV spectrum usually using a 
xenon source. CD spectrometers can record this difference as a function of the 
wavelength, temperature and chemical environment, to give absorption bands of 
chiral molecules. The light is rotated around its propagation direction to give a left or 
right handed helix, which causes a displacement of charge upon interaction with a 
molecule. The two oppositely chiral beams will react differently with chiral molecules 
allowing the difference to be measured  
 The spectra are useful for characterising the secondary and tertiary structure of the 
molecule and for determining the structural family to which it belongs. This allows 
the comparison of proteins from different expression systems or the study of the 
conformational stability of the protein under different stresses or conditions. 
 Far UV spectra (<250nm) give the secondary structure protein characteristics and 
can be used to estimate the fractions of the molecule that are in the different 
conformations. Near UV spectra (250-300nm) provide information on the tertiary 
structure of the molecule, although the traces cannot readily be assigned to 
particular 3D structures. 
 Issues with use of the system for biological applications involve the use of buffer 
solutions. Typical buffers such as phosphate, acetate and carbonate differentially 
absorb the beams making them incompatible unless extremely dilute. The system is 
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also less specific than comparable crystallography or spectroscopy methods, which 
can give more information such as atomic resolution data. CD is however a quick, 
low sample requiring, low data processing method that can be used on experiments 
involving large numbers of variables (Fasman, 1996).  
2.3.3.2 Spectroscopy 
 Spectroscopy is the use of electromagnetic radiation to measure a quantity as a 
function of wavelength. The results are usually in the form of a spectrum of the 
response of the quantity at varying wavelengths and show an average of the entire 
molecular population. 
 Nuclear magnetic resonance imaging utilises the fact that an atom will absorb 
electromagnetic fields and radiate the energy back out at specific frequencies 
dependent on the strength of the field and the atom. The method analyses the 
magnetic properties of atomic nuclei, such as hydrogen, to determine different local 
environments. This can be used to help elucidate the compound’s structure. 
Absorbance spectroscopy works on the basis that different material will absorb light 
at different wavelengths to varying degrees and this can be quantified by measuring 
the transmission. 
 Simple forms of spectroscopy like near infrared spectroscopy shine monochromatic 
light through a sample and measure the transmission and then repeat for each 
different wavelength. This near infrared range can be used for biochemical testing 
and is often employed for particle sizing. 
 Similar but complementary information is provided by Raman spectroscopy, which 
relies on inelastic light scattering to shift the energy levels of laser light. This method 
can be used to determine changes in the secondary structure or hydrophilic 
exposure of any side-chains. It is also able to identify reversible and non-reversible 
changes by determining the presence of more disordered structures common in 
unfolded proteins (Chen et al., 1974). 
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 A detailed study into using ultraviolet Raman spectroscopy (Lednev et al., 2009) 
reports that the method is capable of detecting structural intermediates at early 
stages of fibrillation and determining their sequential order using 2D correctional 
analysis. The same report states that since the method does not require isotope 
labelling, it can be used for comparative characterisation of β-sheet structure in 
fibrils made from fragmented or full proteins and the real time kinetics of formation 
can be monitored.  
 Fourier transform spectroscopy is a more developed method to get the same 
information and involves passing a beam containing multiple frequencies through 
the sample and measuring how much of the beam is absorbed before changing the 
composition of the frequencies and repeating. After many repetitions the data is 
computer analysed to infer the absorption at each wavelength (Hammes, 2005).  
 Finally, there is mass spectrometry which uses the principles of ionization of 
chemical compounds to generate charged molecules that can have their mass to 
charge ratio measured. A promising mass spectroscopy method for biological 
analysis is matrix assisted laser desorption ionisation (MALDI) imaging. In MALDI 
analysis the sample is mixed with a matrix and placed on a metal surface. When the 
UV laser is fired at the matrix it is excited and charge-transfer moves the mix into the 
gas phase. This gas phase is then accelerated and detected (Bruggeman, 2010).  
2.3.4 Assessing aggregation propensity 
2.3.4.1 Self interaction chromatography 
 Self interaction chromatography (SIC) is a relatively unrefined technique to 
determine the Osmotic second viral coefficient (B22) of antibodies. The antibody of 
interest is covalently immobilised on chromatographic particles and packed into a 
column before the same antibody is passed through the column. The retention time 
reflects the average protein interactions between free and immobilised protein. This 
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can then be linked to B22 by using the potential of mean force and is comparable to 
the results given by classical techniques (Tessier and Lenhoff, 2003).  
 In terms of sample volumes, the technique is currently capable of giving results 
from less than 2.5mg of protein at concentrations of up to 20mg/ml and each run is 
much faster than SLS. 
2.3.4.2 Self-interaction nanoparticle spectroscopy 
 
Figure ‎2-10: Diagram of SINS mode of action. 
 
 Self-interaction nanoparticle spectroscopy (SINS) is another technique to determine 
the B22 of a protein-protein interaction. The advantage of this method is an ability to 
characterise protein solutions in a parallel format for high-throughput screening. The 
method is rather new and suffers from a poor affinity of the proteins to adsorb to the 
nanoparticle surfaces, which complicates the analysis of the self-association 
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behaviour. Recent work however has been performed with a highly specific 
approach to coating the nano-particles with proteins, shown in figure 2-10, using 
biotin-avidin interactions to generate protein-nanoparticle conjugates that report 
protein self-interactions through changes in their optical properties (Bengali and 
Tessier, 2009). 
 The SINS method is based on the separation-dependent optical properties of gold 
nanoparticles which are utilized for characterising protein self-association. The 
surface Plasmon mode shifts to larger wavelengths as the interparticle distance 
between nanoparticles is decreased. Since B22 is based on the preferred separation 
distances of proteins, the Plasmon mode shift will be inversely correlated with it 
(Bengali and Tessier, 2009). 
 Using the method it is possible to perform 96 or 384 measurements in less than a 
minute using a standard plate reader and each sample requires less than a 
microgram of protein. However, the method is less quantitative than SLS or SIC. 
Currently, it is not possible to calculate the value of B22 from SINS with those 
conducting the research positing that the contribution of the particle size to the 
Plasmon shift needs to be separated from the contribution of the intermolecular 
protein interactions (Bengali and Tessier, 2009). 
2.3.4.3 Interfacial shear device 
 
 The interfacial shear device method was developed at UCL where a previous EngD 
student used a custom made rig to produce a controlled shear environment using a 
spinning disc inside a 7ml thermally regulated chamber (Biddlecombe et al., 2007, 
Biddlecombe et al., 2009). 
 The device gives a measure of the relative stability of a protein by subjecting it to 
the environment of the spinning disc. It is shown that it is the adsorption of the 
proteins to the surface of the disc and subsequent removal that causes the proteins 
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to aggregate. The high shear environment present does not directly cause the 
aggregation of the proteins, but does contribute to the process by changing their 
conformation, providing good mixing, and helping to disengage proteins from the 
disc surface.  
 
Figure ‎2-11: Diagram of previously described shear device used in work by J. 
Biddlecombe at UCL. 
 
To get a measureable output, 0.1ml samples are removed from the chamber at 15 
minute intervals using positive displacement. These samples are analysed using 
SE-HPLC to look at the level of monomer determined compared to the level in the 
sample at time=0. By taking samples for 2 hours, the relative monomer loss can be 
correlated over the operational period using the formula for an exponential decay 
curve: 
C(t) = C0e
-kt 
 
 Where C(t) is the monomer concentration (mg/ml) at time t (h), C0 is monomer 
concentration at time zero and k is the protein decay coefficient (PDC) (h-1). The 
PDC can then be used as a comparator between different antibodies at set 
conditions to give a measure of relative stability. 
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2.3.4.4 Computational modelling of aggregation propensity 
 
Figure ‎2-12: Image of a fucosylated IgG1 Fc region as a molecular model. 
 
 As technology advances, new methods are always being developed to help 
determine protein stability. With the huge strides forward in computer science, the 
ability to use computers to determine protein stability has become more 
sophisticated. What had begun with trying to fold proteins from a known sequence in 
the correct way (Sali and Blundell, 1993), had been developed to incorporate 
homology modelling from crystallographic data (Pearlstein et al., 2003) and a series 
of steps to give a better result for modelling the antibody shape (Combet et al., 
2002).  
 Further advances in the field meant the models were able to look at electrostatic 
and hydrophobic properties of protein surfaces (Chennamsetty et al., 2009a, 
Chennamsetty et al., 2009b). These models could now be used to predict the effect 
of mutations (Oganesyan et al., 2009, Oganesyan et al., 2008, Chennamsetty et al., 
2010) and the effect of glycosylation (Kayser et al., 2011) on the stability of the 
antibody.  
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Figure ‎2-13: Surface charge distribution on an IgG1 Fc molecular model. 
 
 Surface charge distributions have been utilized for some time, which break down 
the surface charge to positive, negative or neutral, as shown in figure 2-13. 
However, Spatial Aggregation Propensity (SAP) has become the preferred method 
for comparing the stabilities of antibodies as it allows various sites of aggregation 
propensity to be chosen and analysed in isolation (Agrawal et al., 2011) as shown in 
figure 2-14.  
 
Figure ‎2-14: Hydrophobic surface distribution from SAP analysis on an IgG1 Fc 
molecular model. 
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2.4 Factors affecting protein aggregation 
2.4.1 Aggregation factors 
2.4.1.1 Overview 
 To be able to halt protein aggregation there must be an understanding of the factors 
causing the aggregation to occur in the first place. Many studies have gone into 
determining the causes of aggregation of proteins and although there are still no 
definitive laws which have been set for the process, there are many trends that can 
be seen in the aggregation of many antibodies. 
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Figure ‎2-15: Diagram of monoclonal antibody regions. 
 
 In general, conditions that alter the proteins chemical and physical stability result in 
denaturation, precipitation, adsorption or aggregation (Pease et al., 2008, Mahler et 
al., 2005) in bioprocessing. 
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 It has been shown in contrast to model proteins, that antibody stability is not 
necessarily dependent on protein concentration, buffer concentration, salt 
concentration or agitation, suggesting the mechanism of aggregation is counter 
intuitive and unlike other proteins (Perico et al., 2009). 
 Denatured protein shows a failure of the protein’s tertiary and secondary structures 
and the transition to a denatured state can be direct or can pass through many other 
intermediary states. Once in this denatured state, aggregation comes into 
competition with refolding to the native protein structure depending on the level of 
unfolding it has been exposed to (Mahler et al., 2005). If the protein has been fully 
unfolded the refolding may result in non reactive molecules when refolded. The 
aggregation pathway leads first to soluble particles and then to insoluble 
macroscopic aggregates. However it has been reported that small sized reversible 
aggregates are more stable and resistant to aggregation than monomers (Sluzky et 
al., 1991). 
 Studies have looked into the use of spatial aggregation propensities (SAP) to 
predict the aggregation prone motifs and regions within monoclonal antibodies 
(Chennamsetty et al., 2009a). In these studies it was found that IgG1 has more 
aggregation prone motifs in the Fc fragment compared to the constant region of the 
Fab fragment. The highest concentration of these motifs was found around the lower 
hinge region close to the Fc. The motifs found were almost exclusively within the 
loop and hinge regions connecting the domains and very rarely within the β-sheet 
regions. Further work confirmed that antibodies within the IgG subclass have similar 
aggregation prone motifs. 
 It is accepted that aggregation occurs due to factors effecting protein stability during 
production, storage, shipping and handling. These factors can include Temperature 
pH co-solvents, surfactants, stabilizers, hydrophobic interfaces or surfaces (Mahler 
et al., 2005). Some proteins need to create an intermediate before aggregating, 
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which gives a lag time in aggregate formation (Sluzky et al., 1991), a phenomenon 
that will be discussed later. 
 It has previously been suggested that there is a need to investigate the protein 
conformations in aggregates (Carpenter et al., 2009) and that molecules absorbed 
to aggregates had been shown to be able to retain their native conformations.  
 As previously mentioned, cleavage sites for mAbs are located predominately in the 
hinge region of the heavy chain. It has been observed that the nature of this site 
specific fragmentation is driven by molecular kinetics from clipping of the antibody 
structure leading to a net increase in aggregation at elevated temperatures (Perico 
et al., 2009) and therefore not by protease contaminants. The same study found that 
this heterogeneity affected the overall conformation and flexibility of the antibody. 
2.4.1.2 Hydrophobic interactions 
 Hydrophobic interactions are important in the aggregation of proteins. This 
importance has been proved in experiments where mutations were engineered in 
proteins to reduce hydrophobic regions, leading to an increase in the stability of the 
proteins (Chennamsetty et al., 2009b). Aggregate formation can be initiated by the 
intermolecular interaction of hydrophobic regions of at least two unfolded or partially 
unfolded denatured protein molecules (Mahler et al., 2005). 
 The molecular hydration properties near the surface of the protein are determined 
by the amino acid composition (Gekko and Timasheff, 1981). An increase in the 
hydrophobic interface with the protein will cause faster aggregation, further 
facilitated by a simultaneous increase in agitation rate (Sluzky et al., 1991). In 
certain proteins it has been observed that the molecule is destabilised by adsorption 
at hydrophobic interfaces creating small intermediate aggregates (Thurow and 
Geisen, 1984). This adsorption of proteins to hydrophobic surfaces and air water 
interfaces involves the accumulation of denatured molecules at the surface in 
question, fostering aggregation processes (Mahler et al., 2005). These intermediate 
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species of denatured proteins then help facilitate further aggregation (Sluzky et al., 
1991). 
 The introduction of agitation to a system with hydrophobic surfaces dramatically 
increases the air-water interface and unlike with static storage, continuously 
refreshes the surface available for reaction (Fesinmeyer et al., 2009). 
2.4.1.3 Mechanical stress 
 Mechanical stress generates a shear in the solution. The solution shear stress 
magnitude is given by the formula in equation 2-2. From the formula it is possible to 
see that the composition of the solution has a high effect on the magnitude of the 
shear stress. The dynamic viscosity of glycerol, for example, is 430 times greater 
than that of water, giving much higher shear stresses in more organic solutions. In 
general the maximum shear rate evolved in normal processing is around 20,000 s-1 
(Bee et al., 2009). This mechanical stress can be generated by pumping, filtration, 
mixing, fill finishing, shipping or shaking (Mahler et al., 2005).  
 
Equation ‎2-2: Equation for shear stress magnitude. 
 
 
 It is important to note that shear alone does not appear to cause the formation of 
large aggregates in mixing, but causes protein unfolding which could lead to 
aggregation. In experiments done on the response of concentrated mAb’s to high 
shear rates in a stainless steel rheometer (Bee et al., 2009), it was observed that 
prolonged exposure to shear causes minor reversible aggregation as described on 
page 28. Previously in the same study, monomeric mAb showed no aggregation 
after 30-51ms exposures to shears of up to 250,000s-1 and after 300s at 20,000s-1 
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the mAb only gave reversible aggregates in the 40 to 60 unit range. A second 
sample with an aggregation population of 17% was not significantly altered by the 
shear rates. 
 In the same study it was observed that shear has a lower effect than air water 
interfaces and adsorption to solid surfaces, which could arise from contamination by 
particulates or pump cavitation stresses. However the shear induced desorption 
could act together with surface adsorption to give greater levels of aggregation. 
Finally it was noted that this cavitation-induced protein damage may be exacerbated 
if solutions are degassed by filtration immediately before pumping. This is because 
the degassing creates a large liquid-air interface that causes partial denaturation of 
proteins at the interface. 
 A further study showed that different types and levels of aggregation were produced 
if a solution was stirred or if it was shaken (Kiese et al., 2008). It was found that 
shaking produced lower levels of aggregation than stirring. It is suggested that shear 
may only cause minor conformational changes to the native structure as 
demonstrated by 16 hours of shear at a rate of  100,000 s-1 (Maa and Hsu, 1996). 
This can also be reversible as seen with the unfolding of lysosyme, refolding 
occurred soon after flow was stopped (Ashton et al., 2009). 
 A major contribution of mechanical agitation to aggregation in a bioprocess is that 
the protein aggregation rate is dependent upon collisions. The greater the agitation 
rate, the more evenly distributed the protein molecules are in the solution, meaning 
a higher chance of collisions and therefore a higher aggregation rate (Kiese et al., 
2008). Related to this effect, it was shown that temperature will affect samples 
differently depending on the agitation regime the protein solution is exposed to 
(Kiese et al., 2008). 
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2.4.1.4 Protein concentration 
 The effect of concentration on protein stability has some cases where it is 
exceptional. In a study on insulin stability (Sluzky et al., 1991), it was found that 
stability was enhanced at higher concentrations. Insulin’s self-interaction into more 
stable dimers and trimers was disrupted by dilution. 
 A review of protein concentration during storage conditions reports that increasing 
protein concentrations enhance the formation of protein aggregates for many 
proteins (Mahler et al., 2009). In this study it was found that formation of aggregates 
occurs by, at minimum, a bimolecular reaction, and so the reaction is concentration 
dependent.  
 It has been shown that an increase in protein concentration causes an increase in 
aggregate size for B-lactoglobulin (Roefs and De Kruif, 1994). This study showed 
that in general the controlling factor of aggregation is kinetics and that the 
aggregation rate is proportional to the protein concentration. 
2.4.1.5 Surfactants and additives 
 During unit operations on a manufacturing scale, it is common to add non-ionic 
surfactants to protein solutions. These amphiphilic molecules tend to position 
themselves to minimize the exposure of the hydrophobic domain of the molecule 
and help prevent unwanted adsorption and aggregation at interfaces by limiting the 
extent of protein adsorption to the surface.  
 Surfactants behave like other co-solutes by differentially binding to both the native 
and non-native state of the protein, which will affect the conformational stability of 
the protein. The most common effect of the preferential binding results in an 
increase in non-native protein stability (Chi et al., 2003), but the surfactants still 
inhibit protein interactions at interfaces. For example polysorbate 80 has been used 
to prevent aggregation of proteins (Jones LaToya et al., 1997). 
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 Surfactants have been shown to act as chemical chaperones, increasing the rates 
of protein refolding, helping to reduce aggregation (Jones LaToya et al., 1997, Bam 
et al., 1996). This was shown to be due to a stabilisation of the proteins native state 
(Timasheff, 1993). It is suggested that the surfactant molecules could interact with 
the exposed hydrophobic regions of the protein and therefore cover such sites that 
cause aggregation (Kiese et al., 2008). 
2.4.1.6 Temperature 
 Native protein conformations only have marginal thermodynamic stabilities, with 
average stabilities only 5-20 Kcal/mol greater in free energy than unfolded proteins 
(Chi et al., 2003). This free energy comes from many interactions, forces and 
intrinsic properties, but because of the low conformational stability of the native 
state, relatively small changes in temperature can destabilise the protein structure 
and cause denaturation. In addition, this stability in terms of temperature is 
characterised by a parabolic profile meaning that moving to a too high or too low 
temperature can cause conformational change. 
 Incubation of protein solutions at high temperatures leads to physical degradation 
by promoting chemical reactions including oxidation and deamidation, and by 
directly affecting the conformation of the polypeptide chain structure on secondary, 
tertiary and quaternary levels (Fesinmeyer et al., 2009). 
 This degradation becomes reversible by aggregation of the modified proteins. The 
stability of proteins against heat is measured by the melting temperature (Tm) 
(Wang, 1999), which is the temperature at which 50% of the protein molecules are 
unfolded. This value is between 40˚C and 50˚C but in general proteins are stored 
well below this temperature at around 2˚C to 8˚C (Mahler et al., 2009). 
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 Protein aggregation is usually observed at temperatures well below the melting 
temperature (Dong et al., 1995), adding evidence to the idea that aggregation does 
not occur from fully unfolded protein molecules.  
 It has been shown in lysosyme that brief temperature denaturation under 75˚C is 
reversible, with refolding occurring within 20 seconds of the flow stopping (Ashton et 
al., 2009). 
 Temperature has been used to perform accelerated stability studies on protein 
aggregation using high temperatures such as 40˚C to gain stability data in 
comparably short times. This inherent assumption about the utility of the accelerated 
data is questioned by many sources (Perico et al., 2009, Mahler et al., 2009).  
 It was found in a study involving capillary electrophoresis and matrix assisted laser 
desorption/ionisation (MALDI) mass spectrometry that there was site specific 
fragmentation of peptide backbones and disulphide bond linkages (Perico et al., 
2009). This study found trends at 4°C and 29°C involving pH dependence and 
concentration dependence on the level of protein “clipping” and aggregation, and 
showed a reversal in most of the trends at 37°C. This all showed that accelerated 
data at high temperatures was not indicative of long term stability at temperatures 
used to store proteins. 
2.4.1.7 Salts and ions 
 Ions have complex effects on the physical stability of proteins by modifying the 
conformational stability, equilibrium solubility and the rate of formation of 
aggregates. 
 The ability of ions to alter protein conformational stability and solubility can be 
ranked with the use of the Hofmeister series. Chaotropes have a low charge density 
and are able to increase protein solubility and decrease conformational stability at 
moderate to high salt concentrations (greater than 0.3M) by pairing with each other 
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to allow a greater number of water-water interactions. Kosmotropic agents have a 
high charge density and are able to form more favourable electrostatic interactions 
with other small ions, so have the opposite effect (Fesinmeyer et al., 2009). 
 Molar concentrations can be used to promote protein denaturation and 
crystallisation and to modulate protein-protein interactions. There are two competing 
theories for these effects. One involves the ions affecting protein solubility and 
stability through changes in the bulk water structure. The more predominant theory 
is that the ions interact directly with the protein (Fesinmeyer et al., 2009). At lower 
concentrations however, charge neutralisation can have a critical effect on the 
proteins stability and solubility, allowing small concentrations of kosmotrophic ions to 
solubilise proteins, using charge shielding to reduce the energetic favourability of 
protein-protein interactions. 
 Salts bind to proteins by ion interactions with unpaired charged side chains on the 
protein surface. Binding multivalent ions to the side chains can lead to cross linkage 
of charged residues on the protein surface which can lead to stabilisation of the 
native protein state if the ions bind more strongly to it than to the non-native state 
(Chi et al., 2003). 
 Salts alter the strength of electrostatic interactions between charged groups both 
within the protein molecules and between them. So intramolecular charge 
interactions affect conformational stability, and intermolecular forces effect the 
equilibrium and rate of aggregate formation (Chi et al., 2003).   
 Buffering salts can be added to solutions to maintain a desired pH and non-
buffering salts can be used to make the solution more isotonic or reduce the 
viscosity (Fesinmeyer et al., 2009). Whereas some other salts can carry over from 
chromatography purification steps and potentially effect stability in final dosage. 
 In a study of the impact of ion strength and density on the effect of agitation and 
heat on protein aggregation, the propensity for both agitation and heat induced 
aggregation increases as the charge density of the anion decreases. There was a 
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dependence of the measured melting temperature on the anion but not on the cation 
(Fesinmeyer et al., 2009). 
 It has been noted that the effect of the anionic species follows the ranking of the 
Hoffmeister series and is much greater than that of the cationic molecules (Arosio et 
al., 2012).  By supercharging these molecules it was found that the maximum 
charge states of protonated ions formed from native solutions is greater than those 
obtained from conventional denaturing solutions consisting of water, methanol or 
acid. The trend of increased charge state runs the opposite direction from the 
Hoffmeister series (Cassou and Williams, 2014). 
 Finally, because the pH determines the charge size and location on the proteins, 
salt binding effects can be strongly pH dependent. 
2.4.1.8 pH 
 Changes in pH have a strong influence on the aggregation rate as the pH 
determines the electrostatic interactions through charge size and distribution on the 
protein surface (Chi et al., 2003).  
 The conformational stabilities of antibodies have been shown to be highly 
dependent on pH (Perico et al., 2009). As the number of charged groups on the 
protein is increased by modification of the pH, there is destabilisation of a protein’s 
folded conformation due to increased charge repulsion. 
 Under acidic conditions protein cleavage may occur, whereas under neutral to 
alkaline conditions, deamidation and oxidation are favoured (Mahler et al., 2009). So 
pH induced unfolding gives a lower electrostatic free energy. There is also however 
the chance of salt bridge formation or ion pairing which could help stabilise the 
protein.  
 The overall modification of charge is dependent on the protein primary sequence 
and the protein structure. It affects protein aggregation differently in different buffer 
systems with equivalent pHs (Kameoka et al., 2007). 
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 In general it is found that antibodies are most stable against aggregation at pH 4.5-
5.5 and that aggregation increases dramatically both outside this range and near 
neutral pH, or the isoelectric point (pI) (Szenczi et al., 2006). This occurrence at pI is 
due to protein groups possessing both positive and negative charges giving 
distributions across the protein surface, leading to dipole formation. In these 
circumstances, protein-protein interactions could be highly favourable and drive 
aggregation (Chi et al., 2003). 
2.4.1.9 Freeze thawing 
 Freeze thawing is a stress that therapeutic proteins are commonly exposed to 
during the life cycle of a product, both to store it and to analyse it. The low 
temperature causes a change in the pH of the solution due to buffer crystallisation 
and exposes the protein molecules to ice-liquid interfaces. These forces disturb the 
protein and cause protein aggregation. 
 The freezing will also induce localised increases in salt concentration, which will 
reduce intermolecular repulsion between protein molecules through increased 
charge shielding, creating more favourable conditions for aggregation (Kueltzo et al., 
2008).  
Increases in the initial concentration of proteins have often given a reduction in the 
percentage of protein aggregating in solution. It has been suggested in a study 
(Kueltzo et al., 2008) that this is due to a reduction in the fraction of protein exposed 
to the ice liquid interface. This effect can be controlled by the warming and cooling 
rates used, with a faster cooling rate resulting in larger numbers of smaller ice 
crystals and therefore more protein damage. A similar effect was observed with the 
container material and geometry, where adsorption to the container was shown to 
be a source of product loss by using different containers for storage. 
 The same report suggested that pH and ionic strength are amongst the most critical 
factors affecting the magnitude and the nature of the freezing induced stresses. 
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Using derivative absorbance spectra of the model IgG2 used, five major peaks were 
identified. By tracking the shifts in these peaks it was possible to gain insight as to 
the proteins tertiary structure. It was shown that the protein conformation was 
relatively insensitive to pH changes in range of pH 4-8, but that there was a large 
shift in the peak position both a pH 2 and at pH 10-12. Analysis of aggregates 
produced at pH 3, 4 or 5 found them to be irreversible. 
2.4.1.10 Osmotic second virial coefficient 
 The osmotic second virial coefficient (B22) is a thermodynamic measure of protein-
protein interactions to the dissociation constant for weak protein interactions. A 
positive value for B22 represents repulsion, while negative represents attraction 
(Tessier and Lenhoff, 2003). 
Equation ‎2-3: Osmotic virial expansion. 
 
 
 
 
 
 
 
 
 
 Techniques to measure B22 include measuring the osmotic pressure of protein 
solutions. However this has problems with experimental complications and low 
throughput. The most common method is static light scattering (SLS) but this 
approach has limitations in terms of throughput, protein consumption and the pre-
disposition of the method to pick up larger particles, such as aggregates, much more 
preferentially (Bengali and Tessier, 2009). Other methods include self-interaction 
chromatography and self-interaction Nanoparticle spectroscopy, which have been 
previously described in this document. 
 
   π   = 1 + B22 . c + … 
c R T    
 
π –  Osmotic pressure 
c  –  Protein concentration 
R  –  Gas constant 
T  –  Absolute temperature 
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2.4.2 Factors in bioprocessing 
2.4.2.1 Filtration operations 
 Filtration membranes are used throughout the purification chain in bioprocessing to 
remove impurities, perform buffer exchange and decrease the volume of feed during 
downstream processing. This is done in order to decrease the handling and storage 
costs of the processes and thus allow for smaller unit operations or larger product 
throughputs. 
 Ultrafiltration/Diafiltration is typically used in buffer exchange and protein 
concentration. During UF, proteins face pumping, flow induced shear stress, 
extensive contact to membrane surfaces and exposure to air-liquid interfaces which 
produce small aggregations of proteins in a state that is a precursor for larger 
aggregation (Rosenberg et al., 2009). 
 Additionally, there are extremely high concentrations in the gel and polarization 
boundary layer near the membrane (Cromwell et al., 2006) and aggregation at this 
point is partly responsible for membrane fouling. It was reported that pore blockage 
in microfiltration is directly related to the concentration of the protein aggregate in 
the solution (Palacio et al., 2002). 
 
Figure ‎2-16: Diagram of mode of action of diafiltration of antibodies. 
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Adsorption to the membrane itself can be a source of aggregation (Bódalo et al., 
2004) and the induction of the aggregates and particles to the membrane increases 
with shear stress, which has a negative effect on the permeate flux. 
 In a study of the effects of shear on globular proteins during ultrafiltration 
(Rosenberg et al., 2009), it was found that constant pressure filtration gives rapid 
loss in flux and increases in the levels of aggregates. To reduce the generation of 
aggregates of different sizes, shear induced transport had to be limited. Decreasing 
the transmembrane pressure during concentration was found to improve the 
permeate flux, decreasing the process time, avoiding aggregation and causing less 
accelerated bed degradation due to fouling. 
Equation ‎2-4: Formula for permeate flux. 
 
 The theory behind this effect is explained in equation 2-4 (Porter, 1972). It is 
obvious that J can be improved by decreasing δ to get a higher trans-membrane 
pressure, but this does not take into account for hydrophobic protein interactions in 
the filter. 
 During tangential flow filtration, the protein is reported to be exposed to shear rates 
of between 1000 and 10,000 s-1 for a couple of seconds per pass over the 
membrane (Bee et al., 2009).  
 Analysis of the residues from membrane operations were analysed (Rosenberg et 
al., 2009) and it was found that membrane absorbed proteins remained in a state 
very close to native state, and the separated insoluble aggregates showed a loss in 
the proportion of their β-sheets. 
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 In addition to the membrane, the protein solution is continually being pumped, with 
a typical membrane operation involving 50 passes through the system, adding 
mechanical stress to the proteins which could further encourage aggregation 
(Cromwell et al., 2006). 
2.4.2.2 Chromatography operations 
 
Figure ‎2-17: Diagram of interaction between chromatography column and antibody. 
 
 Chromatography is a technique used in the downstream processing of therapeutics, 
which can separate substances based on different attributes. For the processing of 
mAbs Protein-A or G affinity chromatography are powerful purification techniques 
that can produce up to and sometimes higher than 95% purities due to high affinities 
for the Fc region of the antibody (Arakawa et al., 2004) of the resin. This high affinity 
requires relatively strong acidic conditions to denature the proteins to allow them to 
elute, as experimentally shown in the lack of elution of any antibody at pH 5.8 
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(Arakawa et al., 2004). Exposure to these conditions can result in the formation of 
aggregates, for example a 25% aggregated material solution from an elution at pH 
3.2 (Cromwell et al., 2006). 
 The electrostatic interaction with affinity chromatography depends critically on the 
distance between the charged atoms. A study performed on the effect of the 
introduction of a histidine at various candidate positions within eight Angstroms of 
the site of protein G interaction with the Fc (Watanabe et al., 2009) shows the pH 
sensitivity can be drastically improved, lowering the required pH change for elution. 
 Another study was performed on the use of Arginine as an eluent (Arakawa et al., 
2004) and the results were then compared with those of the more typically used 
citrate buffer. Arginine does not affect the native protein conformational stability but 
seems to prevent aggregation during refolding, like a chaperone. SE-HPLC tests on 
the eluted fractions indicated that the proteins were mostly monomeric.  
 A possible complication with protein-A has been observed when a histidyl residue in 
the middle of the protein’s protein-A binding faced a complementary histidyl residue 
on the protein A. At low pH, the residues develop positive charges and cause a 
destabilisation of the product structure, leading to greater levels of aggregation than 
with low pH alone (Shukla et al., 2007a). 
 A further factor in the strength of the ligand-Fc bond is the glycosylation of the 
antibody, as it was shown that antibodies with higher mannose oligosaccharides, 
eluted later from a protein-A column and earlier from protein-G (Gaza-Bulseco et al., 
2009). 
 It has been suggested the pH required for elution of the protein from a protein-A 
column should be increased, thereby reducing the level of protein deformation, by 
the addition of various substances to the elution buffer. These additives include 
sodium chloride or hydrophobic competitors (surfactants) such as ethylene glycol 
(Shukla et al., 2007a). 
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 Another type of chromatography sometimes used for monoclonal antibodies is 
Hydrophobic Interaction Chromatography, which also interacts with the hinge region 
of the IgG subclasses. There is variability in the strength of the interaction with 
different subclasses due to their differing hinge regions allowing separation of 
subclasses of proteins. More importantly this suggests the resin interacts more 
strongly with protein complexes the more aggregated they are (Wang and Ghosh, 
2009). 
 Moving on from the columns themselves, the proteins will elute off and be stored in 
protein rich formulation, with concentrations of up to 40g/L possible. This will again 
be a potential source of aggregation. 
2.4.2.3 Pump filling and vialing operations 
 Pump filling is used to transfer the product from the final holding and mixing tank 
into vials for transport before use. There are no filtration or aggregation removal 
steps after pump filling, so it is important not to produce any unwanted aggregates 
at this point. 
 A study performed on the operation (Carpenter et al., 2009) found that during pump 
filling, IgG formed hundreds of thousands of particles per mL in the 1.5 to 3μm size 
range, but critically less than 1000 particles in the 8-15μm ranges. 
 Vial filling is typically performed using a positive displacement pump to inject 
solution into each of the vials. There are two main locations for possible aggregation 
to occur in this operation. The first of these is in the pump used to displace the liquid 
and the second is in the vials themselves. 
 The type of pump can be the reason for any aggregation. It was shown in a study, 
that while a rotary piston pump caused aggregation, the same system with a rolling 
diaphragm pump could be used to stop aggregation (Cromwell et al., 2006). 
Unfortunately this quick fix cannot always be used, usually due to constraints of the 
manufacturing site and previously validated processes. A further study (Tyagi et al., 
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2009) determined that nano particles shed from the surface of the pump in contact 
with the solution acted as heterogeneous nuclei for protein aggregation and particle 
formation. 
 A study was also taken into the vials used to receive the protein solution (Chi et al., 
2005) and it was found that glass nanoparticles left at the bottom of the vials were in 
some cases responsible for heterogeneous nucleation of the protein.  
2.4.2.4 Pumping materials 
 Pumps are required in large scale bioprocessing to ensure the movement of the 
feed from one unit operation to the next. Pumps exert forces on the liquid phase due 
to a changing of internal dimensions from the surrounding pipes and because of 
high piston or rotary velocities. Most fluid in a pump will experience similar orders of 
magnitudes of shear rates as in the adjacent pipes (Bee et al., 2009).  
 Monoclonal antibodies have been found to unfold at shear rates around 10,000 s-1 
(Jaspe and Hagen, 2006), and  the rates evolved in piston and rotary lobe pumps 
are around 20,000s-1. It has been reported however that using a rolling diaphragm 
pump instead of a radial piston pump will reduce the level of aggregation (Bee et al., 
2009). 
 There are two possible factors for the difference in aggregation levels. The first is 
that leaching or fragmentation of metals or polymers could act as particulates to 
catalyse the aggregate formation (Bee et al., 2009). The second and more prevalent 
factor is that cavitation occurs in the pumps and valves as the movement creates 
and destroys microbubbles in the fluid. These bubbles have a large hydrophobic 
surface area that would cause protein to be drawn to them (Narendranathan and 
Dunnill, 1982). During certain unit operations there would be multiple passes 
through pumps and valves, further increasing the level of aggregation. 
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2.5 Aggregate formation 
2.5.1 Introduction to mechanisms 
 The first possible mechanism of protein aggregation was published in 1954 (Lumry 
and Eyring, 1954) when Lumry and Eyring described it as a change in protein 
conformation that led to an altered state of the protein that was then susceptible to 
aggregation. They described the protein unfolding to form an unstable intermediate 
state that is in equilibrium with the native protein structure. This then serves as an 
intermediate leading to an irreversible aggregated state. 
 Since this definition many, further studies have been performed into the area, but to 
a great extent, the findings seem to be case dependent, with most protein 
aggregations dependent on protein concentration, buffer concentration and 
agitation. Antibody stability is not necessarily dependent on these factors, 
suggesting the mechanism is counter intuitive and unlike other proteins (Perico et 
al., 2009). Certain studies have used bioinformatics techniques to try and model the 
locations on the antibody at which adherence to other proteins is likely. One 
particular group (Chennamsetty et al., 2009a) showed the strength of their technique 
of using what they term spatial aggregation propensity (SAP) to predict the 
aggregation prone motifs and regions on the antibodies. These regions with high 
SAP were areas of hydrophobicity on the protein surface. Mutation of the primary 
structure of these areas to make them more hydrophilic resulted in increased 
stability of the tertiary structure, showing that the hydrophobic interactions are 
important for aggregation. 
 Having discussed the causes of aggregation, and the methods available to analyse 
the resulting species, it is time to look at the different forms of aggregation and the 
way in which they are produced. Figure 2-18 shows some of the different ways in 
which we can categorise aggregates.   
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 It would be interesting to show which of these subcategories of aggregates are 
produced with different mechanisms of aggregation and which lie on the same 
aggregation pathways.  
Many studies have been performed on the effect of aggregation on the proteins 
within the multimers to determine their secondary structure. It has been reported in 
some cases (Schule et al., 2007) that a β-sheet structure appears in the secondary 
structure; however it has not yet been confirmed if this change is always related to 
aggregation. 
 In terms of the structures, it is suggested that reversible denaturation occurs due to 
changes in the tertiary structure whereas irreversible changes are changes in the 
secondary structure (Lumry and Eyring, 1954). 
A study on the effect of temperature on the local conformational perturbation of the 
antibodies (Perico et al., 2009) suggested that the structure of the antibody became 
perturbed well below the global thermal unfolding point, and that acidic formulations 
at elevated temperatures underwent clipping that led to higher order aggregates. 
The amount of high molecular weight aggregate generated then depends quite 
strongly on the product concentration (Shukla et al., 2007a). 
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Figure ‎2-18: Possible protein aggregation pathways based on literature. 
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2.5.1.1 Aggregation rates 
 
Equation ‎2-5: Kinetic rate equation. 
 
 
 
 
 
 
 
 
 
 The different possible mechanisms for aggregation produce not only different 
shapes and sizes, but can take different amounts of time, with various stages 
sometimes acting as rate limiting steps. Kinetic mechanisms that have been 
proposed have different rates of reaction and different orders of magnitude, which 
do not have to be whole numbers. The rate equation is shown in equation 2-5 and 
shows the relationship between the reaction rate, the rate coefficient and the 
concentrations and orders of magnitude of the various components. The rate 
equations for multistep mechanisms cannot usually be derived from any 
stoichiometry and require experimental determination.  
 The reaction orders can be determined by the effect the concentration of the 
component has on the rate of reaction. A zero-order constituent’s concentration will 
have no effect on the rate. A first-order reaction depends only on the concentration 
of one of the reactants, so any other reactions occurring will be zero-order. Second 
order reactions can then depend on either one second-order reactant or two first-
order reactants. Second order reactants have half lives which progressively double, 
giving a second-order exponential decay of reactants. 
 Equilibrium reactions are common in aggregation whether this be for protein 
conformation or protein-protein interactions leading to temporary intermediate 
species. In these reactions, a pair of forward and reverse reactions act on a point in 
the reaction and the reaction rate can be expressed as shown in equation 2-6. 
r = k(T) [A]
n’
[B]
m’ 
 
k(T)= Reaction rate coefficient 
[A]=Concentration of component A 
[B}=Concentration of component B 
n’
=Reaction order for A
 
m’
=Reaction order for B
 
 
k 
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External factors can sometimes affect the equilibrium in the favour of a state that 
promotes aggregation which can then allow a sequential reaction to begin the 
production of aggregates. 
Equation ‎2-6: Rate equation for a reversible reaction. 
 
 
 
 
 
 Real world examples can be found in the literature. One paper (Shukla et al., 
2007a) shows that their mAb is highly susceptible to aggregation at low pH and was 
found to have first order kinetics over a wide range of conditions. This study also 
found that elution from the protein-A resin increased the rate constant which would 
be expected with pH degradation alone, suggesting that the protein-A destabilizes 
the product structure and increases the tendency to aggregate. 
 Another paper (Perico et al., 2009) shows a reaction which has greater aggregation 
with increasing pH but with an inversed pH dependence being concentration 
dependent, suggesting a reaction rate-limited by self association. 
2.5.2 Nucleation and fibrillation of aggregates 
 Many aggregation reactions seem to start when aggregation prone monomers 
assemble into fibrils and rapidly elongate via a slower nucleation-dependent 
pathway (Kim et al., 2002). As previously described, the proteins aggregate when 
structurally perturbed intermediary species react with each other to give larger 
assemblies of proteins. Some reports refer to this nucleation as the formation of a 
minimal fibril unit, but they agree that this represents the rate limiting step of the fibril 
formation, with subsequent growth proceeding rapidly via the incorporation of 
monomers into the ends of the nucleated fibrils (Sasahara et al., 2008). 
r = k1 [A]s [B]t – k2 [X]u [Y]v 
r = Reaction rate 
k1 = Forward rate coefficient 
k2 = Backwards rate coefficient 
[C] = Concentration of component 
x = Order of reaction 
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 The nucleation step is relatively poorly characterised, with few experimental 
technique available to allow the direct monitoring of the nucleus formation. In a 
study into the nucleation step on egg lysozyme, it was found that in a parallel 
process mechanism, the sheet and random coil are produced directly from the 
native protein. β-sheet was found to develop from the partially unfolded intermediate 
and the formation of the β-sheet and the partially unfolded intermediate could be 
partially correlated. When followed step by step, a newly formed β-sheet in solution 
could be assigned to the fibrillation nucleus. The independence of characteristic 
times on the protein concentration indicated that the early stages of fibrillation, 
irreversible partial unfolding and nucleus formation were intramolecular processes 
(Lednev et al., 2009). 
 The fibrillar structures that can form are then dependent on a variety of factors, with 
one report showing that β2-m protein can produce a well organised mature, long 
fibril at low ionic strength with a lag phase in aggregate production. At higher salt 
concentrations, rapid formation with no lag phase results in short curved and thin, 
worm like fibrils. The more mature fibrils were more thermodynamically stable than 
the worm like fibrils (Sasahara et al., 2008). 
 One paper states that the assumption that a lag phase in the kinetics always 
represents nucleation is a fallacy and that the end of the lag phase does not always 
correspond to the end of nucleation (Ferrone, 1999).  This same paper goes on to 
explain that although initially imagined to be an abrupt transition, nucleation has a 
curved thermodynamic barrier. The nucleus size is also shown to be dependent on 
the concentration of monomer. 
2.5.3 Reversible self association of proteins 
 Reversible self association (RSA) is a phenomenon that is slowly becoming more 
observed as more exotic and hydrophobic monoclonal antibodies are produced. At 
higher concentrations antibodies come within closer contact of each other and are 
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more likely to interact (Kanai et al., 2008). In these conditions the antibodies in their 
native configuration begin to form loose bonding to each other where they begin to 
form clusters in the solution (Chaudhri, 2012). These clusters have been reported to 
differ in size from 2 units to many more. One known result of RSA is that the 
viscosity of solution is increased (Liu et al., 2005), but in general there is little 
documented about the phenomenon. 
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3 Materials and methods 
3.1 Antibodies utilised in studies 
3.1.1 Medi/UCL001 
 One human monoclonal antibody (IgG1) designated Medi/UCL001 was provided by 
MedImmune (Cambridge, UK) in a state after primary clarification of broth from 
fermentation. The samples provided were taken from 5 days before the normal 
harvest time and then for two days after the time. The concentration of antibody at 
the end of the fermentation was around 2g/L.  
 Buffers used for elution from Protein-A were sodium based. The buffer used for viral 
inactivation was Acetic acid and Tris was used for neutralisation. 
3.1.2 Medi/UCL002 
 One human monoclonal antibody (IgG1) designated Medi/UCL002 was provided by 
MedImmune (Cambridge, UK) in a fully purified state at a concentration of 50mg/ml 
in PBS. This was diluted to a concentration of 0.5mg/ml before experiments. 
3.1.3 Medi/UCL003-008 
 Six lots of human monoclonal antibody were designated, Medi/UCL003, 
Medi/UCL004, Medi/UCL005, Medi/UCL006, Medi/UCL007 and Medi/UCL008. For 
initial experiments purified amounts of these antibodies were supplied by 
MedImmune in stability buffer for testing. These were tested for purity and then 
diluted to 1mg/ml prior to filtration and aliquoting. 
 During the course of the project, more material was needed and so approximately 
30L of fermentation broth of each of the antibodies was produced by the sponsor 
company using their platform process. 
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 The antibodies all had identical variable regions but the Fc region was modified as 
below. The YTE/TM nomenclature is explained in section 3.2: 
Medi/UCL003 & 007 - IgG4 YTE 
Medi/UCL004   - IgG4 
Medi/UCL005  - IgG1 TM YTE 
Medi/UCL006  - IgG1 YTE 
Medi/UCL008  - IgG1 
 The material was then purified using the same protocol in each case. Firstly, the 
antibody was filtered using a 0.45µm pore size membrane prior to purification using 
Protein-A chromatography. Viral Inactivation was then performed, followed by a 
Fractogel polishing chromatography step. Purified material was then formulated 
using UF/DF to a final concentration of 50mg/ml in a stability buffer comprising of a 
mixture of L-Histidine and Trehalose at a pH of 5.5. 
3.1.4 Medi/UCL009 
 One human monoclonal antibody (IgG1) designated Medi/UCL009 was provided by 
MedImmune (Cambridge, UK) in a purified state at 50mg/mL in a pH 5.5 L-Histidine 
and D (+) trehalose stability buffer. The antibody was reformulated using desalting 
columns into nine different formulations outlined in table 3-1. 
Table ‎3-1: Conditions used for formulating Medi/UCL009. 
 
Sample pH 
Salt Conc. 
( M ) 
Ab Conc. 
( mg mL
-1 
) 
1 4.4 0.03 5 
2 4.4 0.03 15 
3 4.4 0.15 5 
4 4.4 0.15 15 
5 5 0.09 10 
6 5.6 0.03 5 
7 5.6 0.03 15 
8 5.6 0.15 5 
9 5.6 0.15 15 
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3.2 Modifications used in studies 
 Medi/UCL003-008 were modified using a combination of two triple amino acid 
substitutions. These mutations were developed as stand alone modifications to 
change the pharmacokinetic properties of any antibodies they were inserted into. 
3.2.1 YTE 
M252Y
S254T
T256E
 
Figure ‎3-1: Image of YTE mutation locations on an IgG1 Fc. 
 
 The YTE modification (Dall'Acqua et al., 2006a, Dall'Acqua et al., 2006b) comprises 
of the triple antibody substitution M252Y/S254T/T256E shown in figure 3-1. The 
modifications increase the IgG binding to the neonatal Fc receptor (FcRn) giving a 
10 fold increase in both Human and cynomolgus monkey over the non-modified 
state. This results in a four-fold increase in the serum half life of the molecule. The 
modification was also shown to modulate the antibody-dependent cell-mediated 
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cytotoxicity (ADCC) of a humanised IgG1 directed against the human integrin αvβ3 
(Dall'Acqua et al., 2006b). Molecular modelling of the modification suggests that this 
behaviour is accounted for by potential favourable hydrogen bonds and an increase 
in surface contact between the antibody and the FcRn (Oganesyan et al., 2009). 
3.2.2 TM 
L235E
P331S
L234F
 
Figure ‎3-2: Image of TM mutation locations on an IgG1 Fc. 
 
 The TM modification (Oganesyan et al., 2008) comprises of the triple amino acid 
substitution L234F/L235E/P331S shown in figure 3-2. The modification eliminates 
various antibody effector functions, which is thought to decrease the IgG-mediated 
toxicity events. The modification results in a large decrease in the binding activity of 
the Fc portion of human IgG to human C1q, CD64, CD32A and CD16 which are 
known to trigger ADCC and complement dependent cytotoxicity (CDC) events.  
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 Work done on modelling of antibodies including the mutation has shown that the 
broad ranging effects of TM cannot be explained in terms of major structural 
rearrangements in the vicinity of the modification. 
3.3 Primary recovery; filtration 
 Antibody produced for this study was clarified in one of two ways depending on the 
volume needed to be processed. Volumes larger than one or two litres were filtered 
using a sterile, inline, disposable Millipak™ (Millipore, Billerica, MA, USA) filter with 
0.45 micron Durapore™ (Millipore, Billerica, MA, USA) PVDF membranes.  Feed 
was pumped through from a storage vessel using a LoadSure peristaltic pump 
(Watson-Marlow, Falmouth, UK) into a sterilised disposable plastic vessel ready for 
the next stage in its purification. 
 Volumes up to and around two litres were filtered using 1L volume Stericups™ 
(Millipore, Billerica, MA, USA) with 0.45 micron Durapore™ (Millipore, Billerica, MA, 
USA) PVDF membranes. The filtrate was collected in a sterile container connected 
to the membrane ready for the next stage in its purification. 
3.4 Chromatography techniques 
 Antibody was purified using chromatographic techniques. This project used Protein 
A, size exclusion and ion exchange chromatography as methods for protein 
separation. The exact column used and the stages run were dependent on the type 
of chromatography and the volume of matrix needed for that step. 
 In all cases an AKTA purifier (GE Healthcare, Uppsala, Sweden) was used to pump 
the media through the column. UV, pH and conductivity results were used to monitor 
the process as different wash steps were put across the column before elution and 
stripping of bound proteins (MedImmune, Cambridge, UK). 
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Figure ‎3-3: Diagram of chromatography rig. 
 
 All processes were controlled using Unicorn software (GE Healthcare, Uppsala, 
Sweden) and the software was used to determine when to collect the antibody in 
aliquots, using Falcon Bluemax™ conical tubes (BD, NJ, USA), by tracking when 
the absorbance at 280nm went up at a previously defined rate in the elution stage. 
 For smaller matrix volumes a HiTrap™ or Tricorn™ column (GE Healthcare, 
Uppsala, Sweden) was used, but these were upgraded to an XK 16, XK26 or XK50 
column (GE Healthcare, Uppsala, Sweden)  as the volume of matrix demanded a 
larger diameter while keeping a fixed bed height of around 20cm for all columns 
except the HiTrap™.  
 The method of protein loading depended on the volume of antibody that required 
purifying. For smaller volumes of up to 50ml, a super loop (GE Healthcare, Uppsala, 
Sweden) was used. For larger volumes of up to 30L, the feed was loaded directly 
using one of the buffer lines.  
 The matrix used depended on the type of separation that was required. For a 
primary purification step, this project always used MabSelect sure matrix™ (GE 
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Healthcare, Uppsala, Sweden). If anion exchange was required, Fractogel™ matrix 
(GE Healthcare, Uppsala, Sweden) was used. 
 The Protein-A chromatography step was run at a constant linear flowrate of 
200cm/h and started with an equilibration step for 10 column volumes using PBS 
buffer followed by the loading step. Wash step 1 used 5 column volumes of PBS to 
wash off any unbound material from the matrix. Wash buffers 2 and 3 then 
incremented towards the conditions used in the elution step. After elution, 5 column 
volumes of 100mM Acetic acid was used to strip the column before CIP using 2 
column volumes of NaOH and a 15 minute hold. 
 The anion exchange chromatography was performed at a linear flow rate of 
200cm/h and started with equilibration of the column for 10 column volumes using a 
low salt buffer. The antibody was then loaded onto the column and the column was 
rinsed with another low salt buffer. The salt molarity of buffer was then steadily 
increased and fractions were collected as various proteins were unbound from the 
column. High salt buffer containing EDTA was then used to strip the column before 
CIP using 2 column volumes of NaOH and a 15 minute hold. 
3.5 Viral inactivation 
 A Meterlab® PHM220 lab pH meter (Radiometer Analytical SAS, Villeurbanne 
Cedex, France) was put in the eluate from Protein-A to view the pH which was 
slowly reduced using Acetic acid to a low holding pH. After an hour, a sample was 
taken from the treated eluate before Tris buffer was used to neutralise the pH. A 
further sample was taken at this point. 
3.6 Viral filtration 
In the course of the study on reversible aggregation a pressurised viral filtration step 
was performed. A diagram of the equipment is shown in Figure 3-4. 
 86 
 Feed streams consisted of purified material formulated into a final buffer. The 
material was loaded into a pressure vessel (Millipore, Darmstadt, Germany) and 
passed through a series of filters each with a 3.94cm height and 3.10cm diameter 
with purge valves on the permeate side. A stop valve was placed between each of 
the filters to allow sequential purging of each filter. The first filter was a Virosolve pre 
filter (Millipore, Darmstadt, Germany) with a mixed cellulose ester membrane. The 
second filter was a Virosolve guard filter with a polyethersulfone (PES) membrane. 
The third filter was a Virosolve Pro filter with 20nm pore size PES membrane. 
 
Figure ‎3-4: Diagram of viral filtration equipment setup. 
 
 Operation of the device began by filling the sample reservoir with water and sealing 
the lid before setting the pressure to 30 PSI. The filters were then wetted one at a 
time from the top by closing the stop valve below the filter and collecting 15ml of 
liquid through the purge valve. The purge valve for the first filter was then closed 
and the valve below opened to allow wetting of the second filter which was then 
purged for 15ml before repeating for the third. After the wetting, the water in the 
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reservoir was removed and some buffer was placed in the reservoir to equilibrate 
the filter membranes. The process of sequential purging was then repeated and the 
buffer replaced by the antibody feed. At this point the scales (Sartorius, Epsom, UK) 
were tared and a system link to the PC was initiated to record the value on the 
balance on an Excel (Microsoft, CA, USA) spreadsheet. At this point all the valves 
were opened and measurement of flux began until either it fell below 100LMH or the 
sample was finished.  
3.7 SE-HPLC analysis of low molecular weight aggregates 
 For SE-HPLC analysis the System used was an Agilent 1200 series (Agilent 
technologies, Santa Clara, CA, USA) rig comprising of a solvent pump, degasser, 
injector and a diode array detector (DAD) UV detector. A 4cm by 6.0mm TOSOH 
TSK gel SWXL Guardcol (TOSOH Biosciences, Tokyo, Japan) followed by a 30cm 
by 7.8mm TOSOH Hichrom TSK gel G300SWXL column (TOSOH Biosciences, 
Tokyo, Japan) were used to analyse results. The running buffer (MedImmune 
specification, Gaithersburg, USA) was pumped through at 1ml/min to equilibrate the 
column for half an hour prior to a run. The flowrate and buffer were kept the same 
and 25µL samples were injected onto the column. The eluate was monitored for 
absorbance at 280nm wavelength and the peaks were integrated using the Agilent 
HPLC software. 
 Prior to analysis all samples were either filtered using Ultrafree® MC 0.5ml 
Centrifugal filters with Durapore PVDF 0.45μm membranes (Millipore, Billerica, MA, 
USA) for 1 minute at 13000 rpm in a Micro centaur centrifuge (MSE, London, UK) or 
span down for 10 minutes at 13000 rpm in a Micro centaur centrifuge in a 1.5ml test 
tube (eppendorf, Hamburg, Germany), to remove any aggregates larger than the 
SE-HPLC columns could differentiate. Samples of 1μm volume were then pipetted 
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into HPLC vials with 0.1ml inserts (Kinesis, Cambridgeshire, England) before being 
placed in the HPLC machine. 
3.8 280nm absorbance of proteins 
 A Beckman DU 520 UV/VIS-spectrophotometer (Beckman Coulter, Brea, CA, USA) 
was used to determine the absorbance at 280nm to allow the determination of the 
concentration of the solutions. The samples taken from various experiments were 
diluted to approximately 0.5mg/ml prior to analysis with their native buffer, before 
being placed in the colorimeter to give a reliable absorbance reading in the 0-1AU 
range. A quick analysis of the amount of absorbance at 280nm gives a value which 
can be put into the Beer-Lambert law equation for molar absorbance along with the 
extinction coefficient to give the concentration of the solution. 
3.9 Ultrafiltration/diafiltration of samples 
 The experimental setup for the ultrafiltration/diafiltration (UF/DF) step is shown in 
figure 3-5. The pilot scale filtrations were performed using a Minim™ rig (Pall, NY, 
USA) running a Minimate™ capsule membrane filter unit. Circulation of the retentate 
was achieved with the use of a peristaltic pump on the rig itself. The inlet flow rate 
was controlled by adjusting the pump rate. The transmembrane pressure was 
adjusted to 20 bars by adjusting the valves and was kept at this value over the 
course of the unit operation. The permeate valve was left open during operation of 
the rig and the permeate mass was measured by collection in a vessel placed on a 
CPA4202s tabletop scale (Sartorius, IL, USA). 
 During Ultrafiltration operation of the rig, the reservoir top was left unsealed and 
volume of liquid in the reservoir was allowed to reduce. During Diafiltration the 
reservoir was vacuum sealed with a pipe leading to the Diafiltration buffer to replace 
the buffer that was being lost in the permeate. 
 89 
 Membrane equilibration was performed using the buffer that the sample had been 
eluted with from the previous step, for samples that were being purified, or by using 
the buffer the antibody had been formulated in for samples that were being buffer 
exchanged. Membrane cleaning was performed after each experiment by 
recirculation of 0.5M NaOH solution for 5 minutes, followed by a 30 min hold. After 
cleaning, the entire system was rinsed with deionised water. 
 
Figure ‎3-5: Diagram of a TFF filtration rig. 
 
3.10 Desalting columns 
 Desalting columns were used for buffer exchange when small volumes of many 
different formulations were required. Disposable PD10 columns (GE Healthcare, 
Uppsala, Sweden) were equilibrated by running through 5ml of the formulation 
buffer required until the liquid had finished passing through the column. This was 
repeated four more times and the column left until there was no more liquid waiting 
to pass through the matrix. 2.5ml of the sample was then added to the column and 
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allowed to pass through before placing a receptacle to collect the eluate and a final 
3.5ml of the formulation buffer was added to push through the eluate. 
3.11  Shear device operation 
 
Figure ‎3-6: Diagram of redesigned disc interfacial shear device. 
 
 The shear device used is an upgrade of one previously described in a paper 
(Biddlecombe et al., 2007) and uses a magnetically driven ferrous disc in the centre 
of a chamber to simulate liquid-solid interface shear damage with the absence of 
any liquid-air interfaces. The disc is driven by a magnet in the outer casing, which is 
in turn driven by a motor. For the experiments, the disc speeds used were 3000, 
6000, 7500, 9000, 12000 and 15000rpm. Each 2 hour experiment had samples 
taken every 15 minutes to be analysed by SE-HPLC. Figure 3-6 shows a 
diagrammatic representation of the device while figure 3-7 and 3-8 show the device 
in various stages of assembly. 
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Figure ‎3-7:  Images of the shear device clockwise from the top left; the magnet 
seat, cooling jacket lid, assembled shear device base, assembled lid with disc 
attached and one way valve adjacent. 
 
Solution was introduced to the device at the base of the chamber by a one way 
injection port running down from the top face and time samples were taken via a 
separate sample port at the top of the chamber. A LoadSure peristaltic pump 
(Watson-Marlow, Falmouth, UK) was used to pump water from a cooling tank to the 
cooling jacket around the sample to allow temperature control at high shear rates. 
 CIP consisted of running the device with Sodium Hydroxide for 10 minutes, 
emptying the chamber, then running the device with phosphoric acid for 10 minutes 
before emptying the chamber and equilibrating the device with the formulation buffer 
of the sample to be analysed.  
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Figure ‎3-8:  Image of the fully assembled device connected to the power pack, with 
rubber tubing leading to a water bath and pump assembly. 
 
3.12 Nanoparticle tracking analysis 
 The device used was a Nanosight LM10 (Nanosight ltd, London, England) which 
shines laser light at particles and tracks them using a microscope connected to 
Nanoparticle Tracking Analysis (NTA) software (Nanosight ltd, London, England) 
capable of automatically tracking and sizing nanoparticles on an individual basis. 
The instrument itself is based on a normal optical microscope with a CCD camera 
allowing the images to be viewed on a computer. 
 For the analysis, 3ml of sample were injected into the visualising area before the 
image was captured for 60 seconds. The resulting video was analysed with the NTA 
software (Nanosight ltd, London, England), correcting the number of counts per 
frame to around 100 using the level of sensitivity in picking up particles to give 
results for particles size and concentration.  
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3.13 Differential scanning calorimetry 
 The Differential Scanning Calorimetry (DSC) technique was performed using a 
Microcal VP-Capillary DSC (GE Healthcare, Bucks, UK). Samples were prepared on 
a 96-well plate in triplicate suspended in stability buffer at concentrations of 1mg/ml. 
The change in the heat capacity of the sample was measured in comparison to a 
sample of buffer alone as samples were heated from 45°C to 95°C at a rate of 
60°C/hour in the device. The heat capacity data was normalized and corrected for 
the baseline to improve the ability to compare peaks.  
3.14  Accelerated stability of proteins 
 Accelerated stability was performed by preparing 5ml aliquots of samples in Falcon 
Bluemax™ conical tubes (BD, Oxford, UK) and storing these tubes at either 20°C or 
40°C for a month. Before storage, the samples were tested using the SE-HPLC 
method to give an absorbance area value under the monomer peak at 280nm. After 
one month, the samples were again tested using the SE-HPLC method and the 
absorbance area value was compared against the original value to give a 
percentage loss of monomer over the course of the hold. 
3.15  Fourier transform infra-red spectroscopy 
 The Fourier Transform Infra-Red Spectroscopy (FTIR) technique was performed 
using a Spectrum 100 optica (Perkin-Elmer, MA, USA) with a glass Biocell (Biotools, 
FL, USA). 15uL of antibody solution was loaded onto the Biocell before analysis 
from 1000-3000cm-1 frequency. Analysis was performed using Grams AI software 
(Thermo Scientific, PA, USA) with PROTA (Biotools, FL, USA). The protein solution 
absorbance was determined by removing the background absorbance from the 
protein spectrum. The Buffer absorbance was then determined by removing the 
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background absorbance from the buffer spectrum. The buffer spectrum was then 
subtracted from that of the protein solution to give a spectrum for the protein. This 
spectrum then had the water vapor spectrum subtracted from it before being 
processed by the software to give results for the secondary structure. 
3.16 Proteo-stat® dyes 
 The method first involved preparation of the positive and negative controls for 
monitoring and detection of protein aggregation. Both controls were supplied as 
300μg aliquots of lyophilized powder. Each was reconstituted using 500μL of 
deionised water to generate a 40μM stock solution. These solutions were gently 
mixed with vortexing and bubbles were avoided for their effect on protein stability.  
 Proteo-stat® dye (Enzo Life Sciences, NY, USA) was prepared by addition of 10μL 
of Proteo-stat detection reagent and 20μL of 10x assay buffer into 170μL of 
deionised water before mixing. 
 2μL of the prepared Proteo-Stat® detection reagent was dispensed into the bottom 
of each well of a 96 microwell plate (Life technologies, Paisley, UK). 98μL of the 
protein of interest was then added to each well in triplicate for each sample at a 
concentration range of 1μg/ml to 10mg/ml. 
 The microwell plate was then incubated for 15 minutes in the dark at room 
temperature before being placed into a fluorescence microwell plate reader using an 
excitation setting of 550nm and an emission filter of 600nm.  
 Emission data from buffer samples was then subtracted from the antibody samples 
using Excel (Microsoft, CA, USA) to give an emission spectrum for each. 
3.17 Design of experiment   
 Jmp software (SAS, NC, USA) was used to perform design of experiment. By 
inputting the variables to be tested and the number of midpoints into a 3x3 matrix 
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the software determined the order of experiments to do. Following input of the 
experimental results, their analysis gave the trends reported. 
3.18 Capillary shear device operation 
 The capillary shear device method was developed during the course of the project 
and the usage parameters were defined as part of the project. The device consisted 
of an Aladdin-6 syringe pump (WPI, Herts, UK) with six 316 grade stainless steel 18 
gauge capillaries fitted with luer fittings (Coopers Needle Works, Birmingham, UK) 
connected to each of the 6 syringes in the pump. 0.6ml of sample was loaded into a 
sample tube (eppendorf, Stevenage, UK) and placed at the end of the device with a 
capillary resting at the bottom of each one. The device is shown in figure 3-9 with a 
diagram in figure 3-10. 
 The capillaries were primed by extracting 0.075ml of sample from the sample tube 
before regular withdrawing and dispensing of 0.45ml of sample for different periods 
of time.  
 When the method had finished, the entire sample was expelled from the capillaries 
into the sample tubes. The samples were then analysed using the SE-HPLC method 
previously described. 
 
 
Figure ‎3-9: Photograph of capillary syringe device from front view. 
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Figure ‎3-10: Diagram of capillary shear device from a top view and a front on view. 
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3.19 Creating molecular models 
 Molecular modelling was performed on the Fc regions of several of the antibodies 
used in the project. Crystallographic data was either downloaded from the 
corresponding files on PDB or from data donated by the sponsor company. If the full 
crystallographic data of the protein Fc regions was not available online, homology 
models were produced.  
 The flow chart for producing homology models is outlined in figure 3-11. 
Choose to model 
molecule 
Cut model sequence 
at THT site
Align model to 
template
Asses if 
homology model 
is good fit
Parallel model 
building
Cut crystalography 
model datas as 
templates 
Choose most 
stable model
Perform SAP 
analysis
Perform 
Electrostatic Charge 
analysis
 
Figure ‎3-11: Flow chart of modelling operation. 
 
 Having chosen the complete models to use in producing parts of the homology 
model, the sequences were downloaded in FASTA format and cut at the appropriate 
points in the sequence. Theses were then aligned in Discovery Studio 3.5 
(Accelyrys, CA, USA), as shown in figure 3-12, to give a fit for the entire molecule.  
 
Figure ‎3-12: Screenshot of aligning sequences for molecular models. 
 
 The crystallographic data was then opened in PyMol software (Schrodinger, 
Munich, Germany) and the models were cut to the same points as the sequence 
data and aligned with each other, as shown in figure 3-13. 
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Figure ‎3-13: Screenshot of molecule in Pymol. 
 
 The software was then used to create 100 different models in parallel, based on 
folding using a proprietary MedImmune force field. The force field used the data 
provided in the sequence and the structural data files and a manual input of data on 
disulfide bridges and Cis-Pro bonding in and between the two halves of the Fc to 
build differentially folded proteins. 
 The models created were then ranked using PDF total energy and DOPE scores to 
give a view of how stable the molecular configurations were. The lowest scores for 
both these rankings were chosen for this study provided they checked against a 
ramachandran plot, as in figure 3-14, and the Procheck tool on the software.  
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Figure ‎3-14: Ramachandran plot of an acceptable molecular model. 
3.20  Using molecular models to determine molecular 
properties 
 Once the models were ready, Discovery Studio 3.5 (Accelyrys, CA, USA) was used 
to perform the operations required as part of this study. 
 First, the software could be used to calculate the developability index of the 
molecule to give a measure of the molecular stability. Next the SAP was determined 
by using a 5Å atomic radius to give SAP scores for individual aggregation hot-spots 
as well as an overall map of SAP on the molecular surface. Finally the electrostatic 
surface charge was calculated using a fine grid filled by solute. 
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4 Characterising antibody purification, assays and 
shear device methods 
4.1 Introduction 
 Before commencing any investigations, it was necessary to define a range of 
operating procedures. This chapter details the work needed to prepare for the 
experiments that would follow.  
 Details such as the effect of the day of fermentor harvest on the level of 
aggregation were looked into, before defining the entire downstream process to be 
used. 
 The reproducibility of the SE-HPLC and absorbance at 280nm methods was 
checked to give a measure of the error in the results reported using these methods. 
 Finally aspects of the shear device operation were examined to determine best 
operating procedures for future experiments. 
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4.2 Choosing a harvest time for fermentation 
 The first parameter to be examined was the day of harvesting antibodies grown for 
use in the project. The sponsor company had its own standard operating procedures 
for the day of fermentor harvest, so the effect of harvesting 7 different days around 
this standard was investigated. Samples of IgG1 (Medi/UCL001) were taken each 
day from a fermentor 5 days before the normal day of harvest until 2 days after. 
Upon sampling, the concentration of the antibody was determined. This was done 
by filtering and performing protein-A on the sample before using absorbance at 
280nm. By knowing the total mass of protein collected and the original sample 
volume, the concentration in fermentation could be determined. 
 
Figure ‎4-1: Graph of antibody concentration over day of harvest of IgG1 
(Medi/UCL001) during fed batch production using defined media. Error 
bars using compounded standard sampling error and error of 
measurement.  
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 The results for this, seen in figure 4-1, show a clear trend that the longer the 
fermentation is run, the higher the antibody concentration in the sample. This trend 
does seem to peak the day after normal harvest, followed by a drop the day after 
that. This could be due to antibody loss to large complex aggregates within the 
fermentor, or from digestion of peptides in the fermentor by enzymes released by 
cell apoptosis (Mahler et al., 2009). 
 
Figure ‎4-2: Graph of monomer percentage determined by SE-HPLC over day of 
harvest for IgG1 (Medi/UCL001) during fed batch production using 
defined media. Error bars determines from standard error of HPLC 
method. 
 
 The samples were then checked for the purity of monomer within the antibody that 
had been clarified using the SE-HPLC method. The percentage of monomer for 
each day is shown in figure 4-2. There is an obvious exception to the trend on the 
first measurement, but the antibody concentration is so low at this point that this 
could be due to a lot of experimental factors. Results from day -3 to day +1 show a 
consistant level of monomer in the samples. In day +2 however we do see a drop in 
the monomer percentage as the sample begins to degrade. This would suggest that 
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either the antibody that is produced later into fermentation is less well folded and so 
prone to forming smaller aggregates (Jahn and Radford, 2005) or that retention of 
antibody in fermentation conditions for too long will cause proteins to slowly lose 
stability (Welfle et al., 1999). For this project, large amounts of relatively stable 
antibody needed to be produced, so it was decided to keep the fermentation day as 
the company standard, as a compromise to the two factors. 
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4.3 Downstream processing operations for antibody 
purification 
 Production and purification of large masses of IgG1 and IgG4 antibodies 
(Medi/UCL003-008) were required for the project, so the fermentation and 
subsequent purification steps had to be defined. A platform process was defined as 
shown in figure 4-3 and all antibodies were purified using it.  
Fermentation
-30L wavebags
Filtration
-POD filtration
- In line filters
-Stericups
Protein A
-Mabselect Sure
Viral inactivation
-pH < 4
Ion exchange 
Chromatography
-Fractogel
UF/DF
-Pellicon cartridge
-PD10 desalting 
columns
Filtration
-Stericups
 
Figure ‎4-3: Flowchart of antibody purification process used in purification of 
samples for experimental use. 
 
 Due to competitive nature of biopharmaceutical purification and the cost of research 
into process optimisation, many of the descriptions of these steps here and in the 
materials and methods section will use generalisations to protect proprietary 
information. The methods are described in detail in the materials and methods 
section. 
 Fermentation was performed by the MedImmune upstream development team in 
Cambridge, UK. Standard MedImmune procedures were used to grow up to 27L of 
fermentation media in un-optimised conditions giving concentrations ranging from 
0.1 to 3 g/L using disposable wavebag technology and defined media. 
 Primary recovery was performed with the use of membrane filtration to remove 
whole cells, particulates, cell debris and organelles from the fermented feed.  
 Protein-A chromatography was then used to purify the antibody. This step is widely 
used in the purification of monoclonal antibodies because of its highly specific 
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binding to the Fc region of the antibodies and the high affinity of the molecule allows 
for high dynamic binding capacities to be achieved. 
 
Figure ‎4-4: Graph of absorbance at 280nm after the column during protein-A 
operation for purification of IgG1. Column volume of 109ml and a 
volumetric flow rate of 31ml/min. 
 
 Figure 4-4 shows a chromatogram of the protein-A step for one of the purifications. 
This particular run has a long loading time due to the low concentration of antibody 
in the load and the high affinity of the matrix. It clearly shows the waste coming 
through the column during the load stage followed by one large peak corresponding 
to the antibody monomer. This is followed by one small impurity peak and then a 
sharp, larger impurity peak corresponding to impurities removed in the strip and CIP 
steps respectively. 
 Viral inactivation was then performed by lowering the pH to below 4 to kill off any 
virus that had not been purified out from the sample before beginning the anion 
exchange chromatography step. In this step, the feed was loaded onto a fractogel 
column and as the elution step started, fractions were collected and pooled. During 
the course of this operation the majority of fragments, aggregates, antibodies with 
different isoelectric points or any other impurities that was still in the solution would 
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separate out from the monomer. Figure 4-5 is an elution curve from the operation 
showing a large peak of monomer with a small tail that would not have been 
collected. There was also a sharp peak after this which corresponds to the strip and 
CIP stages. 
 
Figure ‎4-5: Graph of absorbance at 280nm after the column during fractogel 
operation for purification of IgG1. Column volume of 80ml and a 
volumetric flow rate of 31ml/min. 
 
 The antibody was then diafiltered into the stability buffer and the concentration was 
altered to the required level using either ultrafiltration or addition of buffer. The 
formulated protein was then filtered using a Stericup™ filter and aliquots 
apportioned into storage vials using aseptic technique. 
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4.4 Characterisation of analytical methods 
4.4.1 SE-HPLC for low molecular weight aggregates 
 
Figure ‎4-6: SE-HPLC chromatogram of IgG1 (Medi/UCL001) using Tosoh TSK gel 
SWXL3000 column with MedImmune running buffer running at 1mg/ml. 
 
 Figure 4-6 is a SE-HPLC chromatogram taken using the protocol defined in the 
material and methods section that shows a pure monomer peak. The sharp 
resolution of the peak and the symmetry show that the method uses a matrix that 
has a very high plate number and that it is nearly perfectly packed. 
 
Table ‎4-1: SE-HPLC validation test results for 1mg/ml IgG1 (Medi/UCL008) using 
Tosoh TSK gel SWXL3000 column with MedImmune running buffer 
running at 1ml/min. 
 
Vial 1 2 3 4 5 AVG S.D 
A280 Reading (mAU) 8646 8681 8692 8749 8728 8699 40 
 
Many of the experiments in this project rely on the accuracy and reproducibility of 
the SE-HPLC technique to give a good representation of the differences between 
samples taken from a system to be able to draw conclusions. To have utmost faith 
in these results, it is critical that the method itself should be validated. To achieve 
validation of the method, five samples were taken from a 5mg/ml solution of IgG1 
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(Medi/UCL008) and run sequentially on the SE-HPLC. The results are shown in 
table 4-1 and show an average reading for the sample of 8700 mAU with a standard 
deviation of 40 mAU. This means the error for the device is around 0.46%, allowing 
the conclusion to be drawn that the technique is very reliable and reproducible. 
4.4.2 Absorbance at 280nm for protein concentration 
 The absorbance at 280nm is used to determine the concentrations of antibody in 
solution. It is paramount to have an accurate reading for concentration because a 
false concentration of antibody used in the experiments may have an effect on the 
mechanisms observed and in turn, could skew the result. To determine the risk of 
getting an erroneous reading, the reproducibility of the method was tested. It was 
decided that both a low concentration reading and a high concentration reading 
would be taken to determine if there was a more reliable concentration to take 
absorbance readings at. 
 
Table ‎4-2: A280 validation test results for IgG1 (Medi/UCL008)  using a Beckman 
DU 520 UV/VIS-spectrophotometer. 
 
Attempt 1 2 3 4 5 AVG S.D 
Low 
value 0.467 0.467 0.466 0.467 0.465 0.466 8.94E-04 
High 
value 0.841 0.839 0.837 0.839 0.841 0.839 1.67E-04 
 
Table 4-2 shows that the low value gave an average of 0.466 and a standard 
deviation of 8.94 x10-4 which equated to a 0.2% error.  The high value gave an 
average of 0.839 and a standard deviation of 1.67 x10-4 which also equated to a 
0.2% error. This showed that not only was the method highly reliable, but the 
concentration of antibody used in the device, if within specifications, did not affect 
reliability of the concentration reading result. 
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4.5 Determining optimal conditions for disc shear device 
operation 
 Operation of the shear device method was defined by previous work (Biddlecombe 
et al., 2007) but before continuing with its use, the decision was made to look at a 
wider range of operating factors to determine the optimum operating conditions.  
4.5.1 Optimisation of the cooling jacket temperature 
 The operation of the shear device exposes the antibody to interfaces and levels of 
shear that lead to monomer loss through aggregation pathways, but the rate of 
monomer loss is also affected by the temperature of the solution (Hawe et al., 
2009). To negate the effect of increased heat generation from increases in the 
rotational speed of the spinning disc that are needed to generate higher levels of 
shear in the solution, the coolant temperature would need to be adjusted. 
 The relationship between cooling water temperature and shear rate was determined 
with Alex Berrill (Post-Doc, UCL, UK) by shearing PBS solution in the chamber and 
fixing the cooling water flow rate. A temperature probe was used to determine the 
cooling water temperature needed to keep the chamber temperature constant. In 
this determination, 5 sample points were used at 1, 4, 8, 12 and 15 x103 rpm.  
 By plotting the points on a graph as shown on figure 4-7, it was possible to derive 
Equation 4-1, which could be used to determine the temperature needed for 
whichever disc speed was chosen. 
 
Equation ‎4-1: Equation to determine cooling jacket temperature. 
 
Cooling Temp (°C) = -3x10-8 Disc speed2 – 4x10-6Disc speed +19.59 
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Figure ‎4-7: Graph to determine the cooling water tank temperature required for 
cooling jacket to keep shear device chamber at 20°C at a flowrate of 
200ml/min. 
 
 The cooling temperature needed for each of the conditions used in the study were 
then calculated and shown in figure 4-3. 
Table ‎4-3: Table of Shear strain rates and Cooling temperatures. 
 
Run RPM RPS 
Shear strain 
rate ( s
-1
 ) 
Cooling 
temp ( °C ) 
1 3000 50 1.35 19.3 
2 6000 100 1.86 18.4 
3 7500 125 2.12 18 
4 9000 150 2.38 16.9 
5 12000 200 2.89 14.9 
 
4.5.2 Choosing an absorbance wavelength for SE-HPLC analysis 
 Once samples were prepared and put through the SE-HPLC, they were analysed at 
two different wavelengths using the DAD detector to determine the level of monomer 
loss. Any large aggregates formed would have been removed from the solution 
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before this reading with the use of a centrifuge or a centrifugal filter. The 
wavelengths used were 220nm to look at the peptide bonds in the antibodies and 
280nm to look at the amino acids with aromatic rings present in the antibodies which 
would include Tyrosine and Tryptophan. 
 The results for the loss of signal at 220nm and 280nm for a set of shear device 
experiments on 1mg/ml IgG1 (Medi/UCL002) are shown in figures 4-8 and 4-9 
respectively. These graphs both show unequivocally that there is significant loss of 
monomer from the solution during the 2 hours of shear. The results taken are 
adjusted to compensate for the reduction in the concentration of monomer in the 
chamber due to the process of taking of samples. Each sample volume taken is 
around 1% of the total chamber volume.  
 
Figure ‎4-8: Loss of signal at 220nm at 15 minute intervals over 2 hours of shear for 
various speeds using IgG1 1mg/ml (Medi/UCL002) in PBS buffer. Error 
bars corresponding to standard error from line of best fit. 
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Figure ‎4-9: Loss of signal at 280nm at 15 minute intervals over 2 hours of shear for 
various speeds using 1mg/ml IgG1 (Medi/UCL002) in PBS buffer. Error 
bars corresponding to standard error from line of best fit. 
 
 Looking at figures 4-8 and 4-9, we can see there is a definite trend in the level of 
monomer loss dependent on the shear rate. The higher the shear rate, the higher 
the rate of monomer loss, and ultimately the less monomer left in solution.  
 In the 12000rpm experiments at both 220nm and 280nm, it seems like the rate of 
monomer loss slows down again in what would appear to be a second order kinetic 
reaction.  
 The data in figures 4-8 and 4-9 do however show a difference in the overall level of 
loss which is highlighted in figure 4-10. This is due to the different parameters that 
the wavelengths measure against, and this difference could hint to the type of 
effects the shear is having on the monomers. If there is more of a loss at 280nm 
absorption than at 220nm absorption, then there must be a change in the ability of 
the protein to absorb the waves at one of the wavelengths. The 280nm reading 
looks at the aromatic rings within certain amino acids, and as such is less likely to 
be effected by strains in the peptide backbone caused by exposure to the shear 
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device chambers environment. Thus it was concluded that using the 280nm reading 
would give a more reliable result. 
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Figure ‎4-10: Effect of disc speed on monomer loss after 2 hours of shear as 
determined at 220nm and 280nm for 1mg/ml IgG1 (Medi/UCL002) in 
PBS buffer. 
 
4.5.3 Choosing a disc speed for the shear device 
 The rate at which the disc revolves inside the chamber affects the level of monomer 
loss subsequently measured by SE-HPLC. Being able to set the disc speed allows 
for choosing the level of degradation that will give optimum level of monomer loss. 
The parameters that define the optimum level of monomer loss were chosen to be 
the differentiation of antibodies during the course of a two hour operation and the 
error in the measurements when fitting the first order exponential decay curve. 
Having a greater level of differentiation would allow for selection between antibodies 
with more similar stabilities. The fit with the first order exponential decay curve will 
determine how accurate and reliable the PDC value determined by the method is. 
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 Figure 4-11 shows the monomer loss profiles of 1mg/ml IgG4 (Medi/UCL003) at 
increasing disc speeds. It shows a clear trend of decreasing fit with the exponential 
decay curve as the disc speed increases.  
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Figure ‎4-11: Monomer loss seen at disc speeds of 6000, 7500, 9000 and 12000 rpm 
for 1mg/ml IgG4 (Medi/UCL003) in L-Histidine and (D+) Trehalose buffer 
pH5.5. 
 
 Figure 4-12 shows a fitting of the PDC values for 1mg/ml IgG4 (Medi/UCL003-008) 
in L-Histidine and D (+) trehalose buffer at pH 5.5 for the various disc speeds. By 
increasing the disc speed there is a clear trend of increasing the differentiation of the 
molecules. 
 By comparing the two parameters for deciding the optimum disc speed, there is a 
compromise that needs to be found between increased differentiation of antibodies 
and reproducibility of results. As the differentiation of stability would in turn allow for 
greater margins of error for the individual results, it was decided to assign it higher 
priority. Moving to a second order decay after a certain amount of monomer loss 
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was not desired, so this then discounted the highest disc speed. Ultimately it was 
decided that the optimum disc speed was 9000rpm. 
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Figure ‎4-12: PDC determined for various disc speeds for 1mg/ml IgG1 and IgG4 
antibodies (Medi/UCL003-008) in L-Histidine and (D+) Trehalose buffer 
pH5.5. 
 
4.5.4 Choosing the sample’s antibody concentration 
 The concentration chosen to perform the tests on would affect various factors 
associated with operation of the shear device. The first aspect is that having a 
higher concentration within the device would require the production of a larger 
amount of antibody. During the early stages of drug development, companies would 
decide upon their lead molecule using a whole host of methods to determine key 
product attributes. Producing large amounts of all the different candidates is 
extremely expensive, so if the company is interested in keeping costs down, then a 
lower antibody concentration would be advantageous.   
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 The second aspect of concentration is the fit with the exponential decay curve. As 
with other operational parameters, a worse fit will equate to a less reliable reading. 
 The third parameter is the differentiation of the antibodies analysed. The larger the 
differentiation achieved, the better, because it would allow selection of the most 
stable of similar antibodies. 
 Due to the constraint of the antibody concentration that can be accurately read by 
the UV lamp before there is oversaturation of the HPLC sensors, samples taken 
from the shear device with concentrations over 10mg/ml had to be diluted before 
being placed on the HPLC. This exposed the results for the 25mg/ml and 50mg/ml 
samples to another significant source of error from the small volumes of liquids 
being handled. Any antibody adhering to the outside wall of the transfer pipette or 
any air in the pipette chamber would have a significant effect on the level of 
monomer present as determined by SE-HPLC. When looking at the levels of 
monomer loss occurring between the 15 minute sample times in the device, the 
cumulative levels of error could possibly give erroneous PDC results. 
 A further source of error that would become more significant with higher 
concentrations of antibody is that any solution held in the hold up volume between 
the chamber and the accessible area of the sample port between 15 minute 
samples would mix with the later sample and have an effect on the monomer loss 
viewed. 
 Figure 4-13 shows the monomer loss results for IgG4 (Medi/UCL004) in an L-
Histidine and D (+) trehalose buffer at pH 5.5 at 50, 25 and 5 mg/ml at 9000rpm. 
The data shows that the trends are a lot noisier with higher concentrations of 
antibody solution. Therefore, it would appear that lower concentrations of antibody 
solutions give more reproducible PDC. The trends themselves however do still exist 
and show that the higher the concentration of the feed, the lower the relative level of 
monomer loss. The overall mass of monomer lost however, does increase with 
increased concentration, from 31mg total loss at 5mg/ml to 120mg at 25mg/ml and 
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128mg at 50mg/ml. This suggests that with higher concentrations there is a limiting 
factor to the forces involved in the aggregation mechanism of the device. 
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Figure ‎4-13: Monomer remaining during processing in disc device at 15 minute time 
points over 2 hours for IgG4 (Medi/UCL004) at 5, 25 and 50mg/ml in L-
Histidine and (D+) Trehalose buffer pH5.5. 
 
Figure 4-14 shows the PDC’s of IgG1 and IgG4 antibodies (Medi/UCL003-008) 
formulated at 5, 25 and 50mg/ml in L-Histidine and D (+) trehalose buffer at pH 5.5 
after 2 hours shear at 9000rpm. The results show that more differentiation of 
antibody candidates is possible at higher antibody concentrations. This however 
may be an effect of the higher level of error at the higher antibody concentrations, 
and therefore unreliable as a metric to determine the optimum antibody 
concentration. 
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Figure ‎4-14: PDC of IgG1 and IgG4 antibodies (Medi/UCL003-008) in L-Histidine and 
D (+) trehalose buffer at pH 5.5 at different antibody concentrations. 
 
It was concluded that keeping the concentration of antibody relatively low would be 
optimal. This gave the most reliable results, and importantly keeps the mass of 
protein required to a minimum. It is recommended that an antibody concentration of 
1mg/ml be used to determine relative stability between different proteins. 
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4.6 Summary of technique development 
 The section summarized some of the background work that went into the 
development of the techniques used in the course of the research. The details for 
the harvesting and a platform process for the purification of the antibodies to be 
used in experiments are developed and defined, as is standard practice in industry 
(Shukla et al., 2007b). The main analytical methods to be used are also 
characterized and shown to be highly accurate and reproducible. Finally the 
operating conditions for the interfacial shear disc device are explored and the 
recommendations for use are given, in addition to what was currently published 
(Biddlecombe et al., 2007). They include cooling jacket temperatures to be used, the 
use of 280nm wavelength readings for SE-HPLC, running the disc at 9000rpm and 
using an antibody concentration of 1mg/ml. 
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5 Design and operation of the capillary shear device 
5.1 Introduction 
 In the course of the project, the author determined that the shear device method 
consumed too much material and was not optimised for taking many readings. This 
led to the development of a device that could produce a comparable measurement 
using a fraction of the material, in a fraction of the time, in a way that could later be 
automated to allow scale up of the method. The device was designed and 
assembled, operating methods were optimised and proof of concept work was 
conducted using 1mg/ml IgG1 and IgG4 antibodies (Medi/UCL003-008) formulated 
in a pH5.5 L-Histidine and (D+) Trehelose buffer to determine the validity of the 
method. It was then used to determine the relative stabilities of Medi/UCL003-008 to 
be compared with the results from the rotating disc shear device. 
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5.2 Designing the capillary shear device 
 The device was developed by trying to understand the reason for the monomer loss 
observed in the rotating disc shear device. With the disc device, it is believed that 
the antibody associates with the disc and it is at the surface that modifications occur 
to the antibody structure which then disassociate from the surface, possibly due to 
shear and remain in the boundary layer. In the boundary layer they react with other 
antibodies to create aggregates which can grow before re-entering the bulk solution. 
The role of the shear in the device is to help disassociate the antibody from the 
surface and to promote mixing of these highly reactive aggregates out of the 
boundary layer and into the bulk solution. Increasing the rate of rotation of the disc is 
hypothesized in practice to increase the effective surface area for association during 
a set period because the disc surface is “wiped” of antibodies more often. 
 It was postulated that a similar force could be applied to antibodies along a linear 
path with the use of a capillary. The low volume and high surface area of a thin 
capillary would help increase the effective surface area for association of antibody. 
The disassociation would be provided by shear produced by pumping fluid 
backwards and forwards through the capillary.  
  In designing the method, it was important to limit the role of liquid/air interfaces and 
to try and focus on the solid/liquid interface effects. For this reason it was decided to 
prime the capillaries with a small amount of the sample prior to any regular 
processing of the antibody. This would limit the air liquid interface on one side of the 
sample to the cross sectional area of capillary, and on the other to the cross 
sectional area of the sample tube. It would also eliminate any potential bubbling or 
micro cavitation that could introduce more air/liquid interface to the system as the 
sample was dispensed back into the sample tube. 
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 When dispensing the liquid, the sample was pushed by the air coming from the 
syringe and displacement was quick. However when extracting the liquid, the 
syringe would create a vacuum which would then cause the liquid to be drawn up 
the capillary, which was found to be slightly slower. To stop this affecting the net 
volume of sample left in the sample tube after each draw-dispense cycle, it was 
decided to introduce a 2 second pause between each change in direction to allow 
the liquid to settle at the correct level. 
 It was noted during initial testing that any difference in the path taken by the 
capillaries would slightly affect the amount of sample that was extracted by the 
capillary. Over a two hour operation this would have a significant effect on the 
effective surface area the antibody was exposed to, so it was concluded that each 
capillary should be coiled in the same way. 
 Further testing showed that vertical coils were capable of holding up amounts of 
liquid that would subsequently be drawn up further into the capillary and eventually 
into the syringe. It was concluded that to mitigate against any holdup of sample, the 
capillaries should be coiled in a horizontal plane, making sure that when leaving the 
syringe there was always a decline in the capillaries vertical path so that sample 
would always naturally drain into the sample tube.  
5.2.1 Determining the methods mode of operation 
 With the design of the device finalised, the mode of operation was formalised. It 
was decided that the sample size would be set at 0.6ml. This would allow 0.075ml to 
be initially drawn as a primer to mitigate bubble formation and then 0.45ml of the 
sample to be withdrawn and dispensed over the course of the operation. This would 
leave 0.075ml of sample in the sample tube at the end of the withdrawal, enough to 
come above the end of the capillary, and therefore stop the formation of any air 
liquid interface that would introduce bubbles.  
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Figure ‎5-1: Program steps for capillary shear device operation. 
 
The flow rate was set as 236ml/h, and the pump was programmed with the steps 
shown in figure 5-1. This would give the stages for liquid pumping as shown in figure 
5-2. The process was then timed using a stopwatch for the required amount of time 
and the capillaries were manually purged to ensure the entire sample was collected 
into the sample tube to be analysed for level of monomer loss compared to an 
unprocessed sample using the SE-HPLC method. 
 
Figure ‎5-2: Diagram of capillary shear device mode of action showing the empty, 
prepped, withdrawn and dispensed positions of the liquid level. 
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 The CIP for the method was performed by placing sample tubes containing 0.6ml of 
0.5M NaOH into the sample area and performing the standard operation of the 
device. The capillary was then cleared by processing a sample tube containing 1ml 
of de-ionised water for a further 5 minutes. The length of the NaOH CIP required 
was determined by testing increasingly long periods of operation and then operating 
a buffer sample for 20 minutes after the water clearing step. The results for 5 and 10 
minutes are shown in figure 5-3, and show that the capillaries are cleaned fully at 10 
minutes. 
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Figure ‎5-3: Signal at 280nm determined by SE-HPLC for different lengths of time of 
NaOH wash during CIP of device. 
 
5.2.2 Syringe selection to increase method reproducibility 
 During initial operation of the device it was observed that there was a lot of disparity 
in the levels of liquid withdrawn from the sample tubes. One of the main causes of 
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this was determined to be the size of the syringe being utilized. The volumetric flow 
rate was constrained by the maximum speed at which the syringe pump’s turning 
screw could move the plunger shelf to either push it in or pull it out of the syringe 
casing. Initially a 50ml syringe was used because the large diameter allowed for a 
faster volumetric flow rate which meant a higher effective surface area for a given 
time. Each draw gives a surface area exposure of 300mm2, the 50ml syringe with an 
ID of 26.6mm gives a nine times faster displacement of solution than the 2mm 
syringe with an ID of 8.66mm. This would expose the antibody in solution to nine 
times more surface area for the time of displacement, giving a higher loss of 
monomer to aggregate. However, the moving shelf did not seem to always give an 
even horizontal distance moved for all the syringes. With the 50ml syringe, this was 
equivalent to a high degree of variability due to the distance needed to push or pull 
2ml volume. This error led to a great difference in the measurements calculated 
from each syringe. 
 
Figure ‎5-4: Diagram to illustrate how syringe size effects capillary shear device 
operation and reproducibility (not to scale). 
 
 
Figure 5-4 gives a not to scale graphical representation of the distances required by 
different sized syringes to displace 2ml. From this it could be determined that by 
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using a smaller syringe the effect of this error would be greatly reduced and this was 
experimentally proven to be so. 
 The 5ml syringe was used to give the maximum level of reproducibility available to 
the use of the syringe pump, and the results of the level of reproducibility across all 
six capillaries in the device are shown in figure 5-5. It was however concluded that 
should the device be developed further, an alternative to the syringe pump would be 
required to produce the push and pull of the samples in the capillary. 
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Figure ‎5-5: Reproducibility of results as determined by SE-HPLC after 2 hours 
processing of 5mg/ml IgG1 (Medi/UCL008) in L-Histidine and (D+) 
Trehalose buffer pH5.5 in the capillary shear device. 
5.3 Calculating the capillary flow regime 
 The capillaries would be pumped at a volumetric flow rate of 236ml/hr, which would 
translate to a linear flow rate of 0.119m/s. By using a 5mg/ml sample of IgG1 
(Medi/UCL008) in L-histidine and (D+) Trehelose buffer at pH5.6 as an example, the 
flow regime in the capillary can be determined. By using the measured kinematic 
viscosity of the solution at 1.02m2/s and assuming a density of 1050 kg/m3 for the 
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solution, the dynamic viscosity can be determined for the sample. By using the 
equation for Reynolds number in a pipe: 
Equation ‎5-1:  Reynolds number in a pipe. 
 
Re = Duρ 
        μ 
 
 Where D is pipe diameter, u is average linear velocity of the fluid, ρ is fluid density 
and μ is the dynamic viscosity. By putting in the values determined for the 18 gauge 
capillary and the sample solution into the equation, the Reynolds number returned is 
102, which corresponds to laminar flow in the capillary (Doran, 1995). 
5.4 The effect of time on antibody monomer loss 
 
Figure ‎5-6: Effect of flowrate of pumping on the level of monomer lost using 
5mg/ml IgG1 (Medi/UCL008) in L-Histidine and (D+) Trehalose buffer 
pH5.5 in capillary shear device. Error bars for the standard error of the 
SEC measurement technique and the experimental method. 
 
 To test the theory of effective surface area being the cause of the monomer loss 
and that monomer loss was not being propagated simply by the time spent in the 
capillary or the shear evolved, samples were run at the highest flow rate for one 
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hour and then further samples were run for two hours. As expected, the level of 
monomer loss increased almost double from around 4.5% to around 7.5%. Samples 
were then run at half the volumetric flow rate for two hours, effectively exposing the 
antibody to half the effective surface area as at full speed, or the same effective 
surface area as running the device at full speed for one hour. During this operation, 
there would be much lower shear evolved due to the lower fluid velocities at the 
capillary surface and the sample would be in the capillary for the same amount of 
time.  
 Figure 5-6 shows the monomer loss from the three samples and confirms that the 
half rate samples have the same level of monomer loss as the samples processed 
for half the time at the full rate, supporting the effective surface area hypothesis.  
 Since the length of time that the samples would be processed at would affect the 
effective surface area that the antibody would be exposed to, by having a greater 
effective surface area, the level of monomer loss would be increased in a sample. 
This would not only marginalise any sources of outside error, but also help 
differentiate antibodies with more closely related stabilities. 
 Figure 5-7 shows the results for IgG1 (Medi/UCL008) samples at 5mg/ml in L-
Histidine and (D+) Trehelose buffer at pH5.5 processed for 1, 2, 3, 4, 5 and 6 hours 
and tested for the level of monomer remaining. These results show that the level of 
monomer loss follows a near linear path, similar to the path of the shear device 
during degradation at the same levels of monomer loss. This path seems to 
intercept the y-axis at 2% monomer loss. This 2% loss could be accounted for by 
the amount of protein that is adsorbed to the surface (Dee et al., 2003). This would 
amount to 0.045mg of protein bound to a surface area of 2.63x10-3 m2 at a density 
of 17.1 g m-2. To determine if this is the case, capillaries of various diameters could 
be used to determine if the density calculated is similar. 
 A monomer loss of 7% at 2 hours in Figure 5-7 was significant for the IgG1 
(Medi/UCL008) which was one of the more stable antibodies tested in the disc shear 
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device and the high level of reproducibility of the method would ensure that any 
differentiation of stability between antibodies was detected. It was concluded that to 
keep the operating time down, the method would be run for 2 hours. 
 
 
Figure ‎5-7: IgG1 (Medi/UCL008) monomer remaining after 1-6 hours of capillary 
shear device operation. 5mg/ml protein samples suspended in L-
histidine and (D+) Trehelose buffer at pH5.5. 
 
5.5 The effect of concentration on monomer loss in the 
capillary 
 When operating the disc shear device, increasing the concentration of the sample 
appeared to be limited in its effect of increasing monomer degradation rate. It was 
hypothesized that this was due to limited surface area available on the disc to allow 
monomer to bind. When using a capillary, the surface area to volume ratio changes 
from 228m-1 in the shear device to 4773m-1 due to the capillaries inner diameter of 
0.26mm, an almost 21 fold increase. The capillary device was expected to increase 
the rate of monomer loss to a much greater extent with increased concentration.  
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Figure ‎5-8: Comparison of monomer remaining of IgG1 (Medi/UCL008) at 50 and 5 
mg/ml after 2 hours of processing in capillary shear device. 
 
 Figure 5-8 shows the monomer percentage remaining for increasing the 
concentration 10-fold, from 5mg/ml to 50mg/ml during a two hour operation. For the 
disc device, there is a decrease in the percentage of monomer lost from 45% to 
26% (figure 4-14). In real terms however, this equates to a 5.8 times increase in the 
mass of antibody lost at 50mg/ml, from 1.5mg to 9.1mg.  For the capillary device, 
there is an increase in the percentage of monomer lost when increasing the 
concentration, going from 7% at 5mg/ml to 45% at 50mg/ml. This equates to a 64 
times increase in the mass of antibody lost, going from 0.19mg at 5mg/ml to 
12.38mg at 50mg/ml.  
 When comparing the increase in rate of degradation between the concentrations, 
the capillary device gave an 11-fold greater effect than the disc device for the 20-
fold increase in surface area to volume ratio. 
 This leads to the hypothesis that the rate limiting factor in the disc device was 
indeed the surface area available for adsorption of protein as supported by previous 
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experiments into similar issues (Bee et al., 2010, Brummitt et al., 2011). The protein 
is hypothesized not to become unstable until it comes into contact with the surface 
material and enter a non-native state (Roberts, 2007). 
 The large increase in monomer loss rate from such a low level at 5mg/ml would 
also indicate a limiting factor in the capillary device. With the disc device, the 
turbulent flow ensures good mixing and a near constant refreshing of the 
concentration of monomer at the boundary layer. At 50mg/ml the monomer 
population spread at any given cross section in the capillary is quite dense so 
movement of antibody into the boundary layer is not constrained. At 5mg/ml 
however, the lack of good mixing in the laminar flow of the capillary means the 
concentration gradient between the boundary layer and bulk fluid is not very high 
which may be the reason for the low levels of degradation at low concentration 
(Roberts, 2003). Faster flow rates in the capillary would give better mixing and a 
thinner boundary layer, so improving the concentration gradient across to the 
capillary wall as well as removal of antibody from the wall itself (Doran, 1995).  
 
5.6 Comparability of the capillary device with the disc 
interfacial shear device 
 The final test of the capillary system was to determine comparability with the disc 
device in determining the stability of IgG1 and IgG4 antibodies Medi/UCL003-008. 
By comparing the monomer lost after capillary operation with the PDC determined 
by disc operation, it was hypothesized that there should be a correlation. 
 Figure 5-9 shows that as hypothesised there is a correlation between the stability 
determined by the disc device with the monomer loss determined in the capillary 
device. There is perfect correlation between the IgG1 antibodies. For the IgG4 
candidates, the PDC values are so close that they are within error of each other and 
it is uncertain if they correlate with the capillary results. To better determine whether 
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the methods correlate for the IgG4, conditions with greater differentiation in the disc 
shear device would need to be developed and used. The biggest issue with creating 
such conditions is that the two molecules seem to be so unstable in the disc device 
that they seem to be degrading at the maximum rate for each of the conditions used. 
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Figure ‎5-9: Comparison of monomer loss in capillary device with PDC in disc 
device for various IgG1 and IgG4 candidates (Medi/UCL003-008). Error 
bars for disc device show Standard Error, error bars for capillary show 
Standard Deviation. Disc device corresponds to left Y-axis while 
capillary device corresponds to right Y-Axis. 
 
5.7 Implications of the capillary device on processing time 
Table ‎5-1:  Comparison of disc and capillary devices in terms of sample needed 
and processing time needed. 
 
The ability of the capillaries to enable parallel processing opens the door to using 96 
well plates to allow 96 samples to be queued up. Parallel capillaries could process 8 
wells simultaneously every 2 hours before CIP, with the samples ready to be placed 
directly onto a HPLC for SE-HPLC analysis. 
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    1 sample 8 samples 96 samples 288 samples 
Sample (ml) 
Disc device 7 56 672 2016 
Capillary device 0.6 4.8 57 172 
Time 
(hours) 
Disc device 2.5 20 240 720 
Capillary device 2.25 2.25 27 81 
Working 
days (days) 
Disc device 1 3 32 96 
Capillary device 1 1 2 4 
 
The simplicity of the method could allow automation either on an established robotic 
platform such as a Tecan, or on a custom produced platform that could be designed 
and assembled in the future. A fully developed technique of this kind, with a 15 
minute clean in place protocol would be able to process 96 different samples within 
27 hours. Multiple plates could be loaded onto a system before the weekend to 
allow 192 or 288 samples to be processed in one batch using a total of 57.6mg of 
protein per plate. Using the current method, a maximum of 3 runs can be completed 
in a working day so it would take 32 days, or six and a half weeks and 672mg of 
protein to get the same number of results as one plate. This is an order of 
magnitude reduction in time and material requirements. Details of benefits are given 
in table 5-1. 
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5.8 Conclusions: Is the capillary device capable of giving 
comparable results to the disc device? 
 It is concluded that the capillary device gives a monomer loss reading that is 
dependent on concentration, flow rate, and time of shear. Longer operating times 
give greater levels of monomer loss. With the flow rate conditions used for the proof 
of concept device, the concentration has a big influence on the monomer loss 
observed. It is hypothesized that this is due to a lack of driving force into the 
boundary layer, due to the laminar flow rates, to bring the monomer into contact with 
the capillary surface. The results from the concentration experiments and the 
apparent effect of the increased surface area also points to the adsorption at the 
solid/liquid interface being a key rate limiting step in the mechanism of protein 
aggregation. The significant effect of increasing concentration would support the 
involvement of mass transfer into and out of an intermediate boundary layer. 
 The results of the method were shown to correlate to the results derived from 
operation of the disc device and so lead to a recommendation to develop the 
technique further. Since the maximum volumetric flow rate achievable for the 
syringe pump is utilized, it is recommended for further studies to use a different 
method to withdraw and dispense sample. This experiment was completed towards 
the end of the project, so it was not possible to use device for the rest of the 
experiments and investigations.  
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6 Evaluation of aggregate analysis 
 Having determined the effect of various degradation pathways on the monomer and 
its subsequent rate of loss to the aggregated form, the logical step is to then look at 
the aggregates that are formed.  
 The optimal conditions for running Proteo-stat fluorescent dye experiments were 
determined before testing both thermal and shear degraded samples with the 
method to determine its usefulness in tracking aggregation. 
 The nanoparticle tracking analysis technique run on the Nanosight was then 
evaluated alongside the dynamic light scattering (DLS) method to determine its 
suitability for polydisperse solutions before being used to analyse shear degraded 
samples taken every 20 minutes of operation from the disc shear device. 
 Finally the data was used to try and explore a mechanism for aggregation during 
the interfacial shear methods. 
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6.1 Materials and methods 
 5mg/ml IgG1 (Medi/UCL008) in a pH 5.5 L-Histidine and (D+) Trehelose buffer was 
used. The SE-HPLC method was employed to evaluate antibody degraded at 40°C 
at a low pH for 24 hours compared to antibody degraded by two hours processing in 
the shear device. Proteo-stat dye running conditions were then determined and 
used to look at aggregates formed during shear device operation and thermal 
degradation. Nanosight was then validated and used to determine aggregates for 
samples taken at 20 minute intervals in the shear device. All protocols are described 
in detail in the materials and methods chapter. 
6.2 Using Proteo-stat for determining aggregate levels 
 Proteo-stat dye was used to determine the aggregate levels present in degraded 
samples. The dye is a molecular rotor that rotates like a propeller in the absence of 
protein aggregates and does not fluoresce, as shown in figure 6-1. Upon binding 
with aggregates, the rotation is immobilized and the dye fluoresces (Khurana et al., 
2005). The dye assay kit was relatively new and no characterisation studies had 
been performed by the sponsor company so the operating conditions were 
determined before use. The excitation measurements were read on a plate reader 
across a spectrum from 580nm to 680nm. The reading at 590nm was around the 
peak for most antibody readings, so this was the value used for comparison. 
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Figure ‎6-1:  Structural diagram of Thioflavin T molecule used as Proteo-stat dye. 
Structure based on figure from Proteo-stat website. 
6.2.1 Determining operating conditions 
 The first operating condition to be determined was to look at the size of antibody 
that the method was able to detect. The sample used to test the dyes was IgG1 
(Medi/UCL008) in PBS processed in the disc shear device for 1 hour. To determine 
size detected, unfiltered samples were tested against samples purified with filters of 
different sizes, and then samples with no aggregate present at all to get a 
determination of the level of sensitivity of the technique to aggregates at different 
sizes. 
 Figure 6-2 shows the results for the filter experiment and shows that using filters of 
0.65nm and 0.22nm will decrease the emission from around 3750 RFU to around 
1750 RFU. The buffer has an emission around 500 RFU at 590nm on the spectrum. 
This means that up to 1250 RFU is contributed by the aggregates under the size of 
0.65μm or 1150 RFU are smaller than 0.22μm. This leaves 2000 RFU that is 
contributed by aggregates larger than 0.65μm, representing around 70% of the 
emission overall. It also suggests that there are significant numbers of aggregates 
under the size of 0.22μm in the sample. SE-HPLC of the samples showed no low 
molecular weight aggregates present, so it would appear that the dye has either 
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been activated by monomer or it has helped to precipitate aggregates that were not 
previously present and then bound to them to become activated. This would suggest 
that the optimum method for use of the dyes would not involve the use of filters. 
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Figure ‎6-2: Proteo-stat dye emission values after filtration of aggregated 1mg/ml 
IgG1 (Medi/UCL008) samples in PBS using 0.22 and 0.65μm pore sized 
filter compared to no filtration. 
 
To test the linearity of the emission spectra with regards to the level of aggregate 
present, an aggregated sample of IgG1 (Medi/UCL008) in PBS produced by 2 hours 
processing in the disc shear device was used. Samples of the processed antibody 
were sequentially diluted with monomeric, unprocessed antibody to give samples 
with progressively less aggregate present.  
 139 
% aggregate sample
1% 25% 50% 75% 100%
E
m
is
s
io
n
 (
R
F
U
)
0
2000
4000
6000
 
 
Figure ‎6-3: Proteo-stat dye emission at 590nm for aggregated 5mg/ml IgG1 
(Medi/UCL008) in PBS samples diluted to 100, 75, 50, 25 and 1% of 
original solution with monomeric antibody. 
 
 Figure 6-3 shows the results from the dilution experiment and outlines a near step-
wise loss in the level of emission from 100% processed solution down every 25% 
dilution and at 99% monomer. This supports the manufacturer’s claims that the 
emission of the dye follows a linear path with levels of aggregate.  
 The final parameter to check with the dye was the reproducibility of the results. To 
accomplish this, all readings were performed in triplicate and the standard deviation 
was determined for these readings, figure 6-4 gives the curve for an IgG1 antibody 
(Medi/UCL008) processed for 2 hours in the shear device and not being diluted. The 
graph shows that the standard deviation at around the 590nm wavelength is quite 
high, and would hinder the ability of the technique to be able to differentiate close 
results of total aggregated antibody. 
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Figure ‎6-4: Graph of standard deviation of triplicate readings for Proteo-stat 
results for 5mg/ml IgG1 (Medi/UCL008) in PBS processed for 2 hours at 
9000rpm in disc shear device. 
6.2.2 Analysis of thermally degraded samples 
 The method was used to try and determine the level of aggregate present in 
samples of 5mg/ml IgG1 (Medi/UCL008) that had been denatured for 24 hours at 
40°C at a low pH. The aggregate profile for this was determined by SE-HPLC and 
the chromatogram shown in figure 6-1. SE-HPLC showed the sample to contain a 
great deal of low molecular weight aggregate and very minimal amounts of 
monomer loss from that range. Emission spectra from samples prepared in this way 
all failed to show any increase from the negative controls, leading to the conclusion 
that the dye is incapable of binding to low molecular weight aggregates in the 
conditions used. This is in contradiction to the results gained from the use of shear 
device denatured samples filtered with a 220nm centrifugal filter, which did show 
significant levels of emission. 
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6.2.3 Analysis of shear degraded samples 
 The Proteo-stat dye was used to look at the levels of aggregate present in samples 
of 5mg/ml IgG1 (Medi/UCL008) taken at 15 minute intervals from the disc shear 
device during its normal operation. The results of this are shown in figure 6-5 and 
show that the level of aggregate determined by the technique does increase with the 
increased operating time. While the amount does increase this is within the large 
level of error inherent in the technique and the results are very noisy. There is no 
clear step change in the emission spectra values at 590nm. 
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Figure ‎6-5: Proteo-stat emission from samples of 5mg/ml IgG1 (Medi/UCL008) in 
PBS taken every 15 minutes from the disc shear device operated at 
9000rpm. 
6.2.4 Conclusion regarding Proteo-stat dyes 
 The Proteo-stat method does not seem like an optimal way to measure the levels of 
aggregate formed. The high standard deviation in the results points to an inability of 
the method to differentiate between samples. Additionally, the results from the filter 
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experiments, when coupled with those from the temperature degradation 
experiments, suggest that either the method cannot detect low molecular weight 
aggregates in certain conditions or the dye gives false positives for aggregates in 
certain conditions. For the conditions used, the technique is not recommended for 
use in determining levels of aggregation present. The molecule is however good at 
binding to ordered fibrils, so the technique could be used to determine aggregate 
morphology and tracking fibril growth.  
6.3 Nanoparticle tracking analysis 
 The nanoparticle tracking analysis technique was performed using the Nanosight 
which was used to determine the level of aggregate present in degraded samples 
and to give a measure of the level of each size range of particle present in solution. 
The method individually tracks the refracted light from all the molecules present in a 
cross section of the sample volume viewed by a microscope and determines the 
particle size by assuming Brownian motion (Nanosight, 2009).  
6.3.1 Analysis of shear degraded samples 
 The method was tested on a sample of 1mg/ml IgG1 (Medi/UCL008) in pH 5.5 L-
Histidine and (D+) Trehelose buffer that had been processed in the disc shear 
device for 2 hours at 9000 rpm.  
 Figure 6-6 shows the concentration of the particles at different particle sizes that 
were detected by the method. Since the method takes each particle as one count 
irrespective of size, the standard output of the method does not give a good 
measure for the amount of antibody present in each sample. To account for this, the 
assumption was made that the particles detected were spherical, and it was decided 
to report the level of antibody present as the volume of protein present at each 
particle size using the equation for a sphere, Volume = 4/3 π x Radius3. 
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Figure ‎6-6: Example of Nanosight result from a polydisperse aggregated sample of 
IgG1 (Medi/UCL008) in L-Histidine and (D+) Trehelose buffer pH 5.5 
processed for 2 hours at 9000rpm in the disc shear device. 
 
 The monomer loss for 5mg/ml IgG1 (Medi/UCL008) in pH 5.5 L-Histidine and (D+) 
Trehelose solution over 2 hours processing in the disc shear device is shown in 
figure 6-7 as determined by SE-HPLC. As previously stated, little can be determined 
about the aggregates produced using this method except that there are no low 
molecular weight aggregates present. By taking the samples from the shear device 
and then processing them in real time using the Nanosight, it was possible to get a 
picture of the different sizes of antibody present at different times in the device 
chamber, and as such track the growth of aggregates. 
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Figure ‎6-7: Monomer loss for 5mg/ml IgG1 (Medi/UCL008) in L-Histidine and (D+) 
Trehelose solution at pH5.5 over 2 hour of shear at 9000rpm in the disc shear device 
as determined by SE-HPLC. 
  
Figure 6-8 shows the results from one such run where samples were taken every 20 
minutes due to limitations at the time for turning around the Nanosight technique. As 
previously described, the raw results were adjusted to show the volume of protein 
present. The results can be broken into two distinct regions, the medium sized 
aggregates from the lower limit of the device to around 1000nm, and the large 
aggregates from 1000nm to the upper limit of the device. The large aggregates 
viewable do not seem to give a trend. This can be explained since any large 
particles captured will give a very high reading because the volume of protein rises 
exponentially with size. Thus what appears to be a large reading is in fact a single 
particle being tracked within the sample space. Due to the capture method and the 
relatively small volume of sample that is being tested, the appearance of large 
molecules has a high degree of chance associated with it. This would suggest that 
the method is not very suitable for determining aggregate levels in the larger ranges 
at the same time as looking at the smaller ranges. 
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 In the 50nm to 1000nm range however there does seem to be a clear trend with the 
levels of aggregates in the range. They seem to increase, peak and then decrease. 
 
 
Figure ‎6-8: Particle size distribution for volume of protein in samples of 5mg/ml 
IgG1 (Medi/UCL008) in L-Histidine and (D+) Trehelose buffer at pH5.5 
taken every 20 minutes over 2 hour of processing at 9000rpm in disc 
shear device. 
 
6.3.2 Determining aggregate growth patterns in the shear device 
 It was decided to look further into the aggregate growth pattern, and after refining 
the Nanosight turnaround technique, a further experiment was performed taking 
samples of 5mg/ml IgG1 (Medi/UCL008) in pH 5.5 L-Histidine and (D+) Trehelose 
buffer every 15 minutes from the shear device and analysing them using the 
Nanosight. This time however, the results would be grouped into four different size 
ranges that had been seen to have repeated peaks of certain sizes during operation. 
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Figure ‎6-9: Particle size range distribution for volume of protein in samples of 
5mg/ml IgG1 (Medi/UCL008) in L-Histidine and (D+) Trehelose solution 
at pH5.5 taken every 15 minutes over 2 hour of shear at 9000rpm in 
disc shear device. 
 
 Figure 6-9 shows the results for this experiment. The first size range from 0nm to 
100nm has a very low volume of protein at all times in the processing. This points to 
the size range being home to short lived intermediaries in the subsequent growth of 
larger aggregates. The 101nm to 250nm range seems to stay quite steady with a 
small peak between 60 and 80 minutes of processing, pointing to this size range 
again containing mostly short lived intermediaries. The 251nm to 600nm range has 
the highest volume of protein present and does seem to build up to a maximum 
somewhere between 40 and 60 minutes of processing before again falling. This 
suggests that this size range is a key intermediate in the growth of larger aggregates 
that is longer lived than most. This would corroborate with the work done on defining 
aggregation as nucleation followed by fibrillation (Holm et al., 2007, Bhak et al., 
2009) and seems like a likely candidate for being a relatively stable aggregation 
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nucleus or settling point during growth. This is further corroborated by the results for 
the 601nm to 900nm range, which show a lower level of protein volume that peaks 
around 80 minutes of shear before falling. This shows proof that the aggregates are 
building up on each other on their route to forming the very large and insoluble 
aggregates that cause the solution to become cloudy. The results themselves do 
show a certain amount of noise, so further work should go into finding the best way 
for averaging out the results. 
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6.4 Conclusions: How best to characterise process 
aggregation? 
 Aggregates produced in the course of processing have a wide range of sizes that 
require a series of techniques to determine the levels in all the size ranges. The size 
range is a product of the mechanisms by which aggregates form, with smaller 
aggregates acting as precursors or nuclei for subsequent larger aggregates (Joubert 
et al., 2011). By using complementary techniques, it is possible to create a portfolio 
of techniques that can analyse the aggregates formed in the shortest amount of 
time, with lowest costs and required level of reliability. For very large particles a 
whole range of techniques outlined in the literature review are available, with 
microflow imaging standing out as a particularly reliable, simple and high throughput 
method that can characterise particles from 2μm to 100μm. For low molecular 
weight particles, the SE-HPLC method is an industry standard that can give 
incredibly reliable, high throughput and cheap results on a single column in the size 
range of 1nm to 50nm, as shown in this work and others (Carpenter et al., 2009). 
This leaves the middle and large sized aggregate range from 50nm to 2μm. The 
Proteo-stat dyes tested are unable to give quantitative analysis of the different sizes 
and the DLS is unable to differentiate the different sizes present, giving a weighted 
average in favour of larger particles. The work performed on producing size 
distributions of aggregates every 15 minutes over the operation of the shear device 
shows that the Nanosight is capable of filling this gap as a low cost, quick and 
accurate technique. The technique highlighted the growth and decline in the volume 
of different sizes of aggregates during processing in the disc shear device, showing 
the pathways for formation of large insoluble aggregates. 
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7 Characterising reversible self association in a 
typical biopharmaceutical process 
7.1 Introduction 
 As alternative molecules with higher affinities are developed, the level of 
hydrophobicity present on the molecular surfaces of lead candidates is increasing. 
Reversible self association (RSA) is a phenomenon that occurs during processing of 
highly hydrophobic molecules (Bethea et al., 2012). It was observed that at specific 
conditions, certain molecules would have a hydrodynamic radius measured by DLS 
equivalent to dimeric antibody aggregates. However when these molecules were 
processed using methods such as size exclusion SE-HPLC they would appear to 
consist of only monomer, as shown in figure 7-1. 
 
Figure ‎7-1: SE-HPLC for IgG1 (Medi/UCL009) at 15mg/ml in pH5.6 buffer containing 
30mM L-Histidine and A) 0.03M NaCl with a hydrodynamic radius of 
18.09nm B) 0.15M NaCl with a hydrodynamic radius of 12.29nm. 
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 It is important to understand the effect of these reversibly self associated molecules 
on the purification process. Since the molecules only express the RSA 
characteristics in specific conditions and seem to leave no lasting effect on the 
molecule, it would be possible to change conditions of the solution to remove the 
RSA prior to a step if a certain operation was shown to perform adequately sub-
optimally with RSA present. 
 In this chapter, an IgG1 molecule that was seen to exhibit RSA characteristics was 
investigated. The conditions where the molecule exhibited RSA behaviour were 
determined to allow for process step characterisation. The steps investigated 
included pumping, storage, protein A chromatography and viral filtration. Molecular 
modelling was then performed on the Fc region to determine if there was a cause for 
the RSA that could be determined from the surface chemistry. 
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7.2 Materials and methods 
 IgG1 (Medi/UCL009) was transferred into the different buffer conditions using PD10 
desalting columns for initial stages and UF/DF for the later more antibody intensive 
stages of protein-A and viral filtration. The design of experiment was performed 
using JMP software to give conditions where the expression of RSA occurred by 
altering the pH, salt concentration and antibody concentration. These conditions 
were then carried forward to the rest of the experiment. Shear studies and 
accelerated stability studies were performed for the four higher pH conditions using 
the methods described, where the antibodies were held at 20°C. The effect of RSA 
on loading onto a protein-A column was determined using a Hi-Trap (GE healthcare, 
Uppsala, Sweden). Finally filterability was performed using the viral filtration method 
for the four higher pH conditions. Molecular modelling was then performed on the 
antibody to try and determine the cause of the RSA characteristic. 
7.3 Design of experiment for manipulating antibody size 
 To determine the conditions at which RSA was present for the IgG1 (Medi/UCL009) 
molecule, a 23 factorial design of experiment (DoE) was performed to establish the 
relationship between the three variable conditions and the size of the antibodies in 
the resultant solution, as determined by DLS. As part of the reading, viscosity would 
also be measured. The variables to be considered were chosen to be the 
concentration of salt (NaCl), antibody concentration and the pH of solution. The pH 
range was chosen as 4.4 to 5.6 with a midpoint at 5. The salt concentration range 
was chosen to be 0.03M to 0.15M with a midpoint at 0.09M. The antibody 
concentration range was chosen to be 5mg/ml to 15mg/ml with a midpoint of 
10mg/ml. Three midpoint measurements were taken. As standard, each condition 
would be measured in triplicate.  
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Table ‎7-1: DoE conditions and resultant hydrodynamic diameter readings of IgG1 
(Medi/UCL009). 
 
Sample pH 
Salt Conc.  
( M ) 
Ab Conc. 
( mg mL
-1 
) 
Viscosity  
( mPa s ) 
Hydrodynamic 
diameter (nm) 
1 4.4 0.03 5 1.0552 11.56 
2 4.4 0.03 15 1.1033 11.63 
3 4.4 0.15 5 1.0637 10.95 
4 4.4 0.15 15 1.159 11.51 
5 5 0.09 10 1.1825 12.66 
5 5 0.09 10 1.1825 12.71 
5 5 0.09 10 1.1825 12.78 
6 5.6 0.03 5 1.0797 12.47 
7 5.6 0.03 15 1.2588 18.09 
8 5.6 0.15 5 1.0797 10.83 
9 5.6 0.15 15 1.2127 12.29 
 
 Table 7-1 shows the results seen for the different conditions. The viscosity 
measurements were taken separately prior to analysis with the DLS. There seems 
to be a correlation between the viscosity of the solution and the size of the 
molecules as determined by the DLS method. This could be due to increased Van 
der Waals interactions between the larger molecules with larger surface areas in 
solutions (Bethea et al., 2012). The differences in sizes measured suggest that 
either the different conditions had an effect on the hydrodynamic diameters of the 
molecules by changing the conformation in solution, or that levels of RSA in solution 
were modulated by the solution which would move the average reading of the DLS 
between the monomer and the dimer size (Chu, 1991). Condition 7 was shown to 
promote RSA formation to a large extent. Figure 7-2 shows the contour plots for the 
different variables and their effects on the size of the antibody in solution. The plots 
show the relationships between couples of variables and show that the most 
sensitive conditional changes in molecular size came from a combination of the 
NaCl concentration and pH. 
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Figure ‎7-2: DoE Contour plots for IgG1 (Medi/UCL009) varying pH, antibody 
concentration and salt concentration. 
 
 
 
The factors were tested to see which were the most statistically relevant by using 
the fit least squares function of the DoE software, shown in figure 7-3. Here the 
results again show the most significant factors are the salt concentration and pH of 
solution. This also shows that the effect, beyond statistical doubt, is caused by the 
factors chosen and is not random. 
 Conditions 6, 7, 8 and 9 were chosen to take forward for further testing in order to 
remove the need for one of the variables. It was decided to remove pH as a variable 
to stop the possibility of it affecting the loss of monomer due to degradation at the 
lower pH. 
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Figure ‎7-3: DoE fit least squares for IgG1 (Medi/UCL009) from varying pH, antibody 
concentration and salt concentration. 
7.4 The effect of shear and accelerated stability on 
monomer levels at different conditions 
 During the course of antibody purification, the sample will come into contact with 
many solid-liquid interfaces, high levels of shear and will be held in various tanks 
and vessels for short periods of time. All these factors will promote aggregation (Bee 
et al., 2010, Tyagi et al., 2009). Conditions 6, 7, 8 and 9 of IgG1 (Medi/UCL009) 
were processed in the shear device to asses the effect of RSA on antibody stability 
in shear conditions during processing. 
 Holding samples for accelerated stability experiments was done in conjunction with 
the shear study to more fully characterise the conditions the proteins would be 
exposed to in processing. 
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 Figure 7-4 shows the monomer percentage of samples processed over two hours in 
the shear device. The monomer loss shows that there is very little difference 
between the conditions during operation.  
 
Figure ‎7-4: Monomer loss of IgG1 (Medi/UCL009) in conditions 6-9 at 15 minute 
intervals over 2 hours processing in disc interfacial shear device. Error 
bars for error in the shear device method. 
 
 There is however a subtle difference in the results. When increasing antibody 
concentration from condition 8 to condition 9 there was an increase in the stability of 
solution, as was shown in previous experiments to determine the effect of increased 
concentration on shear device results. When increasing the concentration in 
condition 6 to condition 7 however, there was a decrease in stability. This would 
suggest that the presence of RSA does have a slight negative effect on the stability 
of the solution when exposed to shear. The change in salt concentration may also 
affect the level of monomer loss outside the effect on protein size. Studies have 
shown the effect of NaCl on solid-liquid interfaces (Chao and Paolo, 2012), causing 
an increase in the surface tension and residence time of interfacial water molecules. 
This would effectively increase the viscosity at the interface and so affect the shear 
rate on the proteins as well as reduce the Reynolds number in the chamber. 
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 There is a concentration difference between samples 6 and 8 at 5 mg/ml and 7 and 
9 at 15 mg/ml. To take this into account, figure 7-5 shows the mass of antibody lost 
in each of the runs assuming a sample volume of 7ml. The data shows that there is 
a greater amount of antibody lost with the higher concentrations, as is to be 
expected. Overall it can be concluded that there is such a low difference in stability 
for the different conditions that it is not a factor that needs to be considered during 
high shear operations in processing of an antibody. 
 
Figure ‎7-5: Mass of IgG1 (Medi/UCL009) in conditions 6-9 lost at 15 minute 
intervals over 2 hours processing in disc interfacial shear device. Error 
bars for error in the shear device method. 
 
When looking at the accelerated stability results over the month hold, shown in 
figure 7-6, the level of monomer loss is quite consistent and low between all the 
conditions. For the non RSA conditions there seems to be more monomer loss in 
antibody samples that had been sheared then there was for antibody samples that 
had not been sheared. This seems to be reversed in the conditions where RSA is 
present. However, the level of monomer loss is so low over such a long period of 
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time that again it is not recommended to be a factor to be considered during 
processing of an antibody. 
 
 
Figure ‎7-6: Accelerated stability results of IgG1 (Medi/UCL009) in conditions 6-9 
both with and without 2 hours processing in disc interfacial shear 
device prior to storage. 
 
7.5 The effect of RSA and size on the DBC of protein-A  
 The most important unit operations through the purification of a protein therapeutic 
are the chromatography steps. During these steps it is important to keep the level of 
antibody loss to a minimum to keep the purification process as profitable as 
possible. With antibody therapeutics, the Protein-A step is the work horse of the 
process, able to provide up to 95% purity and retention of the antibody of interest. 
Medi/UCL009 (IgG1) was formulated in conditions 6 and 7 as well as in PBS buffer. 
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Medi/UCL008 (IgG1) was also formulated in these three conditions to provide a 
control for any effect of the buffer. 
 The dynamic binding capacity (DBC) was used as the comparator to determine the 
effect of RSA on the step. To determine a benchmark DBC value, Medi/UCL008 and 
Medi/UCL009 formulated in PBS buffer were run at a linear flow rate of 200cm/hour 
on a standard Protein-A HiTrap. The HiTrap has a suggested DBC of 40mg of 
antibody, so 100mg of antibody was loaded onto the column to get full loading of the 
matrix. The matrix was eluted and the eluate was collected in pre weighed 15ml 
Falcon Bluemax™ tubes. The strip was also collected to check there was no 
antibody that kept bound to the matrix due to conformational changes. 
 The tubes, filled with eluate and strip, were weighed again to allow the 
determination of the mass of liquid collected. The concentrations of these samples 
were then determined by analysis of absorbance at 280nm. These two readings 
allowed the mass of antibody bound to the column to be calculated. 
 
Table ‎7-2: Protein-A capacity for Medi/UCL008 (IgG1) and Medi/UCL009 (IgG1) 
prepared in conditions 6, 7 and at 5mg/ml in PBS. 
 
Condition 
Hydrodynamic 
diameter (nm) 
Mass of Ab bound 
to column (mg) 
Medi/UCL008 - 7- pH5.6, [Ab} 15mg/ml,[Salt] 0.03M 12.31 39.4 
Medi/UCL008 - 6- pH5.6, [Ab} 5mg/ml,[Salt] 0.03M 12.28 42.8 
Medi/UCL008 - PBS 11.87 46.7 
Medi/UCL009 - 7 - pH5.6, [Ab} 15mg/ml,[Salt] 0.03M 18.04 42.6 
Medi/UCL009 - 6- pH5.6, [Ab} 5mg/ml,[Salt] 0.03M 12.47 48.0 
Medi/UCL009 - PBS 11.54 52.8 
 
 Table 7-2 shows the values of the mass of antibody bound to the matrix for the six 
conditions examined. The results show that the DBC for Medi/UCL009 is inherently 
better than that of Medi/UCL008. The PBS buffer condition is close to the ideal 
loading conditions for a protein-A column, so it was used as the base case for both 
antibodies. The other conditions were prepared as a percentage of the capacity of 
the PBS condition and plotted on figure 7-7. The results show firstly that the pH 5.6 
and 0.03M NaCl condition gives a much less ideal environment for binding to the 
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protein-A matrix as witnessed by the average drops of around 10% and 18% binding 
for conditions 6 and 7. Secondly, it appears that the higher concentration of antibody 
gives a lower DBC. This is due to the rate of absorption of antibody into the matrix 
beads reaching its limit, so any extra antibody in the higher concentration feed will 
be excluded from the beads and pass through the column unbound. For the RSA 
condition of Medi/UCL009 there seems to be a greater level of loss of DBC than for 
Medi/UCL008, but this is only around 4% extra on a drop of 16% from the PBS 
condition, and in real terms the total mass of protein bound is greater. From a 
processing point of view, it would appear that RSA is not a major problem to be 
worried about during protein-A chromatography. 
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Figure ‎7-7: Percentage of DBC of PBS condition on protein-A of Medi/UCL008 
(IgG1) and Medi/UCL009 (IgG1) in conditions 6- pH5.6, [Ab} 
5mg/ml,[Salt] 0.03M and 7- pH5.6, [Ab} 15mg/ml,[Salt] 0.03M. 
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7.6 The effect of RSA and size on viral filtration 
 The viral filtration step of a process is the final step before filling vials ready for 
transport (Shukla et al., 2007b). At this point in the process the antibody will be 
formulated in its final stability buffer. The effect of RSA on the viral filtration step of a 
process was determined by using conditions 6, 7, 8 and 9 with IgG1 (Medi/UCL009). 
 To test the membrane system each buffer was run through the viral filtration rig for 
40 minutes as part of the equilibration process prior to running through the antibody 
solutions. In each case, there was no drop in the flux after 40 minutes of flow.  
 
 
Figure ‎7-8: Flux of IgG1 (Medi/UCL009) in buffer conditions 6-9 through a 20nm 
pore sized membrane. 
 
 Figure 7-8 shows the flux of antibody feed through the membrane until it reached 
100LMH. The results clearly show that condition 8, which ran out of sample before 
the flux hit below 100LMH, has a much longer membrane life than the other 
conditions. They also show that with condition 7, the RSA condition blocks the 
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membrane almost instantly. This suggests that the RSA with a hydrodynamic 
diameter of 18nm blocks the filter pores which are at an average of 20m. This could 
be due to mechanical blockage of the pores or due to adhesion of the RSA to the 
membrane surface which would exclude further material passing through the filter 
(van Reis and Zydney, 2001). The low operating times of conditions 6 and 9 would 
suggest that the reason their DLS results show larger antibody hydrodynamic 
diameter is that there is RSA present in these samples which skews the peak 
towards a larger hydrodynamic diameter reading. 
 
 
Figure ‎7-9: Mass of IgG1 (Medi/UCL009) in conditions 6-9 through 20nm pore sized 
membrane. 
 
 Figure 7-9 shows the mass of antibody that was passed through the membrane for 
each condition. It is evident that despite blocking the membrane quicker, condition 9 
allows more mass of antibody to permeate the membrane. By plotting the mass of 
antibody that is filtered through the membrane against the hydrodynamic diameter of 
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the sample derived from DLS in figure 7-10, it is apparent that there is a correlation. 
The larger the measure of hydrodynamic diameter, the less mass of antibody 
permeates the membrane before blockage occurs. If as postulated, the larger 
hydrodynamic diameter determined by the DLS is due to a skewing of the 
distribution by the presence of RSA, then the larger hydrodynamic diameter samples 
would have a larger proportion of RSA present. With the larger proportions of RSA 
present, the amount of monomer that can pass through the viral filter before the 
level of RSA required to block the filter comes into contact with it is reduced. 
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Figure ‎7-10: Mass of IgG1 (Medi/UCL009) permeated through membrane against 
Hydrodynamic diameter. 
  
 It is concluded that for viral filtration, RSA is a concern and has to be avoided in the 
final formulation step. Additionally it is recommended that the effect of RSA should 
be of concern in any dead end filtration taking place in a process. 
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7.7 Molecular modelling of Medi/UCL009 
 To determine the reason for RSA behaviour, molecular modelling was performed on 
the Fc region of IgG1 molecule Medi/UCL009 and compared to that of 
Medi/UCL008, an IgG1 with significantly enhanced bioprocessing-related 
physicochemical properties that has never shown any RSA behaviour. 
 
 
 
Figure ‎7-11: Comparison of SAP of Molecular models of Medi/UCL009 (IgG1) and 
Medi/UCL008 (IgG1) rotated views from left to right showing hinge end, 
upwards side, c-terminus, downwards side. 
 
 
 Figure 7-11 shows the molecules created when they were tested using SAP 
analysis. The molecules are shown in 4 equal stages of 360° rotation along an axis 
running through both chains of the Fc at the midpoint of the section, starting from 
the view of the hinge end and then rotating so the hinge end is at the top. Figure 7-
12 was then produced using electrostatic potential analysis with a 5Å radius size to 
give a surface charge map of the molecules. These were again shown in 4 equal 
stages of 360° rotation along an axis running through both chains of the Fc at the 
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midpoint of the section, starting from the view of the hinge end and then rotating so 
the hinge end is at the top. 
 The surface charge analysis does not show any obvious large areas where there is 
a lack of charge and similarly, the spread of charge in both molecules is also quite 
even, although there is a large patch of positive charge on the c-terminus. 
 
 
Figure ‎7-12: Comparison of Surface charge of Molecular models of Medi/UCL009 
(IgG1) and Medi/UCL008 (IgG1) rotated views from left to right showing 
hinge end, upwards side, c-terminus, downwards side.  
 
There is however a major difference in figure 7-11 where a large patch on the c-
terminus, reaching around to the anterior face of the Fc is predicted to be 
aggregation-prone by the SAP algorithm (Kayser et al., 2011, Chennamsetty et al., 
2010). This region would normally be exposed to the solution, and it is postulated 
that it would have a tendency to bind reversibly with one other similar unit on the 
mirrored patch on its c-terminus. The factors that were determined to effect RSA 
formation help support this. Salt concentration in solution would regulate the level of 
ionic shielding and higher concentrations of salt, to a certain point, would help shield 
the patches from each other and keep them separated (Dandliker et al., 1967). By 
extension, higher concentrations of antibodies would cause the individual antibodies 
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to be in closer proximity to each other and so have a greater probability of 
interacting. The effect of pH on the presence of RSA would likely be related to the 
regulation of the surface charge on the c-terminus, which at certain levels must be 
able to keep the molecules separated from each other. 
7.8 Conclusions: Should RSA be a cause for concern at 
certain stages of bioprocessing? 
 It has been concluded in this chapter that RSA is an avoidable problem in the 
purification of an antibody product if antibodies are not screened for it prior to lead 
selection. This screening should be performed in conjunction with the use of the disc 
shear device to make process development easier. If RSA is a characteristic, it does 
not critically affect primary recovery, pumping and holding operations, UF/DF or 
protein-A chromatography. RSA was shown however to cause problems when 
performing viral filtration and potentially any depth filtration, so it is important when 
designing a process with an RSA exhibiting molecule to formulate the antibody in a 
condition that does not present RSA prior to the final viral filtration step or in any 
other filtration steps. 
 The cause of RSA as exhibited by the IgG1 (Medi/UCL009) has been concluded to 
be the hydrophobic patch on the c-terminus of the Fc region identified from the high 
SAP score (Chennamsetty et al., 2010), which could react with similar patches on 
other Medi/UCL009 molecules to form reversible dimers. The interaction of these 
patches would be regulated by antibody concentration, salt concentration and pH 
both experimentally and from the literature (Dandliker et al., 1967). 
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8 Comparison of monomer loss in thermal and shear 
techniques and the effect of antibody structure 
 In this chapter, the effects of controlled antibody modifications TM and YTE on a 
drug candidate’s secondary and tertiary structure and overall charge were 
evaluated. The relative stabilities of these candidates were then determined and 
compared with the use of the protein decay coefficient (PDC), using a custom shear 
device to create surface adsorption in a high shear environment. This technique was 
then compared with melting temperature (Tm) data from differential scanning 
calorimetry (DSC) and the results from a 4 week accelerated stability study to 
determine if the shear method could be used as a complementary or replacement 
stability indicator for lead antibody screening. 
 Both Fourier Transform Infra-Red (FTIR) spectroscopy and molecular modeling 
techniques were used to help determine the effect of the modifications on the 
secondary and tertiary structures of the antibodies to help explain any trends seen. 
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8.1 Antibody candidates utilised 
 
 
Figure ‎8-1: Diagram showing the site of each mutation on the structure of the 
antibody and the resultant antibody formats used for comparison with 
3D protein structure taken from PDB, filename 2DQT. 
 
 The mutations used to modify the IgG1 and IgG4 base structures and the resultant 
antibodies are shown in figure 8-1. The YTE modification gives an increase in the 
serum half life by reducing binding to the Fc neonatal receptor. The TM modification 
was shown to decrease toxicity by reducing ADCC and CDC. The resultant 
antibodies were named Medi/UCL003-008 as described in the materials and 
methods section. However, in this section they will be denoted as their base 
structure followed by the modification or WT (wild type) for ease of reference.  
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8.2 Shear device results 
 The five different antibodies were processed in the shear device at 6000, 7500, 
9000 and 12000rpm. Each processed sample was cloudy when removed from the 
chamber, indicating the presence of aggregate. The insoluble material was removed 
by centrifugation prior to SE-HPLC. The area under the monomer curve at 15 
minute intervals was fitted to an exponential decay curve: 
C(t) = C0e
-kt 
 Where C(t) is the monomer concentration (mg/ml) at time t(h), C0 is monomer 
concentration at time zero and k is the PDC (h-1). Statistical T-tests performed on 
the groups of results from each shear rate gave a confidence level of 97.5% that the 
trend seen was significant. 
 
Table ‎8-1: PDC results from shear device for 2 hour processing of 1mg/ml 
samples of IgG1 and IgG4 molecules (Medi/UCL003-008) in L-Histidine 
and (D+) Trehalose buffer pH5.5 at different disc speeds. 
 
Antibody 
Protein Decay Coefficient 
(hour-1) 
6000 7500 9000 12000 
IgG1 WT 0.095 0.136 0.179 0.285 
IgG1 YTE 0.077 0.108 0.115 0.223 
IgG1 TM 
YTE 
0.102 0.163 0.272 0.420 
IgG4 WT 0.147 0.209 0.285 0.476 
IgG4 YTE 1 0.168 0.212 0.298 0.471 
IgG4 YTE 2 0.184 0.219 0.305 0.470 
 
 The PDC values for different disk speeds were used to compare monomer losses 
between each run. These were fitted to a second order regression to highlight clear 
trends that showed the antibodies to have varying levels of sensitivity to increases in 
the disk speed shown in table 8-1, caused by their different inherent stabilities in 
these conditions.  
 Overall, the IgG1 subtype candidates had a lower monomer loss than the IgG4s at 
any given disc speed. There was however more variability between mutants in the 
IgG1 PDC values at each disc speed, with the IgG4 candidates showing similar, 
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high PDC values possibly indicating their interfacial shear stability is already 
compromised. This is likely related to the lack of a stable hinge region holding the 
antibody halves together (Aalberse and Schuurman, 2002). 
 Two distinct lots of the IgG4 YTE were separately produced and purified to test the 
reproducibility of the interfacial shear device result. The results showed the error of 
the PDC derived decreases with disk speed, creating a need to compromise 
between ensuring reproducibility of data without losing sensitivity of the technique. A 
disk speed of 9000rpm was chosen to be the optimum level. 
 The increase in soluble monomer loss with disk speed could be due to an increase 
in its loss to aggregate nuclei in solution or to an increase in the rate of dissociation 
of aggregate precursors from the disk surface, resulting in an increased rate of 
aggregation. The work also supported previous observations that an increase in 
large aggregates (based on the increased opalescence of the solution) did not serve 
to increase the rate of monomer loss (Biddlecombe et al., 2007). The relatively 
steady rate of monomer loss differs from some reported routes of protein 
aggregation where the level of monomer loss seems to be low for a nucleation 
phase, followed by rapid fibrillation (Sasahara et al., 2008, Kim et al., 2002), 
indicating the presence of different mechanisms of aggregation. 
8.3 Differential scanning calorimetry of candidates 
 The DSC profiles in figure 8-2 shows that the antibodies have two clearly resolved 
transitions, each peak in the trace giving a melting temperature value for the 
unfolding of each protein domain. The first peak (Tm1) representing the unfolding 
transition of the CH2 domain was well resolved for most of the antibody candidates. 
The Fab and CH3 were unresolved in the second unfolding transition (Tm2) with a 
higher enthalpy than in Tm1, possibly indicating stronger interactions between sub 
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domains in this region(Tischenko et al., 1982). As expected, the modifications in the 
CH2 change the Tm1 value significantly. 
 
Figure ‎8-2: Effect of modifications on thermal stability determined by DSC using 1 
mg/ml samples of IgG1 WT, YTE, TM YTE and IgG4 WT and YTE in L-
histidine and D (+) trehalose buffer pH5.5. 
 
The Tm1 values for the antibody variants showed a greater range than the Tm2 
values giving different resolutions of the peaks. Some previous work intimates that 
peak resolution is related to the level of inter-domain interaction in the antibody 
(Privalov and Potekhin, 1986, Gill et al., 2010), suggesting the closer and less 
resolved two peaks appear, the more interaction they have with each other during 
unfolding. Other sources however dispute this and state that the individual domain 
peaks unfold independently (Vermeer and Norde, 2000) and just happen to overlap 
due to similar unfolding temperatures. IgG1 WT displayed the least resolution of the 
subtype, with closely associated peaks with a high Tm1 value. IgG1 YTE and TM 
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YTE had similar profiles with two distinct individual peaks, but IgG1 TM YTE had a 
lower Tm1 value. It is interesting to note that IgG4 WT also had a near identical Tm2 
value to IgG4 YTE. The Tm1 value for IgG4 WT was much higher than for IgG4 YTE, 
giving less resolution between the peaks. The emerging shoulder on the right of Tm2 
unfolding transition for the IgG1 subtype compared to the trailing edge on the 
corresponding transition for the IgG4 subtype showed the greater stability in the 
CH3 region of the IgG1. It is speculated that the greater areas of the peaks could be 
a result of IgG4’s ability to rotate and translate more than the IgG1 due to the IgG4’s 
aforementioned weaker linker hinge in the Fc. 
The Tm1 value is predominantly used in industry as an approximation to screen the 
relative stability of antibodies and determine the optimal temperature to perform 
accelerated stability testing (Fesinmeyer et al., 2009), although use of this over Tm2 
is being increasingly challenged. Comparison of Tm1 values with the PDC 
comparator obtained from the interfacial shear device monomer loss data would 
show how related the two stability readings are. Based on the greater enthalpy, the 
Tm2 value should represent the major unfolding transition of the molecules. It has 
also been reported that while changes to the protein structure at Tm1 values are 
reversible, changes that occur at Tm2 values are irreversible (Brummitt et al., 2011). 
This could mean the Tm2 value is in fact more pertinent to predicting protein 
aggregation. However, the data showed negligible difference with Tm2 readings for 
the modifications although the IgG1 and IgG4 populations did fall into two distinct 
sub-sets. It is logical that the modifications located in the CH2 region would not 
greatly affect the stability of the Fab transition. The weak linker region in IgG4 
molecules could account for the lower stability seen in general for the IgG4 
candidates. This region has reduced inter-heavy chain disulphide bridge stability, 
allowing the molecule to detach into two monomeric halves (Aalberse and 
Schuurman, 2002). The resistance of the whole molecule to degradation must be 
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greater than the sum of the two halves. It should be stated that the stability of these 
molecules is not necessarily related to their efficacy. 
8.4 Accelerated stability 
 
Figure ‎8-3: Effect of modifications on accelerated stability studies, monomer 
percentage determined by SE-HPLC at 0, 2 and 4 weeks using 10mg/ml 
antibody samples in L-histidine and trehalose buffer pH5.5 held at 
40°C. 
 
 The accelerated stability results did differentiate between the IgG1 and IgG4 
candidates as shown in figure 8-3. In line with previous reports (Ishikawa et al., 
2010) there were minimal amounts of fragmentation present in the thermally 
denatured samples, with the vast majority of monomer loss through aggregation 
mechanisms. Curves for loss were fitted to a second order polynomial curve, 
showing a clear trend for each antibody. IgG4 candidates showed reduced thermal 
stability in comparison to IgG1 candidates. Since the trends reported did not 
converge, the value of the monomer percentage at week four was used for further 
analysis of the data. 
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8.5 Comparison of PDC and thermal stability 
 
Figure ‎8-4: Comparison of protein decay coefficient with melting temperature 1 for 
all candidates at a disc rate of 9000 rpm with Y-axis error bars for 
standard error of PDC fit and X-axis error bars for internal error of 
DSC. 
 
The correlation of the thermal stability measured by DSC with conformational 
stability measured by adsorption to solid surfaces in a high shear environment was 
assessed. The different antibodies are shown in figure 8-4 in terms of their first 
melting temperature, Tm1, which represents unfolding of the CH2 region. This 
comparator is predominantly used in industrial screening of antibody candidates to 
determine the most stable candidates for accelerated stability studies. Comparison 
of the two stability indicators showed that there was no correlation between the 
thermal and the surface adsorption based stability. The IgG4 candidates did show 
that while they were the least stable in the shear device, they had relatively good 
thermal stability for this transition. The lack of correlation suggests that different 
mechanisms of degradation are involved in the two testing methodologies.  
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Figure ‎8-5: Comparison of monomer remaining at week 4 in accelerated stability 
results, determined by SE-HPLC and the PDC as determined for all 
candidates at a disc rate of 9000 rpm with X- Axis error bars for 
standard error of PDC fit. 
 
Comparison of PDC using 1 mg/ml protein with monomer percentage determined 
from accelerated stability studies at 40 °C using 10 mg/ml protein, shown in figure 8-
5,  revealed little trend between the two stability indices. The concentrations of 
antibody solution were kept at the standard operating conditions of each method. 
The IgG4 accelerated stability data supported the Tm2 results from the DSC 
analysis, highlighting the inability of the Tm1 values to differentiate between IgG1 
and IgG4. IgG1 YTE was shown to be significantly more stable to damage via 
interfacial effects than IgG1 WT, yet slightly less thermally stable. This would 
indicate that the two methods are not directly comparable. Finally the monomer 
remaining at week 4 from accelerated stability study was compared to the Tm1 from 
DSC. As with the other comparisons, there was little correlation with the different 
methods, this can be explained by DSC’s inability to differentiate IgG1 and IgG4’s 
stabilities. 
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Figure ‎8-6:  Comparison of monomer remaining at week 4 in accelerated stability 
results, determined by SE-HPLC and melting temperature 1 for all 
candidates with X-axis error bars for internal error of DSC. 
 
8.6 Making molecular models of the candidates 
 Molecular models were produced for each of the antibodies according to the 
method described in the materials and methods section. Each model was tested for 
spatial aggregation propensity (SAP) and the regions with high propensities were 
identified. 
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Figure ‎8-7: Sites of high aggregation propensity on IgG1 candidates as 
determined by SAP analysis. 
 
 Figure 8-7 shows the different regions on both chains of the Fc highlighted against 
a map of the IgG1 YTE amino acid sequence. It is shown clearly that the SAP is 
high in only six different regions down the amino acid sequence of each chain. 
Some regions seem to have a similar SAP score across the antibodies such as 
region 3, but others seem to be modulated by the modifications, like at hot-spots 4 
and 6 which occur at the same point in the sequence on opposite chains. 
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8.7 The effect of the modifications on the secondary 
structure and charge of the candidates 
 FTIR of the antibody and molecular modeling of Fc were used to determine why the 
modifications were affecting the stability of the antibodies. Table 8-2 shows the 
percentages of various motifs in the secondary structures of the candidates, 
intimating a difference in the tertiary structure that is evident in the models. The 
higher levels of more complex motifs in the IgG4 candidates would require more 
energy to unfold and would help explain the inability of DSC analysis to differentiate 
them from the typically more temperature stable IgG1’s. 
 
Table ‎8-2: FTIR and hinge SAP results for IgG1 and IgG4 antibodies 
(Medi/UCL003-008). 
  
Helix 
(%) 
Sheet 
(%) 
Bend 
(%) 
Turn 
(%) 
Coil 
(%) 
Total 
(%) 
Hinge 
SAP 
IgG1 WT 12.0 38.1 9.9 13.7 23.9 97.6 10.4 
IgG1 YTE 11.7 37.7 10.6 13.5 24.1 97.7 12.7 
IgG1 TM YTE 15.9 34.1 9.8 13.2 24.0 96.9 7.9 
IgG4 WT 7.1 39.0 10.5 13.6 25.6 95.9 - 
IgG4 YTE 13.1 36.1 9.3 13.4 24.4 96.2 - 
 
Molecular models of the IgG1 Fc with two internal fucosylated glycans were 
analyzed for their SAP and electrostatic surface charge displayed in figure 8-7. 
There are known docking postures of the Fab onto the hinge and the superior 
surface of the Fc. The CH1-1 loop of the Fab is more intrinsically disordered than 
even vhCDR3 (Sela Culang et al., 2012) and is oriented towards the central hinge in 
the full-length mAb crystal structure (Saphire, 2012), though it does not have 
electron density in the model 1HZH (PDB). This, together with high sequence 
variability in this loop, would imply that it has no conserved interactions with the 
hinge region. The minor hinge, however, has greater sequence conservation and is 
shown in a stably docked posture in the full-length antibody crystal structure 
(Saphire, 2012), orientated with the minor-hinge of the light chain forming an 
interface with the location of the first two mutants of the "TM". 
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There is no significant difference shown in the electrostatic results and the overall 
surface charges of the proteins remain the same, showing that the difference in 
stability is not from electrostatic interactions, a key component of colloidal stability. 
The SAP models do however show a very noticeable difference in the 
hydrophobicity of the hinge region of the Fc with the rest of the molecule not 
showing any significant differences. The an increase in the hinge SAP scores shown 
in figure 8-8 correlates with a reduction in the PDC, suggesting this is the area of the 
molecule responsible for the change in stability documented in this instance. It is 
postulated that having a more hydrophilic upper hinge would reduce the range of 
motion of the Fab in respect to the Fc, giving a more rigid antibody structure that is 
less able to fold in on itself to conserve hydrophobic sections on the Fc. In the case 
of the TM this allows the enhanced binding to the Neonatal Fc Receptor, but also 
seems to allow easier degradation through adsorption at solid/liquid interfaces. It is 
suggested that the mobility of the hinge region is very important, not only in 
exposing effector functions of the Fc (Dall'Acqua et al., 2006a), but in keeping the 
antibody stable in solution. 
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Figure ‎8-8: Comparison of Spatial aggregation propensity and surface charge of 
IgG1 WT Fc with the YTE and TM YTE modified IgG1 Fc’s with site 1 as 
the site of the Tm modification and site 2 as the site of the YTE 
modification. 
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8.7.1 Mechanism of aggregation seen in the shear device 
 
Figure ‎8-9: Diagram of mechanisms of aggregate formation in the shear device. 
 
The shear device does not appear to have any low molecular weight aggregates 
present in samples taken from the device, even if they are placed in the SE-HPLC 
minutes after being taken. This suggests either very short lived intermediaries, or 
intermediary species which form and aggregate together within the boundary layer 
before being released into the bulk solution where they react further. Figure 8-9 
gives a proposed diagrammatic mechanism for this growth to the point where the 
aggregate moves out to bulk solution. There would appear to be a concentration 
dependence on the movement of the antibodies into the boundary layer as reported 
elsewhere (Stenberg and Nygren, 1988, Shojaaee et al., 2012). Materials then 
adhere to the surface (Bee et al., 2010) where the material changes to a non-native 
state. This state exposes aggregation hot spots which quickly react with other 
molecules to start the aggregation process (Roberts, 2007). There are spatial 
limitation on the level of adsorption to the solid/liquid interface which can be altered 
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by changing the disc rotational speed to effect the shear expedited removal of 
material from the interface which will then make its way out of the boundary layer 
and back into the bulk solution (Doran, 1995, Shojaaee et al., 2012), possibly 
aggregating further before returning to the bulk solution. 
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8.8 Conclusion: Which methods to use and how do 
modifications affect stability? 
The systematic use of known monoclonal antibody variants of IgG1 and IgG4 
subtypes reveals the complexity of protein stability in solution. The three testing 
methods used, DSC, accelerated stability at 40°C and stability to solid-liquid 
interfaces all provided different rankings of stability, inferring differing mechanisms 
of damage predominant in each. The shear device provides an orthogonal approach 
that can be used as part of an overall screening process for protein stability. This 
provides the basis to characterize the critical routes of degradation encountered 
during therapeutic protein processing and storage. The shear device gives relative 
stability for routes involving shear and solid-liquid interfaces, which are present in 
many different steps of protein purification and in transport and storage of drug 
product. 
The mechanism of degradation in the device is proposed and involves the transfer 
of antibodies into the boundary layer and adsorption to the surface (Shojaaee et al., 
2012). Degradation occurs on the surface and exposed hydrophobic aggregation hot 
spots initiate aggregation. Aggregates then continue to grow on the surface until 
shear causes their disassociation, at which point, they continue to aggregate in the 
boundary layer until they pass back into the bulk solution. 
 The correlation of the molecular modeling results with the shear device results not 
only helps to explain the reason behind the change in stabilities, but underlines the 
benefits of using in silico methods for the evaluation of drug candidates in the future 
(Zurdo, 2013).  
 A broader knowledge of antibody characteristics earlier in the drug lifecycle would 
allow candidates to be selected for stability through the primary recovery and 
downstream processing stages of production and will allow better analysis of long 
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term storage stability. Increased stability is however not an indicator for increased 
product efficacy, another factor that should be considered. 
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9 Final conclusions and future work 
9.1 Review of project objectives 
9.1.1 Complete characterisation of the custom UCL disc 
interfacial shear device   
 The work that has been described has provided significant further characterisation 
of the disc interfacial shear device. Prior work from the group described a disc shear 
device and the effect of the shear regime within the chamber and the effect of time 
and disc speed on the level of monomer loss, to give results for the stabilities of 
multiple proteins (Biddlecombe et al., 2007, Biddlecombe et al., 2009). The device 
employed in the previous studies built up evidence for using shear devices to 
emulate downstream operating conditions which was different from previous work 
using similar devices to determine the effect of shear on large biological materials 
such as cells. 
 The latest shear device further refines the ability of the method to be applied to 
downstream processing operations. It is designed to give the best level of control 
over air-liquid interfaces by excluding everything but sample from the chamber. It 
has very precise control over the rotational speed of the disc and an optimised 
cooling system.  
 The temperature of cooling water required at a set cooling water recirculation rate 
for different disc speeds was determined to remove the effect of temperature on the 
degradation rate.  
 The wavelength of light to be used in the SE-HPLC analysis of sheared samples 
was defined as 280nm. 
 The optimum disc speed was further defined to 9000rpm as an optimisation 
between the level of monomer loss produced and the reliability of the reading.   
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 Finally, extensive testing was performed on the concentration of monomer to be 
used in the machine. Higher concentrations did give more differentiation of antibody 
stabilities, but this may have been resultant of the lower reliability of the result at 
higher concentrations. It was decided to optimise reliability and in doing so reduce 
protein mass required, by using a low concentration. 1mg/ml was the optimal 
concentration decided upon. 
9.1.2 Develop a higher throughput method of gaining comparable 
results to the disc shear device 
 Strong foundations were set for developing a higher throughput method of obtaining 
comparable results to the disc shear device. The ability of the capillaries to enable 
parallel processing with a similar mechanism of protein aggregation to the disc 
device opens the door to the possibility of producing simpler and further refined 
devices. The use of 96 well plates would allow for 96 samples to be queued up. It is 
possible to use parallel capillary devices to process 8 wells simultaneously every 2 
hours before CIP, with the samples ready to be placed directly onto a HPLC for SE-
HPLC analysis. The work also helped to highlight important stages in the 
mechanism of aggregation in the capillaries that had been witnessed in other 
circumstances, both from entry into the boundary layer (Shojaaee et al., 2012) and 
adsorption to the steel surface (Bee et al., 2010). 
 The simplicity of the method could allow automation either on an established robotic 
platform such as a Tecan, or on a custom produced platform that could be designed 
and assembled in the future. A fully developed technique of this kind, with a 15 
minute clean in place protocol included, would be able to process 96 different 
samples within 27 hours. Multiple plates could be loaded onto a system before the 
weekend to allow 192 or 288 samples to be processed in one batch using a total of 
57.6mg of protein per plate. Using the current method, a maximum of 3 runs can be 
completed in a working day so it would take 32 days, or six and a half weeks and 
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672mg of protein to get the same number of results as one 96 well plate. This is an 
order of magnitude reduction in time and material requirements. 
9.1.3 Finding an appropriate way to analyse aggregates formed 
through processing 
 Aggregates produced in the course of the project were analysed using a wide range 
of techniques not all of which were described in the results section of this study. The 
problem with analysing the aggregate profiles developed was the large range of 
sizes of aggregates produced (Joubert et al., 2011). The range effectively precludes 
the use of a single method to determine the size of aggregates produced (Philo, 
2006). The second major issue is that the cost, time and expertise needed to use 
the majority of the techniques is quite intensive. The project recommends a portfolio 
of three techniques that cover the range from 1nm to 100μm. Two well 
characterised techniques in the SE-HPLC and microflow imaging can be teamed 
with the emerging nanoparticle tracking analysis technique with the use of the 
Nanosight which was shown to be very powerful at imaging particle size with 
excellent resolution in the range between the two other techniques (Filipe et al., 
2009). The Nanosight was shown to be able to accurately track the particle size 
distribution in the linking range of 50nm to 2μm between the SE-HPLC and 
microflow imaging techniques. The results showed the ability of the device to pick 
out the trends in growth and reduction in different size ranges of aggregates as 
more antibody passed into ever larger aggregate species during operation of the 
disc shear device. 
9.1.4 Determine the effect of reversible self-association on the 
bioprocess of a target molecule 
 The work described takes a detailed look at the reversible self association (RSA) of 
an RSA exhibiting IgG1 (Medi/UCL009). RSA is a phenomenon that is becoming 
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noticed more frequently in drug production (Bethea et al., 2012, Chaudhri, 2012) 
The reversible association of antibodies could effect their purification (Liu et al., 
2005) and could lead to further aggregation. By first determining the factors which 
affect the antibody’s tendency to exhibit the phenomenon and subsequently moving 
through the various steps in purification of the molecule, the effect of RSA on 
bioprocessing was characterised. During exposure to interfacial shear in the disc 
device, further aggregation in conditions promoting RSA was not observed which 
does not support the idea that RSA promotes aggregation. It was determined that 
RSA does not prevent nor considerably effect the operation of most of the steps in 
antibody purification. The main consideration taken from the results is that filtration 
steps should not be performed in conditions that encourage RSA. In particular, the 
antibodies should be put into formulation conditions prior to final viral filtration and 
should not have RSA present as this will have a largely detrimental effect on the 
operation of the step. As injection of any aggregated species into a patient is 
advised against (Joubert et al., 2012), this should not greatly effect the operation of 
antibody bioprocessing, but will add another parameter to test for during formulation 
studies performed on the antibody candidates. 
 The RSA in this case was determined to be a product of a large hydrophobic patch 
on the c-terminus of the Fc, reaching around to the anterior face of the Fc 
determined by the SAP algorithm (Kayser et al., 2011, Chennamsetty et al., 2010). 
This region would normally be exposed to the solution, and it is postulated that it 
would have a tendency to bind reversibly with one other similar unit on the mirrored 
patch on its c-terminus. 
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9.1.5 Comparison of interfacial shear disc device with thermal 
methods as tools for determining antibody stability and the 
use of molecular modelling to explain the difference 
 The relationship between the thermal methods for determining antibody stability 
and use of the disc shear device were explored in depth as no current methods are 
fully representative of antibody stability upon storage. Using differential scanning 
calorimetry showed that while it was possible to observe the thermal unfolding of the 
domains, none of the melting temperature transitions were found to correlate with 
accelerated stability results, highlighted by the inability of DSC to distinguish 
between the IgG1 and IgG4 subtypes. The accelerated thermal stability is a well 
known method for predicting the comparative shelf life of an antibody product 
(Joubert et al., 2011) but there is growing consensus in industry that the method is 
far from the golden standard. The disc device results were shown not to correlate 
with the accelerated stability results or the DSC, indicating a fundamental difference 
in the mechanism of aggregation that is determined through each of the 
approaches. Further investigation into the three dimensional antibody structures of 
the molecules showed that the difference in stability determined by the shear device 
correlated to the hydrophobicity of the hinge region of the Fc. This inferred the disc 
device was giving a stability measurement based on the exposed surface of the 
molecule’s three dimensional structure. It is determining the proteins ability to 
conserve this structure and the regions that may be involved in adsorption and 
desorption from surfaces they come into contact with during bioprocessing (Sela 
Culang et al., 2012, Saphire, 2012). It was concluded firstly that the molecular 
modelling techniques are a powerful technique in helping to understand antibody 
stability in preparation for lab scale experiments. Secondly, it was concluded that the 
disc shear device provides an orthogonal approach that can be used as part of an 
overall screening process for ranking protein stability. There are many different 
degradation pathways in a proteins lifecycle and it is important to inhibit the most 
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predominant routes. The shear device gives relative stability for routes involving 
shear and solid-liquid interfaces which are present in many different steps of protein 
purification and in transport and storage of drug product. 
9.2 Final comments  
 The project has looked at a wide variety of process related stability issues and 
highlighted methods that can be used to implement a robust characterisation system 
for antibody stability and measurement of aggregate impurities. Included in this 
system is the recommendation that classical thermal stability testing should be 
augmented with results from the complementary interfacial shear methods. This will 
give an orthogonal measure of protein stability based on the solid-liquid interactions 
that are prevalent in manufacturing shipping and storage of biological products. By 
proving concept and starting to develop a higher throughput method for delivering 
comparable results to the disc shear device, the project naturally leads into a 
programme of extra work in further developing the method to take the measurement 
in an industrially acceptable format. 
 Substantial work was also performed in creating homology models for subsequent 
analysis of antibody stability, a field that is quickly developing and can be used to 
help screen ever larger numbers of drug candidates as computing power becomes 
cheaper. As the available processing power increases, these methods will come to 
the fore in early stability analysis of potential drug molecules. It is therefore 
important to establish correlations to experimental methods and the different 
mechanisms of aggregation. 
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9.3 Future Work 
9.3.1 Short term work (0-3 months) 
 These proposals are designed to be possible during the course of an MEng or MSc 
project by one candidate with supervision from a doctoral level student. 
 
Membrane blockage 
 With respect to the RSA experiments, it would be beneficial to determine the cause 
for membrane blockage with Medi/UCL009 (IgG1) during viral clearance filter 
operation. If there a surface chemistry interaction with the membrane (Ahmad and 
Hairul, 2008) this problem could be solved by using a different material or coating, 
but if it is mechanical blockage of the pores, the conditions going into the filter will 
need to be altered. This could be tested by recreating the blockage of a filter by 
running it through with Medi/UCL009 in RSA forming conditions until the flowrate 
fell. The membrane could then be removed from the filter housing and confocal 
microscopy could be used to look at a cross section of filter membrane to determine 
the cause of blockage (M. Shotton, 1989). If the antibody has permeated to different 
distances through the membrane based on pore sizes, this would point to a 
mechanical blockage, whereas a coating of protein on the membrane surface would 
point to a surface chemistry interaction. 
 
Computational fluid dynamics of capillaries 
 With respect to the higher throughput interfacial shear device, computational fluid 
dynamics analysis should be performed to analyse fluid flow at different flow rates in 
the coiled capillaries, determining the exact flow patterns involved. The effect of 
altering the tightness of the coil should be examined to determine if that is a way to 
increase the shear the antibody is exposed to. It is important to understand and 
maximise the shear in the system to give the greatest level of monomer removal 
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from the capillary surface, which in turn gives a greater level of monomer loss. This 
will allow greater differentiation of different antibodies and can be achieved using an 
appropriate package such as COMSOL to design the 3D capillaries and apply the 
appropriate analysis. 
 
Un-attributed capillary monomer loss 
 With respect to the higher throughput interfacial shear device, it was observed that 
there was a base level monomer loss of 2% that was additional to the rate of 
monomer loss from operation. The capillary device should be investigated to 
determine whether this is due to protein bound to the capillary surface that is not 
expelled with the rest of the sample to be tested. This is important as it would cause 
a source of error in monomer loss readings for devices with different dimensions or 
made with different materials or surface roughness. If the loss is caused by surface 
adsorption, it was calculated that there was a protein density of 17.1g/m-2 at the 
surface. By using capillaries of different diameters it would be possible to have 
different size to volume ratios, with different areas of surface area exposed to the 
sample. By performing experiments using these different sizes for different lengths 
of operating time, it would be possible to calculate the base level of monomer loss 
again and use this percentage to determine the protein density at the surface. If this 
is equal to the 17.1g/m-2 then it would be concluded that the loss is due to protein 
bound to the capillary surface.  
9.3.2 Medium term work (3 months -1 year) 
 These proposals are designed to be sufficient for testing as a significant part of a 
doctoral project or in the course of post-doctoral work. 
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Nanoparticle tracking analysis 
 With regards to the nanoparticle tracking analysis using the Nanosight, it was 
concluded that the Nanosight technique was very powerful at determining the 
particle size distribution within the 50nm to 2μm range for antibody aggregates. It 
was capable of providing these results in a timely manner once the parameters of 
operation were set. Determining the conditions for operation of the device however 
took a long time for different samples and set-up of the device was time consuming 
at the beginning of any set of results. To this end the Nanosight technique should be 
further developed and defined to give a more robust, standard framework for its use. 
This includes work for the physical loading of sample and focussing of the 
microscope as well as developing the settings that should be used to firstly capture 
the samples and then to subsequently process them. 
 During operation of the device it was found that larger particles forming during 
operation of the technique were an issue.  Further work should go into developing 
multiple new methods with their own defined settings that are able to isolate and 
focus on different size ranges of particles within highly disperse samples. This would 
mitigate the effects of the larger aggregates and avoid sampling them as part of the 
results.  
 
The mechanism of protein adsorption to stainless steel 
 With regards to protein adsorption to the stainless steel of the interfacial shear 
devices, it would be beneficial to get more information on the mechanism of protein 
degradation. This could be achieved by using a microscopy technique such as 
confocal microscopy (M. Shotton, 1989) to look at the density of the antibody 
adsorbed to the metal surface after it was exposed to shear and an antibody 
solution. A high density would suggest that the aggregation was occurring at the 
solid/liquid interface, whereas a low concentration would indicate degradation on the 
solid/liquid interface followed by aggregation in the boundary layer. 
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 It would be ideal if a more detailed analysis such as electron tomography (Lučić et 
al., 2005) could also be performed on antibody adsorbed to the metal surface in 
similar process conditions to look into the conformation of the antibodies as they 
undergo different stages of unfolding in the shear device. This would provide a lot of 
information on the mechanism of protein degradation at the solid/liquid interface. 
9.3.3 Long term work (more than 1 year) 
 These proposals are designed to be appropriate for either the main focus of a 
doctoral project or as part of an ongoing portfolio of work within a university 
department. 
 
Development of a capillary interfacial shear device 
 With regards to development of the capillary interfacial device, work would need to 
go into the next generation of the device. Although the syringe pump system gave 
reliable and reproducible results, there was still a level of uncertainty in the results 
and the operator needed to be very careful at every stage not to alter the calibration 
of the device or introduce any unwanted variables. The flowrate achievable in the 
device is not sufficient to give large levels of monomer loss within two hours of 
operation, so using a different pumping method would add to the reliability of the 
results and give more differentiation between samples to be analysed. Finally, the 
device is not suitable for automation, which would allow for a very high throughput 
operation. These factors would make the capillary device highly effective in 
determining relative stability of a whole range of proteins in many different buffers at 
a very low cost. This would be very valuable to industry where they could look at a 
more comprehensive view of the antibody stability earlier in the drug production 
cycle for a very low cost. This would save companies significant amounts of time 
and money on the process development of candidates and help reduce the cost of 
therapies at a time when buyers are putting pressure on them to do so. 
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 The development of the next generation of device can be done by either modifying 
an existing robotic device or platform such as a Tecan, which is able to use 96 well 
plates to use capillaries, or by creating a bespoke automated liquid handling 
platform to achieve the same thing. The use of 96 well plates is important as it is a 
standard lab consumable that the device can be designed around and allows the 
tests to be easily queued up. An additional concern is that if the samples are queued 
for a significant amount of time, they will be exposed to ambient temperatures, 
which over the operating time of the device may affect the stability of the samples. 
To negate this factor, the sample storage chamber should be temperature 
controlled. 
 
Development of modelling techniques 
 Development of modelling techniques is already at the forefront of research into 
protein characterisation. Models can be created for analysing static antibody 
structures relatively easily, but as the technique develops, it is important to be able 
to produce models that also take into account both the variability of glycosylation 
patterns and the dynamic nature of a proteins interaction with its environment. This 
will allow modelling techniques to give predictions of stability based on the entire 
sample. Currently, it is difficult to create models of entire antibodies (Chennamsetty 
et al., 2010) so forcefields need to be developed that allow design of an entire 
antibody model, and that can then map and take into account glycosylation. These 
models need to have heterogeneous glycosylation patterns that would be 
representative of real samples. 
 The next step is allowing dynamic action in the antibody in the model. This will 
permit the model to take into account the specific exposure of different portions of 
the molecule as they move, exposing and conserving different parts to solution. The 
final dynamic interaction that needs to be modelled is the interaction with the 
solution and with ions present. While there are currently ways of producing models 
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that take the solution conditions into account, preparing models for this kind of 
dynamic analysis is incredibly time consuming (Gu et al., 2012) and can take up to 2 
months to get to the point where they can be run. Programs should be developed to 
allow the assembly of complex models to be completed quicker by standardising the 
addition of excipients and water molecules and to take into account the effect of 
changes in pH and salt concentration. As computing power continues to increase, it 
will be more and more important to develop new tools to push the capability of this 
field of research and make it easier to set up analyses. 
 
Development of an understanding of the effect of excipients 
 The ultimate goal of this project and of many research departments is to produce 
more stable antibody therapeutics. This can be done in two ways; either by 
designing the stability into the protein structure, or by stabilising the protein during 
processing and storage with the use of excipients. The solution to this problem is 
ultimately going to be a mixture of the two approaches. This project looked into the 
effect of modifications to the protein primary structure on the stability of the resulting 
three dimensional molecules, but more work needs to go into characterising the 
effect of stabilising agents. To begin with, this work can be done by using tests like 
DSC and high throughput interfacial shear devices to screen the effects of changing 
concentrations of different excipients on the various stability parameters. This 
screening could also introduce controlled amounts of contaminant such as stainless 
steel particulates or glass shavings to the samples to build up information of how 
these all interact with each other. I believe this data should ultimately be used to 
draw up a model for interaction of antibodies with solution excipients that can form 
the basis of a forcefield for molecular modelling. 
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10 Validation chapter (EngD requirement) 
10.1 Introduction 
 The project aims to find ways to reduce the level of antibody aggregation found in 
typical biopharmaceutical processes by either preventing the formation of 
aggregates or removing their precursors from solution.  
 The reason to focus on this issue is the benefits to industry of a better 
understanding of the causes of aggregation. It will not only allow for faster screening 
of potential drug molecules for stability, but increase the stability of the final product. 
The first experiments performed confirmed the results seen in a previous report 
using a shear device, but then the range of antibodies, concentrations and 
excipients were all increased and the Nanosight analytical technique was used to 
elucidate further information. 
 Use of the Nanosight will allow the visualisation of particles between 50nm and 2 
micron in diameter which would help to create a taxonomy of aggregate species 
within this range. 
 The long term objective from this project is to produce a high throughput capillary 
shear device capable of evaluation of antibody stability with different surface 
materials and to validate the accuracy of such a system. 
 With the expanding production of bio-therapeutics, removal of protein aggregates, 
either by stopping their formation or by physical or chemical removal is of ever great 
importance in the bioprocess industry. Since 2007, antibodies have been the highest 
selling category of biologics, with a market value of $21.9 billion which is estimated 
to rise to over $70 billion in 2015 (Visiongain, 2008). In a recent review of 
pharmaceutically relevant monoclonal antibodies and Fc fusion proteins, around half 
of them were found to possess aggregation issues following protein-A purification 
(Shukla et al., 2007a).  
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 A more important factor is the loss of bioactivity of the formulation (Sluzky et al., 
1991, Pease et al., 2008) which will effect the dose required by a patient.  
 Of greatest importance is the possibility of the aggregate eliciting an immunological 
response in patients (Chennamsetty et al., 2009b). This could involve neutralisation 
of antibodies, cross reactive neutralisation of endogenous protein counterparts, or 
anaphylaxis and this is the reason for the strict guidelines on their removal. 
10.2 Regulatory burden 
Regulations currently dictate that the level of aggregates above a certain size has to 
be kept below specific thresholds. Being able to more fully understand the problem 
will not only allow for faster screening of potential drug molecules for stability, 
decreasing the time to market and increasing drug selling time under patent, but 
could allow for smaller doses that could be kept longer if aggregation can be 
stopped throughout drug storage. 
 The regulatory issues faced by my sponsor company, MedImmune, are vast in 
scope. As a company they are involved in the development of numerous drugs at 
various stages in their lifecycle, from pre-clinical to stage 3 clinical trials. There is a 
huge emphasis within the company on acquiring the largest design space 
information for each step of a process, which in turn allows the determination of a 
suitable control space, outside of which the product could still be viable. 
10.3 Quality by design  
 The quality by design begins with prior organisational knowledge. This is one of the 
great advantages of MedImmune and its large portfolio of ongoing projects. The 
quality attributes and process parameters that need to be controlled and the rough 
values that these should be in can all be extracted from prior knowledge, process 
and product understanding. 
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 Getting this prior knowledge, in the form of a platform process into an optimal 
system, for example, requires process development and characterisation which 
involves small scale studies involving process models and Design of Experiment 
(DoE) studies on a whole range of parameters before scaling up to validate these 
results. Worst case studies are performed to view the compounded effect of being at 
the lower, or upper, end of the design space. From these experiments the more 
critical and key factors can be determined and the optimal operating ranges for each 
factor can be set. Quality Control (QC) and good quality assurance (QA) is still 
required to validate the results seen in the initial screenings. 
 The Critical Quality Attributes (CQA) of the drug are needed to be able to determine 
the suitability of a candidate molecule and process, so these are identified and 
ranked before anything else. Prior knowledge and experience is helpful in choosing 
the CQA. 
10.4 Validation at MedImmune 
 The purification process validation is performed to demonstrate that the process 
does what it is supposed to. It must demonstrate that the process as set out will 
remove DNA, host cell proteins, media components and so on to a pre-defined, 
acceptable level. Furthermore it needs to show that this removal is robust, so that 
the level of purification is not affected by process variations and loss of efficiency of 
certain components from reuse. Most importantly, the validation should show that 
the product integrity and activity is maintained. 
 Within each project, the design does not stop with the initial validation. Continuous 
process monitoring and improvement are undertaken to extend the process 
characterisation and increase the knowledge space of the company. Obviously, 
there is full life cycle management of the processes and process performance 
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verification is undertaken with each batch and fed back to continually improve the 
process. 
 There is a very big emphasis within the company on the quality control of the 
reagents used both in process and in research. Every batch of buffer is recorded 
and labelled, with the lot number, date opened and weight of the reagents used, the 
pH and the conductivity of the buffer all recorded.  
 It is also very important to validate the equipment and techniques used to gain any 
results or purification. Equipment is validated upon installation in the labs or process 
facility, but routine validation is required from time to time. In terms of 
chromatography, packed column heights are measured, dynamic binding capacities 
are checked, Height of Equivalent Theoretical Plates (HETP) and asymmetries 
tested and the number of reuses is tracked to view the degradation of the matrix 
beads. There is constant testing of analytical tests, with standards being run at the 
beginning of assays to check the technique is working. With some methods that run 
for a long time, such as Size Exclusion HPLC (SE-HPLC), standards are run after a 
set number of assays to check there is no change in the validity of the results. 
 There is a lot of work that goes into the validation of the formulation used to store 
the drug for long periods of time. Degradation studies are a common technique used 
to determine the stability of a drug in a given solution. Studies used at MedImmune 
include pH, salt concentration, excipient and temperature accelerated studies which 
help validate shelf life of the product. 
10.5 Validation implications of the thesis 
 My research into aggregation and the stability of monoclonal antibodies would have 
a few regulatory validation issues. The research itself has two possible methods of 
reducing the level of aggregation plus methods to determine the ability of these 
reducing methods to do what they say they can. The first of these reducing methods 
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is to find excipients to interact with the antibodies to reduce their ability to aggregate. 
The second possible method is to determine if a sub-population is prone to 
aggregation and then to remove this population early on in the process to stop them 
aggregating later on. 
 The techniques used to determine the propensity of the antibodies to aggregate do 
so by accelerating the process by increasing the level of the solid-liquid interaction 
and the level of the shear the antibodies are exposed to. The current method 
achieves this by using a rotary disc inside a chamber to process 8ml of sample. 
Future work involves a method that achieves similar levels of both these forces 
using pumping through a capillary for 1ml samples. 
 Validation issues with the excipients involve their effect on the solution they are 
added to. If added during a process step, the effect of adding too little or too much 
will have to be determined in terms of the effect on the antibody and on the impurity 
clearance of the step. It would also be needed to show that the excipient has no 
effect on the solutions behaviour on future processing steps before it is removed 
and that it is indeed removed before final formulation if it is needed to be. If the 
excipient is added for long term storage stability then validation needs to be done on 
the levels acceptable and the effective levels. 
 For the aggregate removal solution, validation would centre upon how robust the 
clearance is. It would have to be shown that the same level of aggregate can be 
removed each time, and the effect of having more or less aggregate to begin with 
would have to be assessed on its effect on the aggregation removal step. More 
importantly, the effect of having differing levels of aggregate on subsequent 
optimised steps would have to be looked into. Stability studies would have to be 
performed to prove that the antibody is later less prone to aggregation, and again 
would need to involve excipient, pH, salt concentration and temperature accelerated 
studies. 
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 The effect of any of the modifications to the process may be to change the folding 
properties or the activity of the antibody, so it needs to be shown that this is not the 
case by the use of various analytical techniques such as SDS page, SE-HPLC, or a 
bioactivity assay. 
 Validation of the equipment will involve the development of a stable standard that 
can be used to determine that the equipment is still running according to 
specification. Plenty of suitable standards can be purchased readily from suppliers. 
The standard should be run once every set number of tests to ensure that the 
equipment is still running to specification, as with many other assays. 
10.6 Conclusion 
 To summarise, the regulatory validation issues of my work are very much the 
standard issues already faced by my sponsor company and the industry as a whole. 
Validation requires thorough documentation and traceability of work through GMP 
and GLP, in addition to a good QA department to ensure everything is kept to a high 
standard. 
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Appendix A: Operation of the USD Surface adsorption 
shear device  
Acknowledgement is made to Olatomirin Kolade for formalising this SOP based on 
work by the author. 
 
Introduction   
Shear forces are experienced to varying degrees by protein therapeutics throughout 
the manufacturing process and indirectly contribute to aggregates levels observed in 
the final product.  The rotating disk shear device can be used to simulate interfacial 
shear encountered by protein formulations during manufacture.  Solid-liquid 
interfacial shear is created inside the chamber generating shear strain rates of 3.4 x 
10
4
 s
-1 
at 9000 rpm
1
 
2
.  The device can therefore be used to monitor the stability of 
protein therapeutics under defined levels of shear in the presence or absence of an 
air-liquid interface. 
The device (ID sfadsorp.v2.n1 and n2) features a chamber volume of 7.8 - 10 mL, a 
clear polymethyl methylacrylate (PMMA) lid containing separate ports for sample 
injection (central port) and recovery (angled port), and incorporates a cooling jacket.  
The disk rotates around a hollow shaft and is supported by a Teflon prop above the 
disk and a stainless steel U-ring at its base.  Disks of different material types can be 
used to reflect the range of surfaces encountered by the protein during process 
operations. 
Typically, the effect of interfacial shear is determined by examining reduction in the 
level of monomeric protein by SEC-HPLC 
 
Materials 
10% (w/v) sodium hydroxide  
2.5 % (v/v) orthophosphoric acid  
Distilled water  
Formulation buffer (degassed)  
Protein formulation (0.5 – 10 mg/mL)  
Sterile disposable syringes (1 mL and 20 mL) 
 
Equipment 
Shear device speed controller (sfadsorp.v2.ppk1a and sfadsorp.v2.ppk1b) 
Magnetically driven shear device (sfadsorp.v2.n1/n2) 
Magnetic disk – 8mm height, 26 mm diameter (surfaces - stainless steel 316L, 
borosilicate glass, Teflon) 
One – way valve for attachment to Luer needle 
                                                 
1
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Equipment cont’d 
Water bath to achieve temperature control at 17°C 
Watson-Marlow peristaltic pump 505S or suitable alternative 
Silicone/Tefzel tubing (diameter) 
GF-250 ZORBAX, TSKgel 3000 SWxl or a suitable SE column 
HPLC (or other instrument for monitoring protein species) 
 
Method 
Shear device CIP 
1. Cleaning-in place is performed before operation of the shear device. 
2. Turn on the water bath and check that the temperature set is 16 -17°C. Turn 
on the pump and check the set speed is 150 rpm. These parameters maintain a 
chamber operating temperature of 20°C. 
3. Turn on the speed controller. If using sfadsorp.v2.ppk1a and 
sfadsorp.v2.ppk1b, ensure the current is limiting (i.e. set to maximum). 
4. Carefully remove the stainless steel U-ring from the hollow shaft (Luer 
needle). Use pliers if necessary. Hold the top end of the Luer needle
3
 and 
slowly prise the U-ring from the needle shaft. Leave the Teflon spacer in 
place. 
5. Attach the appropriate disk and re-attach the steel ring so that it is flush with 
the disk but allows it to freely rotate. Hold the top of the Luer needle when 
performing this action. 
6. Carefully seal the chamber with the lid (and attach the one-way Luer valve4)  
7. Fill the chamber with a syringe (approx. 10 mL) through the central port with 
10% v/v NaOH until a bubble appears. Start the shear device on a low setting 
and continuing injecting NaOH until the bubble is removed. Air in the 
chamber is expelled through the angled port. 
8. Run at 9000 ± 300 rpm (for sfadsorp.v2.ppk1a and sfadsorp.v2.ppk1b) for 10 
minutes. Reduce the speed to zero
5
. 
                                                 
3
 The height of the Luer needle is fixed relative to the fitting in the base of the chamber and should 
not be adjusted. If the Luer needle slips during removal/assembly of the steel U-ring, adjust its 
position using an Allen key, but do not over-tighten. If operating device on-site return to A. Craig 
(UCL Biochemical Engineering  Workshop) for repositioning.  
4
 Check valves are available from www.valueplastics.com. Part no. SCV23050 Female locking luer to 
male locking luer, cracking pressure ≤ 0.174 psig, flow rate 90 mL/min, clear SAN with silicone 
diaphragm. 
5
 If using the newer speed controller use the stop switch 
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9. Remove the one-way Luer valve and withdraw the NaOH 
10. Replace the one-way Luer valve and fill the chamber with distilled water 
until the bubble is removed. 
11. Run at 9000 rpm for 10 minutes. Reduce the speed to zero. 
12. Remove the water and replace with 2.5% (v/v) orthophosphoric acid. Run at 
9000 rpm for 10 minutes. Reduce the speed to zero. 
13. Remove the acid and replace with buffer. Run at 9000 rpm for 10 minutes. 
Reduce the speed to zero. 
14. Repeat the buffer step for a total of three times. 
 
Shear Device Operation 
1. Carefully fill the chamber with sample through the central port using the one-
way valve until a bubble appears. 
2. Start the device at high speed (9000 rpm or desired speed) whilst filling until 
the air is expelled from the chamber. 
3. Remove 0.1 mL of sample from the angled sample port (t=0 sample). 
4. Replace the sample syringe with a 1 mL syringe containing 1 mL of 
formulation buffer, taking care not to introduce air into the chamber. 
5. At designated time points, sample 0.1 mL from the device chamber by careful 
injection of 0.1 mL of formulation buffer into the chamber. Samples can be 
stored briefly at 4°C prior to analysis. 
6. Changes in the soluble monomer concentration can be monitored by SEC-
HPLC
6
. Centrifuge samples at 20°C for 10 minutes at 15, 294 g (12, 000 rpm, 
rotor FA45-30-11, Eppendorf 5810R benchtop centrifuge) prior to loading. 
7. After use, perform CIP on the shear device and rinse with water. Wipe the 
outside of the device with water and air-dry all components before 
reassembly of the device. 
8. Do not leave chamber in contact with buffer salts when the device is not in 
operation. 
 
 
 
 
 
                                                 
6
 Dilution of the chamber contents during sampling should be included in calculations of monomer 
concentration/peak area.  
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Safety Precautions 
1. Do not run the shear device without liquid in the chamber. 
2. Do not run the shear device without the appropriate level of cooling. 
3. The shear device should not be operated above 20,000 rpm (n.b. the Teflon 
spacer should be replaced with a PEEK spacer above speeds of 10,000 rpm). 
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one-way valve 
Teflon prop 
U-ring Figure 1. Assembled lid of shear 
device 
Figure 2. Assembled shear device 
